



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : C07H 17/02	A1	(11) International Publication Number: WO 89/ 08114 (43) International Publication Date: 8 September 1989 (08.09.89)
(21) International Application Number: PCT/US88/02809 (22) International Filing Date: 16 August 1988 (16.08.88) (31) Priority Application Number: 160,416 (32) Priority Date: 25 February 1988 (25.02.88) (33) Priority Country: US (71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; Fruit Street, Boston, MA 02114 (US). (72) Inventors: SEED, Brian ; Department of Molecular Biology, Wellman Building, Massachusetts General Hospital, Boston, MA 02114 (US). ALLEN, Janet ; 95 West Cedar Street, Boston, MA 02116 (US). ARUFFO, Alejandro ; 12 Park Road, Belmont, MA 02178 (US). CAMERINI, David ; 99 Hancock Street, Cambridge, MA 02139 (US). LAUFFER, Leander ; 16 Brimmer Street, Boston, MA 02108 (US). OQUENDO, Carmen, Patricia ;		(74) Agents: GREENLEE, Lorraine, L. et al.; Greenlee and Associates, 5370 Manhattan Circle, Suite 201, Boulder, CO 80303 (US). (81) Designated States: AU, DK, FI, HU, JP, KR. Published <i>With international search report.</i>
(54) Title: RAPID IMMUNOSELECTION CLONING METHOD (57) Abstract A simple and highly efficient method for cloning cDNAs from mammalian expression libraries based on transient expression in mammalian host cells has been discovered. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are disclosed. The cloning method of the invention which has been used to clone genes for cell surface antigens of human lymphocytes, has general application in gene cloning. Cell surface antigens cloned according to the present invention have been purified, and the nucleotide and amino acid sequences determined. These antigens have diagnostic and therapeutic utility in immune-mediated infections in mammals, including humans.		

THIS PAGE BLANK (USPTO)

-1-

RAPID IMMUNOSELECTION CLONING METHODBackground

A basic tool in the field of recombinant genetics is the conversion of poly(A)⁺ mRNA to double-stranded (ds) cDNA, which then can be inserted into a cloning vector and expressed in an appropriate host cell. Molecular cloning methods for ds cDNA have been reviewed, for example, by Williams, "The Preparation and Screening of a cDNA Clone Bank," in Williamson, ed., Genetic Engineering, Vol. 1, p. 2, Academic Press, New York (1981); Maniatis, "Recombinant DNA", in Prescott, ed., Cell Biology, Academic Press, New York (1980); and Efstratiadis et al., "Cloning of Double-Stranded DNA," in Stelo et al., Genetic Engineering, Vol. 1, p. 15, Plenum Press, New York (1979).

A substantial number of variables affect the successful cloning of a particular gene and cDNA cloning strategy thus must be chosen with care. A method common to many cDNA cloning strategies involves the construction of a "cDNA library" which is a collection of cDNA clones derived from the total poly(A)⁺ mRNA derived from a cell of the organism of interest.

A mammalian cell may contain up to 30,000 different mRNA sequences, and the number of clones required to obtain low-abundance mRNAs, for example, may be much greater. Methods of constructing genomic eukaryotic DNA libraries in different expression vectors, including bacteriophage λ , cosmids, and viral vectors, are known. Some commonly used methods are described, for example, in Maniatis et al., Molecular Cloning: A Laboratory Manual,

-2-

Cold Spring Harbor Laboratory, publisher, Cold Spring Harbor, New York (1982).

Once a genomic cDNA library has been constructed, it is necessary to isolate from the thousands of host cells the cell containing the particular human gene of interest. Many different methods of isolating target genes from cDNA libraries have been utilized, with varying success. These include, for example, the use of nucleic acid probes, which are labeled mRNA fragments having nucleic acid sequences complementary to the DNA sequence of the target gene. When this method is applied to cDNA clones of abundant mRNAs in transformed bacterial hosts, colonies hybridizing strongly to the probe are likely to contain the target DNA sequences. The identity of the clone then may be proven, for example, by in situ hybridization/selection (Goldberg et al., Methods Enzymol., 68:206 (1979)) hybrid-arrested translation (Paterson et al., Proceedings of the National Academy of Sciences, 74:4370 (1977)), or direct DNA sequencing (Maxam and Gilbert, Proceedings of the National Academy of Sciences, 74:560 (1977); Maat and Smith, Nucleic Acids Res., 5:4537 (1978)).

Such methods, however, have major drawbacks when the object is to clone mRNAs of relatively low abundance from cDNA libraries. For example, using direct in situ colony hybridization, it is very difficult to detect clones containing cDNA complementary to mRNA species present in the initial library population at less than one part in 200. As a result, various methods for enriching mRNA in the total population (e.g. size fractionation, use of synthetic oligodeoxynucleotides, differential hybridization, or immunopurification) have been developed

-3-

and are often used when low abundance mRNAs are cloned. Such methods are described, for example, in Maniatis et al., Molecular Cloning: A Laboratory Manual, supra.

Many functional eukaryotic proteins initially exist
05 in the form of precursor molecules which contain leader or signal sequences at their N-terminal ends. These leader sequences bind to the cell membrane and draw the remainder of the protein through the lipid bilayer, after which the signal sequence is cleaved from the protein by
10 a signal peptidase enzyme. The protein thus functions only after secretion from the cells (for example, insulin, serum albumin, antibodies, and digestive tract enzymes), or after the proteins have been anchored to the outer surface of a cell membrane (for example, histocom-
15 patibility antigens).

The cell surface antigens characteristic of mammalian T lymphocytes are additional examples of proteins that anchor to the cell surface. In mammals, certain cells derived from bone marrow mature into
20 lymphocytes, which are present in the lymphoid organs, including the thymus, spleen, lymph nodes, and lymphoid aggregates, and also circulate actively through the blood and lymph systems. Mature lymphocyte cells may be divided into two populations: thymus-dependent (T)
25 lymphocytes and thymus-independent (B) lymphocytes. T lymphocytes migrate to the interior of the thymus, where they undergo differentiative proliferation. During their differentiation process, they express characteristic cell surface membrane alloantigens, including Thy-1, TLA,
30 gv-1, Ly-1, Ly-2, Ly-3, and Ly-5. As they mature, T lymphocytes lose the TLA antigens and some of the Thy-1 antigens, and gain histocompatibility antigens, acquiring

-4-

the membrane conformation typical of the recirculating T lymphocytes. This is described, for example, by Mota, "Activity of Immune Cells," in Bier et al., eds., Fundamentals of Immunology, 2d Ed., Springer-Verlag, Berlin, pp. 35-62 (1986).

T lymphocytes are involved indirectly in the formation of antibodies and their activities thus have required complex analysis of cell function, rather than simple antibody titer measurement. Partly due to this, their importance in development of immunologic competence was not recognized until relatively recently. Mature T lymphocytes synthesize and express an unique pattern of surface glycoprotein antigens which serve as markers for identification of different T lymphocyte subpopulations, including T helper cells, T suppressor cells, and T cytotoxic cells. Each of these subpopulations plays a very important role in regulating the immune system. (Mota, supra).

In humans, the functional and phenotypic heterogeneity of T lymphocytes is well accepted. Two major subpopulations are known: effector T cells mediating cellular immunity; and regulator T cells containing helper and suppressor T lymphocytes. These two subpopulations have been defined with heteroantisera, autoantibodies, and monoclonal antibodies directed at cell surface antigens. For example, earlier in their development, human lymphoid cells in the thymus express an antigen designated T11 which reacts strongly to a monoclonal antibody designated Cluster of Differentiation 2 (CD2), and react slightly with monoclonal antibody CD5 to cell surface antigen T1. During maturation, these cells lose T11 (CD2) and acquire three new antigens defined by monoclonal antibodies CD4,

-5-

CD8, and CD1. With further maturation, the thymocytes cease to express cell surface antigens reactive with monoclonal antibody CD1, express the T3 antigen reactive with monoclonal antibody CD3, and then segregate into two subpopulations which express either T4 (CD4) or T8 (CD8) antigen. Immunologic competence is acquired at this stage, but is not completely developed until thymic lymphocytes migrate outside the thymus. (Mota, supra.) In contrast with the majority of thymocytes, circulating T lymphocytes express the T1 (CD5) and T3 (CD3) antigens. The T4 (CD4) antigen is present on approximately 55-65% of peripheral T lymphocytes, whereas the T8 (CD8) antigen is expressed on 20-30%. These two subpopulations correspond to helper and to suppressor and cytotoxic T cells, respectively.

In addition to providing a convenient means of distinguishing T lymphocyte subpopulations, these cell surface antigens are important for mature T cell activation and effector function. T cell activation involves a complex series of cell surface interactions between the T cell and the target cell or stimulator cell in addition to binding of the T cell receptor to its specific antigen.

For example, CD2, the human T cell erythrocyte receptor, allows thymocytes and T-lymphocytes to adhere to target cells (e.g., erythrocytes) and to thymic epithelium. This occurs via a specific molecular ligand for CD2, designated LFA-3, in humans, which is a widely distributed surface antigen. This phenomenon has long been employed to detect, assay and purify human cells producing antibodies to sheep erythrocytes and serves as the basis for the E-rosette test, first described by

-6-

- Zaalberg, Nature, 202:1231 (1964). CD2/LFA-3 interactions also have been shown to mediate cytolytic target conjugation (Shaw et al., Nature, 323:262-264 (1986), and the mixed lymphocyte reaction (Märting et al., 05 J. Immunol., 131:180-185 (1983). Anti-CD2 monoclonal antibodies can directly activate peripheral T-lymphocytes via an antigen-independent pathway (Meuer et al., Cell, 36:897-906 (1984), indicating an even wider immunoregulatory role for CD2.
- 10 Recognition that T lymphocytes are the main effectors of cell-mediated immunity and also are involved as helper or suppressor cells in modulating the immune response has resulted in a significant contribution to the increasing practical application of clinical 15 immunology to medicine. The scope of this application includes defense against infections, prevention of diseases by immunization, organ transplantation, blood banking, deficiencies of the immune system, and a variety of disorders that are mediated by immunologic mechanisms. 20 Moreover, immunologic techniques frequently are used in the clinical laboratory, as in the measurement of hormones and drugs. Clinical immunology is described, for example, in Weir, ed., Handbook of Experimental Immunology in Four Volumes: Volume 4: Applications of 25 Immunological Methods in Biomedical Sciences, 4th Ed., Blackwell Scientific Publications, Oxford (1986); Boguslaski et al., eds., Clinical Immunochemistry: Principles of Methods and Applications, Little, Brown & Co., Boston (1984); Holborow et al., eds., Immunology in 30 Medicine: A Comprehensive Guide to Clinical Immunology, 2d Ed., Grune & Stratton, London (1983); and Petersdorf et al., eds., Harrison's Principles of Internal Medicine,

-7-

10th ed., McGraw-Hill, New York, publisher, pp. 344-391 (1983). Clearly, a more thorough understanding of the proteins which mediate the immune system would be of significant value in clinical immunology.

05 Use of mammalian expression libraries to isolate cDNAs encoding mammalian proteins such as those described above would offer several advantages. For example, the protein expressed in a mammalian host cell should be functional and should undergo any normal
10 posttranslational modification. A protein ordinarily transported through the intracellular membrane system to the cell surface should undergo the complete transport process. A mammalian expression system also would allow the study of intracellular transport mechanisms and of
15 the mechanism that insert and anchor cell surface proteins to membranes.

One common mammalian host cell, called a "COS" cell, is formed by infecting monkey kidney cells with a mutant viral vector, designated simian virus strain 40 (SV40),
20 which has functional early and late genes, but lacks a functional origin of replication. In COS cells, any foreign DNA cloned on a vector containing the SV40 origin of replication will replicate because SV40 T antigen is present in COS cells. The foreign DNA will replicate
25 transiently, independently of the cellular DNA.

With the exception of some recent lymphokine cDNAs isolated by expression in COS cells (Wong, G.G., et al., Science, 228:810-815 (1985); Lee, F. et al., Proceedings of the National Academy of Sciences, USA, 83:2061-2065
30 (1986); Yokota, T., et al., Proceedings of the National Academy of Sciences, USA, 83:5894-5898 (1986); Yang, Y., et al., Cell, 47:3-10 (1986)), however, few cDNAs in

-8-

general are isolated from mammalian expression libraries. There appear to be two principal reasons for this: First, the existing technology (Okayama, H. et al., Mol. Cell. Biol., 2:161-170 (1982)) for construction of large
05 plasmid libraries is difficult to master, and library size rarely approaches that accessible by phage cloning techniques. (Huynh, T. et al., In: DNA Cloning Vol. I, A Practical Approach, Glover, D.M. (ed.), IRL Press, Oxford (1985), pp. 49-78). Second, the existing vectors are,
10 with one exception (Wong, G.G., et al., Science, 228:810-815 (1985)), poorly adapted for high level expression, particularly in COS cells. The reported successes with lymphokine cDNAs do not imply a general fitness of the methods used, since these cDNAs are
15 particularly easy to isolate from expression libraries. Lymphokine bioassays are very sensitive ((Wong, G.G., et al., Science, 228:810-815 (1985); Lee, F. et al., Proceedings of the National Academy of Sciences, USA, 83:2061-2065 (1986); Yokota, T. et al., Proceedings of
20 the National Academy of Sciences, USA, 83:5894-5898 (1986); Yang, Y. et al., Cell, 47:3-10 (1986)) and the mRNAs are typically both abundant and short (Wong, G.G. et al., Science, 228:810-815 (1985); Lee, F., et al., Proceedings of the National Academy of Sciences, USA,
25 83:2061-2065 (1986); Yokota, T., et al. Proceedings of the National Academy of Sciences, USA, 83:5894-5898 (1986); Yang, Y., et al., Cell, 47:3-10 (1986)).

Thus, expression in mammalian hosts previously has been most frequently employed solely as a means of
30 verifying the identity of the protein encoded by a gene isolated by more traditional cloning methods. For example, Stuve et al., J. Virol., 61(2):327-335 (1987),

-9-

cloned the gene for glycoprotein gB2 of herpes simplex type II strain 333 by plaque hybridization of M13-based recombinant phage vectors used to transform competent E. coli JM101. The identity of the protein encoded by the clone thus isolated was verified by transfection of mammalian COS and Chinese hamster ovary (CHO) cells. Expression was demonstrated by immunofluorescence and radioimmunoprecipitation.

Oshima et al. used plaque hybridization to screen a phage lambda gt11 cDNA library for the gene encoding human placental beta-glucuronidase. Oshima et al., Proceedings of the National Academy of Sciences, U.S.A., 84:685-689 (1987). The identity of isolated cDNA clones was verified by immunoprecipitation of the protein expressed by COS-7 cells transfected with cloned inserts using the SV40 late promoter.

Transient expression in mammalian cells has been employed as a means of confirming the identity of genes previously isolated by other screening methods. Gerald et al., Journal of General Virology, 67:2695-2703 (1986). Mackenzie, Journal of Biological Chemistry, 261:14112-14117 (1986); Seif et al., Gene, 43:1111-1121 (1986); Orkin et al., Molecular and Cellular Biology, 5(4):762-767 (1985). These methods often are inefficient and tedious and require multiple rounds of screening to identify full-length or overlapping clones. Prior screening methods based upon expression of fusion proteins are inefficient and require large quantities of monoclonal antibodies. Such drawbacks are compounded by use of inefficient expression vectors, which result in protein expression levels that are inadequate to enable efficient selection.

-10-

Summary of the Invention

The present invention relates to a powerful new method for cloning cDNA encoding cell surface antigens, to a method of constructing cDNA libraries to high efficiency expression vectors particularly suited for high level expression in eukaryotic host cells, and to the isolated nucleotide sequences and their encoded products.

The highly efficient cloning technique of the present invention is based upon transient expression of antigen in eukaryotic cells and physical selection of cells expressing the antigen by adhesion to an antibody-coated substrate, such as a culture dish. The methods of the present invention are useful for the isolation and molecular cloning of any protein which can be expressed and transported to the cell surface membrane of a eukaryotic cell.

*Cell broth
for antibody*

The method for cloning cDNA encoding a cell surface antigen of the present invention comprises preparing a cDNA library; introducing this cDNA library into eukaryotic mammalian preferably tissue culture cells; culturing these cells under conditions allowing expression of the cell surface antigen; exposing the cells to a first antibody or antibodies directed against the cell surface antigen, thereby allowing the formation of a cell surface antigen-first antibody complex; subsequently exposing the cells to a substrate coated with a second antibody directed against the first antibody, thereby causing cells expressing the cell surface antigen to adhere to the substrate via the formation of a cell surface antigen-first antibody-second

-11-

antibody complex; and separating adherent from non-adherent cells.

By means of the cloning method of the present invention, isolation and molecular cloning of genes encoding such cell surface antigens as the following have been accomplished: the CD1a, CD1b, CD1c, CD2, CD6, CD7, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD28, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, LFA-3, FcRIa, FcRIb, TLIa, and Lev-8 antigens. The nucleotide sequences of genes cloned by the method of the present invention have been determined and the amino acid sequences of the encoded proteins have been identified. A cloned gene, such as that encoding CD1a, CD1b, CD1c, CD2, CD6, CD7, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD28, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, LFA-3, FcRIa, FcRIb, TLIa, and Lev-8, is also the subject of the present invention.

Once the gene encoding an antigen has been cloned according to the method of the present invention, that gene can be expressed in a prokaryotic or a eukaryotic host cell to produce the encoded protein or portion thereof in substantially pure form such as it does not exist in nature. Another aspect of the present invention relates to substantially pure cell surface antigens, particularly: CD1a, CD1b, CD1c, CD2, CD6, CD7, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD28, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, LFA-3, FcRIa, FcRIb, TLIa, and Lev-8 antigens and their functional analogues and equivalents. The primary amino acid sequences of the CD1a, CD1b, CD2, CD7, CD14, CD16, CD19, CD20, CD22, CD28, CDw32a, CDw32b,

-12-

CD33, CD34, CD40, ICAM, LFA-3, FcRIa, FcRIb and TLIa antigens have been determined. The invention thus also relates to the amino acid sequences of those antigens and their functional equivalents and to the nucleotide sequences encoding those antigens.

This invention also relates to high efficiency cDNA expression vectors which allow the generation of very large mammalian expression libraries and yield large amounts of protein in mammalian host cells, resulting in efficient selection. In a particular embodiment of this invention, a cDNA expression vector comprises a suppressor tRNA gene; an SV40 origin; a synthetic transcription unit, comprising a chimeric promoter composed of human cytomegalovirus AD169 immediate early enhancer sequencer fused to the HIV LTR -60 to +80 sequences, inserted between the suppressor tRNA gene and the SV40 origin; a polylinker comprising two BstXI sites separated by a replaceable DNA sequence and flanked by XbaI sites; and an SV40 small t antigen splice and early region polyadenylation signals.

A further aspect of the present invention comprises a synthetic transcription unit for use in a cDNA expression vector, comprising a chimeric promoter composed of human cytomegalovirus AD169 immediate early enhancer sequences fused to HIV LTR -60 to +80 sequences. The small size and particular arrangement of the sequences of the cDNA expression vector of the present invention allow highly efficient replication in host mammalian tissue culture cells, such as COS cells. Moreover, this vector employs a polylinker containing two inverted BstXI sites separated by a short replaceable DNA segment, which

-13-

allows the use of very efficient oligonucleotide-based cDNA insertion strategy.

In another aspect, the present invention comprises a vector comprising two identical BstXI sites in inverted orientation each with respect to the other, which BstXI sites are separated by a short replaceable DNA fragment. Another aspect of the invention is a polylinker as described above.

A further aspect of the invention relates to an oligonucleotide-based cDNA insertion method, comprising ligating synthetic DNA oligonucleotides to the cDNA segment desired to be inserted into a vector, the synthetic DNA oligonucleotides giving the same terminal sequences as those of the short replaceable DNA fragment of the polylinker of the invention, and inserting the resulting cDNA segment plus synthetic DNA oligonucleotide terminal sequences into the polylinker of the vector, from which the short replaceable DNA fragment previously has been removed.

In preparing cDNA libraries according to the present invention, it has been discovered that many tumors are heavily infiltrated by macrophages and lymphocytes, and thus may be employed as a source of macrophage or lymphocyte transcripts to good effect, instead of tumor cell lines commonly used. In another aspect, then, the present invention relates to the use of tumor cells, particularly human tumor cells, to prepare cDNA libraries for use according to the methods of the present invention.

Another advantage of the powerful selection system of the present invention is that directional insertion of the cDNA is not necessary. The method of the present

-14-

invention results in library construction efficiencies which are on a par with those described for phage vectors such as λ gt10 and λ gt11, with the additional advantage that clones generated according to the methods of the present invention are easier to manipulate.

The immunoselection technique of the present invention allows efficient use of antibodies, which may be monoclonal or polyclonal, in relatively small absolute amounts. The method of the present invention also is quite rapid. Generally, three or fewer cycles of immunoselection and rescue are required to isolate a target cDNA clone. Thus, the method of the present invention also results in the efficient use of labor and materials when cloning genes encoding cell surface antigens. As described above, this method has been employed to successfully clone genes encoding cell surface antigens associated with mammalian T lymphocytes (e.g. antigens CD1a, CD1b, CD1c, CD2, CD6, CD7, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD28, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, LFA-3, FcRIa, FcRIb, TLIa, and Lev-8).

The purified genes and proteins of the present invention are useful for immunodiagnostic and immunotherapeutic applications, including the diagnosis and treatment of immune-mediated infections, diseases, and disorders in animals, including humans. They can also be used to identify, isolate and purify other antibodies and antigens. Such diagnostic and therapeutic uses comprise yet another aspect of the present invention. Moreover, the substantially pure proteins of the present invention may be prepared as medicaments or pharmaceutical compositions for therapeutic administration. The present

-15-

invention further relates to such medicaments and compositions.

Brief Description of the Drawings

Figure 1. Nucleotide sequence of expression vector piH3

05 Nucleotides 1-589 are derived from pMB1 origin (pBR322 ori); nucleotides 590-597 are derived from the SacII linker (ACCGCGT); nucleotides 598-799 are derived from the synthetic tyrosine suppressor tRNA gene (supF gene); nucleotides 800-947 are derived from a remnant of
10 the ASV LTR fragment (PvuII to MluI); nucleotides 948-1500 are derived from the human cytomegalovirus AD169 enhancer; nucleotides 1501-1650 are derived from HIV TATA and tat-responsive elements; nucleotides 1651-1716 are derived from the piLNxAN polylinker (HindIII to Xba);
15 nucleotides 1717-2569 are derived from pSV to splice and poly-Addition signals; nucleotides 2570-2917 are derived from the SV40 origin of replication (pvuII to (HindIII); and nucleotides 2918-2922 are derived from piVX, remnant of R1 site from polylinker.

20 Figure 2. Nucleotide sequence of the CD2cDNA insert

Nucleotide numbering is given in parentheses at right, amino acid numbering, center and left. Locations of the potential sites for addition of asparagine-linked carbohydrate (CHO) are shown, as well as the predicted
25 transmembrane (TM) sequence. The amino acid sequence is numbered from the projected cleavage site of the secretory signal sequence. Proline residues are underscored with asterisks. The presumed polyadenylation signal for the 1.65kb transcript, and a possible

-16-

polyadenylation signal for the 1.3kb transcript, are shown boxed.

Figure 3. Restriction map of the CDM8 expression vector

05 The CDM8 vector includes a deleted version of a mutant polyoma virus early region selected for high efficiency expression in both murine and monkey cells. Substantially all of the human immunodeficiency promoter region has been replaced with the cognate sequences of the human cytomegalovirus immediate early promoter, and
10 by inclusion of a bacteriophage T7 promoter between the eukaryotic promoter and the site of cDNA insertion. Arrows indicate the direction of transcription.

Figure 4. Nucleotide sequence and corresponding amino acid sequence of the LFA-3 antigen

15 WOP cells transfected with a clone encoding the LFA-3 antigen were detected by indirect immunofluorescence, amplified and sequenced. (A) shows the 874 base pair insert containing an open reading frame of 237 residues originating at a methionine codon, and
20 terminating in a series of hydrophobic residues. Hydrophobic and hydrophilic regions within this open reading frame are shown in (B).

Figure 5. Restriction Map of the piH3M vector

25 The direction of transcription is indicated by an arrow. Restriction endonuclease sites flanking the BstXI cloning sites are shown.

-17-

Figure 6. Nucleotide sequence of the piH3M vector

There are 7 segments. Residues 1-587 are from the pBR322 origin of replication, 588-1182 from the M13 origin, 1183-1384 from the supF gene, 1385-2238 are from the chimeric cytomegalovirus/human immunodeficiency virus promoter, 2239-2647 are from the replaceable fragment, 2648-3547 from plasmid pSV2 (splice and polyadenylation signals), and 3548-3900 from the SV40 virus origin.

Figure 7. Nucleotide sequence of the CD28 cDNA

Nucleotide numbering is given in parentheses at right, amino acid numbering, center and left. Location of the potential sites for addition of asparagine-linked carbohydrate (CHO) are shown, as well as the predicted transmembrane (TM) sequence. The amino acid sequence is numbered from the projected cleavage site of the secretory signal sequence. The presumed polyadenylation signal is shown boxed.

Figure 8. Nucleotide sequence of the CD7 cDNA insert

Nucleotide numbering is given in parentheses at right. The amino acid sequence is numbered from the projected cleavage site of the secretory signal sequence. Splice donor and acceptor sites indicated by (/). The location of the potential sites for addition of asparagine-linked carbohydrate (CHO) are shown, the potential fatty acid esterification site is denoted (*), and the predicted transmembrane domain (TM) is underlined. Nucleotide sequences potentially involved in hairpin formation are denoted by (.). The presumed polyadenylation signal is underlined.

-18-

Figure 9. Nucleotide sequence of the CDw32 cDNA

Nucleotide number is given in the parenthesis at right, amino acid numbering, center and left. Locations of the potential sites for addition of asparagine-linked carbohydrate (CHO) are shown, as well as the predicted transmembrane (TM) sequence. The amino acid sequence is numbered from the projected cleavage site of the secretory signal sequence. Cysteine residues are underscored with asterisks.

10 Figure 10. Sequence of the CD20.4 cDNA

A. The sites of potential N-linked glycosylation are denoted by the symbol -CHO-: the hydrophobic regions are underscored. The site of the poly(A)⁺ tail in clone CD20.6 is denoted by an asterisk.

15 B. Hydrophobicity profile of the amino acid sequence in A.

Figure 11. Sequence of ICAM-1

Complete nucleotide sequence of ICAM-1 cDNA insert and predicted protein sequence. Nucleotide numbering is at right, amino acid numbering in parentheses at left. The RGE motif at position 152 is underlined, the potential N-linked glycosylation sites are indicated by -CHO- and the transmembrane domain by -TM-. The amino acid sequence is numbered from the projected cleavage site of the signal peptide. Sequencing was by dideoxy-chain termination (Sanger, F., et al., Proc. Natl. Acad. Sci. USA, 74:5463-5467 (1977)), using a combination of subclones, and specific oligonucleotides.

Figure 12. Nucleotide sequence of CD19

-19-

Figure 13. Nucleotide sequence of CD20

Figure 14. Nucleotide sequence of CD22

Figure 15. Nucleotide sequence of CDw32a

Figure 16. Nucleotide sequence of CDw32b

05 Figure 17. Nucleotide sequence of CD40

Detailed Description of the Invention

This invention relates to a novel method for cloning cDNA encoding a cell surface antigen and to a method of constructing cDNA libraries. It also relates to
10 particular cDNA expression vectors and components thereof, nucleotide sequences or genes isolated by the method, substantially pure cell surface antigens encoded by the cDNA segments, and methods of using the isolated nucleotide sequences and encoded products.

15 In the following description, reference will be made to various methodologies known to those of skill in the art of recombinant genetics. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in
20 their entireties.

Standard reference works setting forth the general principles of recombinant DNA technology include Darnell, J.E. et al., Molecular Cell Biology, Scientific American Books, Inc., publisher, New York, N.Y. (1986); Lewin,
25 B.M., Genes II, John Wiley & Sons, publisher, New York, N.Y. (1985); Old, R.W. et al., Principles of Gene Manipulation: An Introduction to Genetic Engineering, 2d

-20-

edition, University of California Press, Berkeley, CA (1981); and Maniatis, T. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY (1982).

By "cloning" is meant the use of in vitro recombination techniques to insert a particular gene or other DNA sequence into a vector molecule. In order to successfully clone a desired gene, it is necessary to employ methods for generating DNA fragments, for joining the fragments to vector molecules, for introducing the composite DNA molecule into a host cell in which it can replicate, and for selecting the clone having the target gene from amongst the recipient host cells.

By "cDNA" is meant complementary or copy DNA produced from an RNA template by the action of RNA-dependent DNA polymerase (reverse transcriptase). Thus a "cDNA clone" means a duplex DNA sequence complementary to an RNA molecule of interest, carried in a cloning vector.

By "cDNA library" is meant a collection of recombinant DNA molecules containing cDNA inserts which together comprise the entire genome of an organism. Such a cDNA library may be prepared by art-recognized methods described, for example, in Maniatis et al., Molecular Cloning: A Laboratory Manual, supra. Generally, RNA is first isolated from the cells of an organism from whose genome it is desired to clone a particular gene. Preferred for the purposes of the present invention are mammalian, and particularly human, cell lines. More preferred are the human tumor cell line HPB-ALL and the human lymphoblastoid cell line JY. Alternatively, RNA can be isolated from a tumor cell, derived from an animal tumor, and preferably from a human tumor. Thus, a

-21-

library may be prepared from, for example, a human adrenal tumor, but any tumor may be used.

The immunoselection cloning method of the present invention comprises the preparation of a cDNA library by extracting total RNA including a particular gene from a cell, synthesizing a series of complementary double-stranded cDNA fragments from the RNA and introducing these cDNA fragments into mammalian cells in tissue culture. The mammalian cells are maintained under conditions which allow them to express the protein (i.e. the cell surface antigen). The resulting cells are exposed to a first antibody or pool (group) of antibodies directed against the cell surface antigen. This results in formation of a cell surface antigen-first antibody complex. The complexes are exposed to a substrate to which is coated or bound a second antibody directed against the first antibody. Cells expressing the cell surface antigen adhere to the substrate (because of formation of a cell surface antigen-first antibody-second antibody complex). Adherent cells are separated from non-adherent cells.

Isolation of total RNA

The guanidium thiocyanate/CsCl method of isolating total RNA is preferred. More preferred is a guanidium thiocyanate/LiCl variant of the GuSCN/CsCl method, which has added capacity and speed. Briefly, for each ml of mix desired, 0.5g GuSCN are dissolved in 0.58ml of 25% LiCl (stock filtered through 0.45 micron filter) and 20ul of mercaptoethanol is added. Cells are spun out and the pellet is dispersed on walls by flicking, add 1ml of solution to up to 5×10^7 cells. The resulting

-22-

combination is sheared by polytron until nonviscous. For small scale preps (less than 10^8 cells) layer 2ml of sheared mix on 1.5ml of 5.7M CsCl (RNase free; 1.26g CsCl added to every ml 10mM EDTA pH 8), overlay with
05 RNase-free water and spin SW55 50krpm 2h. For large scale preps, layer 25ml on 12ml CsCl in a SW28 tube, overlay, and spin 24k rpm 8h. Aspirate contents carefully with a sterile pasteur pipet connected to a vacuum flask. Once past the CsCl interface, scratch a
10 band around the tube with the pipet tip to prevent the layer on the wall of the tube from creeping down. The remaining CsCl solution is aspirated. The pellets are taken up in water (do not try to redissolve). 1/10 vol. NaOAc and 3 vol. EtOH are added and the resulting
15 combination is spun. If necessary, the pellet is resuspended in water (e.g., at 70°). Adjust concentration to 1mg/ml and freeze. Small RNA (e.g. 5S) does not come down. For small amounts of cells, scale down volumes and overlay GuSCN with RNase-free water on
20 gradient (precipitation is inefficient when RNA is dilute).

Preparation of poly A⁺ RNA

Next, polyA⁺ RNA may be prepared, preferably by the oligo dT selection method. Briefly, a disposable
25 polypropylene column is prepared by washing with 5M NaOH and then rinsing with RNase-free water. For each milligram total RNA about 0.3 ml (final packed bed) oligo dT cellulose is used. Oligo dT cellulose is prepared by resuspending about 0.5 ml of dry powder in 1 ml of 0.1M
30 NaOH and transferring it into the column, or by percolating 0.1 NaOH through a previously used column

-23-

(columns can be reused many times). This is washed with several column volumes of RNase-free water, until pH is neutral, and rinsed with 2-3 ml of loading buffer. The column bed is then removed into a sterile 15ml tube using 05 4-6 ml of loading buffer. The total RNA is heated to 70°C for 2-3 min., LiCl from RNase-free stock is added (to 0.5M), and combined with oligo dT cellulose in a 15 ml tube. This is followed by vortexing or agitation for 10 min. The result is poured into a column and washed with 3 ml 10 loading buffer and then 3 ml of middle wash buffer. mRNA is eluted directly into an SW55 tube with 1.5 ml of 2mM EDTA, 0.1% SDS; the first two or three drops are discarded.

Eluted mRNA is precipitated by adding 1/10 vol. 3M 15 NaOAc and filling the tube with EtOH. This is then mixed, chilled for 30 minutes at -20°C, and spun at 50k rpm at 5°C for 30 min. The EtOH is poured off and the tube is air dried. The mRNA pellet is resuspended in 50-100ul of RNase-free water. Approximately 5 ul is 20 melted at 70° in MOPS/EDTA/formaldehyde and run on an RNase-free 1% agarose gel to check quality.

cDNA Synthesis

From this, cDNA is synthesized. A preferred method of cDNA synthesis is a variant of that described by 25 Gubler and Hoffman (Gene 25:263-269 (1982)). This is carried out as follows:

a. First Strand. 4 ug of mRNA is heated to about 100°C in a microfuge tube for 30 seconds and quenched on ice. The volume is adjusted to 70 ul with 30 RNase-free water. The following are added: 20 ul of RT1 buffer, 2 ul of RNase inhibitor (Boehringer 36 u/ul), 1

-24-

ul of 5 ug/ul of oligo dT (Collaborative Research), 2.5
ul of 20 mM dXTP's (ultrapure), 1 ul of 1 M DTT and 4 ul
of RT-LX (Life Science, 24 u/ul). The resulting
combination is incubated at 42°C for 40 min. It is
05 heated to inactivate (70°C 10 min).

b. Second Strand. 320 ul of RNase free
water, 80 ul of RT2 buffer, 5 ul of DNA Polymerase I
(Boehringer, 5 U/ul), 2 ul RNase H (BRL 2 u/ul). Incu-
bate at 15°C for 1 hr and 22°C for 1 hr. Add 20 ul of
10 0.5M EDTA pH 8.0, phenol extract and EtOH precipitate by
adding NaCl to 0.5M, linear polyacrylamide (carrier) to
20ug/ml, and filling tube with EtOH. Spin 2-3 minutes in
microfuge, remove, vortex to dislodge precipitate high up
on wall of tube, and respin 1 minute.

15 c. Adaptors. Resuspend precipitated cDNA in
240 ul of TE (10/1). Add 30ul of 10x low salt buffer,
30ul of 10X low salt buffer, 30ul of 10X ligation
additions, 3ul (2.4ug) of kinased 12-mer adaptor, 2ul
(1.6ug) of kinased 8-mer adaptor, and 1 ul of T4 DNA
20 ligase (BioLabs, 400 u/ul, or Boehringer, 1 Weiss
unit/ml). Incubate at 15°C overnight. Phenol extract
and EtOH precipitate as above (no extra carrier now
needed), and resuspend in 100 ul of TE.

Use of cDNA fragments in expression vectors

25 For use with the BstXI-based cDNA expression vectors
of the invention, (see infra) oligonucleotide segments
containing terminal sequences corresponding to BstXI
sites on the vectors are ligated to the cDNA fragment
desired to be inserted. The resulting fragments are
30 pooled by fractionation. A preferred method is as
follows:

-25-

Prepare a 20% KOA, 2mM EDTA, 1 ug/ml EthBr solution and a 5% KOAc, 2mM EDTA, 1 ug/ml EthBr solution. Add 2.6 ml of 20% KOAc solution to back chamber of a small gradient maker. Remove air bubble from tube connecting the two chambers by allowing solution to flow into the front chamber and then tilt back. Close passage between chambers, and add 2.5ml. of the 5% solution to the front chamber. If there is liquid in the tubing from a previous run, allow the 5% solution to run just to the end of the tubing, and then return to chamber. Place the apparatus on a stirplate, set the stir bar moving as fast as possible, open the stopcock connecting the two chambers and then open the front stopcock. Fill a polyallomer SW55 tube from the bottom with the KOAc solution. Overlay the gradient with 100 ul of cDNA solution. Prepare a balance tube and spin the gradient for 3 hrs at 50k rpm at 22°C. To collect fractions from the gradient, pierce the SW55 tube with a butterfly infusion set (with the luer hub clipped off) close to the bottom of the tube and collect three 0.5ml fractions and then 6 0.25ml fractions into microfuge tubes (about 22 and 11 drops respectively). EtOH precipitate the fractions by adding linear polyacrylamide to 20 ug/ml and filling the tube to the top with EtOH. After cooling tubes, spin them in a microfuge for 3 min. Vortex and respin 1 min. Rinse pellets with 70% EtOH (respin). Do not dry to completion. Resuspend each 0.25ml fraction in 10 ul of TE. Run 1 ul on a 1% agarose minigel. Pool the first three fractions, and those of the last six which contain no material smaller than 1kb.

Suppressor tRNA plasmids may be propagated by known methods. In a preferred method according to the present

-26-

invention, supF plasmids can be selected in nonsuppressing hosts containing a second plasmid, p3, which contains amber mutated ampicillin and tetracycline drug resistance elements (Seed, 1983). The p3 plasmid is derived from PR1, is 57kb in length, and is a stably maintained, single copy episome. The ampicillin resistance of this plasmid reverts at a high rate, so that amp^r plasmids usually cannot be used in p3-containing strains. Selection for tet resistance alone is almost as good as selection for ammp+tet resistance. However, spontaneous appearance of chromosomal suppressor tRNA mutations presents an unavoidable background (frequency about 10⁻⁹) in this system. Colonies arising from spontaneous suppressor mutations are usually bigger than colonies arising from plasmid transformation. Suppressor plasmids typically are selected for in LB medium containing amp at 12.5 ug/ml and tet at 7.5 ug/ml. For large plasmid preps, M9 casamino acids medium containing glycerol (0.8%) may be used as a carbon source, and the bacteria grown to saturation.

Vector DNA may be isolated by known methods. The following method is preferred for plasmid from 1 liter of saturated cells:

Spin down cells in 1 liter J6 bottles, 4.2k rpm, 25 minutes. Resuspend in 40 ml 10mM EDTA pH 8 (Thump on soft surface). Add 80 ml 0.2M NaOH, 1% SDS, swirl until clearish, viscous. Add 40 ml 5M KOAc, pH4.7 (2.5M KOAc, 2.5M HOAc) shake semi-vigorously (until lumps are 2-3 mm in size). Spin (same bottle) 4.2 rpm, 5 min. Pour supernatant through cheesecloth into 250 ml bottle. Fill bottle with isopropyl alcohol. Spin J6, 4.2k rpm, 5 min. Drain bottle, rinse gently with 70% EtOH (avoid

-27-

fragmenting the pellet). Invert bottle, and remove traces of EtOH with Kimwipe. Resuspend in 3.5 ml Tris base/EDTA 20mM/10mM. Add 3.75 ml of resuspended pellet to 4.5g CsCl. Add 0.75 ml 10/mg/ml ethidium bromide, mix. Fill VTi80 tubes with solution. Run at a speed of 80 rpm for 2.5 hours or longer. Extract bands by visible light with 1 ml syringe and 20 gauge or lower needle. Cut top off tube, insert the needle upwards into the tube at an angle of about 30° with respect to the tube, (i.e., as shallowly possible) at a position about 3mm beneath the band, with the bevel of the needle up. After the band is removed, pour tube contents into bleach. Deposit extracted bands in 13 ml Sarstedt tube. Fill tube to top with n-butanol saturated with 1M NaCl, extract. If a very large quantity of DNA is obtained, reextract. Aspirate butanol into trap containing 5M NaOH (to destroy ethidium). Add about equal volume 1M ammonium acetate to DNA (squirt bottle). Add about 2 volumes 95% ethanol (squirt bottle). Spin 10K rpm, 5 min. J2-21. Rinse pellet carefully with 70% ethanol. Dry with swab, or lyophilizer.

The vector may be prepared for cloning by known methods. A preferred method begins with cutting 20 ug of vector in a 200 ul reaction with 100 units of BstXI (New York Biolabs), cutting at 50°C overnight in a well-thermostatted water bath (i.e., circulating water bath). Prepare 2 KOAc 5-20% gradients in SW55 tubes as described above. Add 100 ul of the digested vector to each tube and run for 3 hrs, 50K rpm at 22°C. Examine the tube under 300nm UV light. The desired band will have migrated 2/3 of the length of the tube. Forward trailing of the band means the gradient is overloaded.

-28-

Remove the band with a 1 ml syringe and 20 gauge needle. Add linear polyacrylamide and precipitate the plasmid by adding 3 volumes of EtOH. Resuspend in 50 ul of TE. Set up ligations using a constant amount of vector and increasing amounts of cDNAs. On the basis of these trial ligations, set up large scale ligation, which can be accomplished by known methods. Usually the entire cDNA prep requires 1-2 ug of cut vector.

Adaptors may be prepared by known methods, but it is preferred to resuspend crude adaptors at a concentration of 1 ug/ul, add MgSO_4 to 10 mM, and precipitate by adding 5 volumes of EtOH. Rinse with 70% EtOH and resuspend in TE at a concentration of 1 ug/ul. To kinase take 25ul of resuspended adaptors, add 3ul of 10X kinasing buffer and 20 units of kinase; incubate 37°C overnight.

Preparation of buffers mentioned in the above description of preferred methods according to the present invention will be evident to those of skill. For convenience, preferred buffer compositions are as follows:

20	Loading Buffer:	0.5 M LiCl, 10mM Tris pH 7.5, 1mM EDTA 0.1% SDS.
	Middle Wash Buffer	0.15 M LiCl, 10mM Tris pH 7.5, 1mM EDTA 0.1% SDS.
25	Rt1 Buffer:	0.25 M Tris pH 8.8 (8.2 at 42°), 0.25 M KCl, 30 mM MgCl_2 .
	RT2 Buffer:	0.1 M Tris pH 7.5, 25 mM MgCl_2 , 0.5 M KCl, 0.25 mg/ml BSA, 50 mM DTT.
	10X Low Salt	60 mM Tris pH 7.5, 60 mM MgCl_2 , 50 mM NaCl, 2.5 mg/ml BSA 70 mM Me.
30	10X Ligation Additions:	1mM ATP, 20 mM DTT, 1 mg/ml BSA 10 mM spermidine.

-29-

10X Kinasing 0.5 M Tris pH 7.5, 10mM ATP, 20mM
Buffer: DTT, 10 mM spermidine, 1 mg/ml BSA
 100 mM MgCl₂.

By "vector" is meant a DNA molecule, derived from a
05 plasmid or bacteriophage, into which fragments of DNA may
be inserted or cloned. A vector will contain one or more
unique restriction sites, and may be capable of autono-
mous replication in a defined host or vehicle organism
such that the cloned sequence is reproducible. Thus, by
10 "DNA expression vector" is meant any autonomous element
capable of replicating in a host independently of the
host's chromosome, after additional sequences of DNA have
been incorporated into the autonomous element's genome.
Such DNA expression vectors include bacterial plasmids
15 and phages.

Preferred for the purposes of the present invention,
however, are viral vectors, such as those derived from
simian virus strain 40 (SV40). SV40 is a papovavirus
having a molecular weight of 28 Mdal, and containing a
20 circular double-stranded DNA molecule having a molecular
weight of 3 Mdal, which comprises the entire genome of
the virus. The entire nucleotide sequence of this
single, small, covalently closed circular DNA molecule
has been determined. Fiers et al., Nature 273:113-120
25 (1978); Reddy et al., Science 200:494-502 (1978). The
viral DNA of SV40 may be obtained in large quantities,
and the genomic regions responsible for various viral
functions have been accurately located with respect to a
detailed physical map of the DNA. Fiers et al., supra;
30 Reddy et al., supra. The viral genome of SV40 can
multiply vegetatively or as an integral part of cellular

-30-

chromosomes, and a wealth of information exists on the replication and expression of this genome.

Also preferred for the purposes of the present invention is a single-stranded bacteriophage cloning vehicle, designated M13, having a closed circular DNA genome of approximately 6.5 kb. An advantage of utilizing M13 as a cloning vehicle is that the phage particles released from infected cells contain single-stranded DNA homologous to only one of the two complementary strands of the cloned DNA, which therefore can be used as a template for DNA sequencing analysis.

Even more preferred for the purposes of the present invention are the expression vectors designated piH3, piH3M, and CDM8, deposited at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852. piH3 was deposited at the ATCC on _____, and has accession number ATCC _____. piH3M was deposited at the ATCC on _____, and has accession number ATCC _____. CDM8 was deposited at the ATCC on _____, and has accession number ATCC _____.

By "tissue culture" is meant the maintenance or growth of animal tissue cells in vitro so as to allow further differentiation and preservation of cell architecture or function or both. "Primary tissue cells" are those taken directly from a population consisting of cells of the same kind performing the same function in an organism. Treating such tissue cells with the proteolytic enzyme trypsin, for example, dissociates them into individual primary tissue cells that grow well when seeded onto culture plates at high densities. Cell cultures arising from multiplication of primary cells in

-31-

tissue culture are called "secondary cell cultures." Most secondary cells divide a finite number of times and then die. A few secondary cells, however, may pass through this "crisis period", after which they are able to multiply indefinitely to form a continuous "cell line." Cell lines often will contain extra chromosomes, and usually are abnormal in other respects as well. The immortality of these cells is a feature shared in common with cancer cells.

Preferred cell lines for use as tissue culture cells according to the present invention include the monkey kidney cell line, designated "COS." COS cells are those that have been transformed by SV40 DNA containing a functional early gene region but a defective origin of viral DNA replication. COS cell clone M6 is particularly preferred for use according to the method of the invention. Also preferred for the purposes of the present invention are murine "WOP" cells, which are NIH 3T3 cells transfected with polyoma origin deletion DNA. cDNA may be introduced into the host tissue culture cells of the present invention by any methods known to those of skill. Transfection may be accomplished by, for example, protoplast fusion by spheroplast fusion, or by the DEAE dextran method (Sussman et al., Cell. Biol. 4:1641-1643 (1984)).

If spheroplast fusion is employed, a preferred method is the following variant based on Sandri-Goldrin et al., Mol. Cell Bio. 1:743-752 (1981). Briefly, for example, a set of six fusions requires 100 ml of cells in broth. Grow cells containing amplifiable plasmid to OD₆₀₀=0.5 in LB. Add spectinomycin to 100 ug/ml (or chloramphenicol to 150 ug/ml). Continue incubation at

-32-

37°C with shaking for 10-16 hours. (Cells begin to lyse with prolonged incubation in spectinomycin or chloramphenicol medium). Spin down 100 ml of culture (JA14/GSA rotor, 250ml bottle) 5 min. at 10,000 rpm.

05 Drain well, resuspend pellet in bottle with 5ml cold 20% sucrose, 50mM Tris-HCL pH 8.0. Incubate on ice 5 min. Add 2 ml cold 0.25M EDTA pH 8.0, incubate 5 min. at 37°C (waterbath). Place on ice, check percent conversion to spheroplasts by microscopy. In flow hood, slowly add

10 20ml of cold DME/10% sucrose/10mM MgCl₂ (dropwise, ca. 2 drops per second). Remove media from cells plated the day before in 6cm dishes (50% confluent). Add 5ml of spheroplast suspension to each dish. Place dishes on top of tube carriers in swinging bucket centrifuge. Up to 6

15 dishes can be comfortably prepared at once. Dishes can be stacked on top of each other, but 3 in a stack is not advisable as the spheroplast layer on the top dish is often torn or detached after centrifugation. Spin at 1000xg 10 min. Force is calculated on the basis of the

20 radius to the bottom plate. Aspirate fluid from dishes carefully. Pipet 1.5-2ml 50% (w/w) PEG1450 (or PEG1000)/50% DME (no serum) into the center of the dish. If necessary, sweep the pipet tip around to ensure that the PEG spreads evenly and radially across the whole

25 dish. After PEG has been added to the last dish, prop all of the dishes up on their lids so that the PEG solution collects at the bottom. Aspirate the PEG. The thin layer of PEG that remains on the cells is sufficient to promote fusion; the layer remaining is easier to wash

30 off, and better cell viability can be obtained, than if the bulk of the PEG is left behind. After 90 to 120 seconds (PEG 1000) or 120 to 150 seconds (PEG 1450) of

-33-

contact with the PEG solution, pipet 1.5ml of DME (no serum) into the center of the dish. The PEG layer will be swept radially by the DME. Tilt the dishes and aspirate. Repeat the DME wash. Add 3ml of DME/10% serum containing 15 ug/ml gentamicin sulfate. Incubate 4-6 hours in incubator. Remove media and remaining bacterial suspension, add more media and incubate 2-3 days. Extensive washing of the cell layer to remove PEG tends to remove many of the cells without any substantial benefit. If the cells are allowed to sit in the second DME wash for a few minutes, most of the spheroplast layer will come up spontaneously; however it is preferred to wash briefly and allow the layer to come off in the complete medium at 37°C.

The PEG solution can be conveniently prepared by melting a fresh bottle of PEG at 60°C and pouring approximate 50 ml aliquots by means of a 50 ml centrifuge tube into preweighed bottles. The aliquoted PEG is stored at 5°C in the dark. To make up a fresh bottle, weigh the aliquot, remelt, and add an equal volume of DME (no serum). Adjust the pH with 7.5% Na Bicarbonate solution if necessary, and filter sterilize. The resulting PEG solution may be stored up to 3 months at room temperature without detectable adverse consequence.

Transfected host cells will be cultured according to the invention in order to accomplish expression of the protein encoded by the cDNA clone, and to increase the absolute numbers of cells available for subsequent immunoselection. Those skilled in the art will know of appropriate methods and media for this purpose, taking into account the cell type and other variables routinely considered. COS cells, for example, may be cultured in

-34-

Dulbecco's modified Eagle's medium (DME) supplemented with 10% calf serum and gentamycin sulfate. Transient expression of transfected cells normally can be expected between 48 and 72 hours posttransfection. However, this
05 time period may vary depending upon the type or strain of host cell used and the cell culture conditions, as will be apparent to those of ordinary skill.

Immunoprecipitation, blotting, and cDNA sequencing of genes cloned according to the methods of the present
10 invention may be carried out by any convenient methods known to those of skill. For example, the immunoprecipitation protocol of Clark et al., Leukocyte Typing II, Vol. II, pp. 155-167 (1986), is preferred. Southern, Northern, or other blot analysis methods known
15 to those of skill may be employed, using hybridization probes prepared by known methods, such as that of Hu et al. (Gene 18:271-277 (1982)). cDNA sequencing also may be accomplished by known methods, including the dideoxynucleotide method of Sanger et al., P.N.A.S. (USA)
20 74:5463-5467 (1977).

The antibodies used according to the present invention may be polyclonal or monoclonal. These may be used singly, or in conjunction with other polyclonal or monoclonal antibodies to effect immunoselection of cells
25 expressing the desired antigen or antigens by the methods of the present invention. Methods of preparing antibodies or fragments thereof for use according to the present invention are known to those of skill.

Standard reference works setting forth general
30 principles of immunology include Klein, J., Immunology: The Science of Self-Nonself Discrimination, John Wiley & Sons, publisher, New York (1982); Kennett, R., et al.,

-35-

eds., Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 13, Elsevier, publisher, Amsterdam (1984).

The term "antibody" is meant to include the intact molecule as well as fragments thereof, such as, for
05 example, Fab and F(ab)'₂ fragments, which also are able to bind to antigen. Polyclonal antibody preparations may be derived directly from the blood of the desired animal species after immunization with the antigen of interest, or a fragment thereof, using any of the standard proto-
10 cols known to those of ordinary skill. Similarly, monoclonal antibodies may be prepared using known methods (Kohler et al., Eur. J. Immunol 6:292 (1976)). Use of monoclonal antibodies is preferred for the purposes of the present invention.

15 For the purposes of immunoselection according to the present invention, the tissue culture host cells which have been exposed to antibodies directed against the target cell surface antigen are separated from host cells which do not express the target antigen by distributing
20 the cells onto a substrate coated with antibody directed against the antigen for the antigen. This technique, termed "panning," will be known to those of skill, and is described, for example, by Mage et al., J. Immunol. Meth. 15:47-56 (1977), and Wysocki and Sato, P.N.A.S. (USA) 75:2844-2848 (1978).
25

Panning according to the methods of the present invention may be carried out as follows:

a. Antibody-coated dishes. Bacteriological
60mm plates, Falcon 1007 or equivalent, or 10cm dishes
30 such as Fisher 8-757-12 may be used. Sheep anti-mouse affinity purified antibody (from, for example, Cooper BioMedical (Cappell)) is diluted to 10ug/ml in 50mM Tris

-36-

HCl, pH 9.5. Add 3ml per 6cm dish, or 10ml per 10cm dish. Let sit ca. 1.5 hrs., remove to next dish 1.5 hrs., then to 3rd dish. Wash plates 3x with 0.15 NaCl (a wash bottle is convenient for this), incubate with 3ml
05 1mg/ml BSA in PBS overnight, aspirate and freeze.

b. Panning. Cells will be in 60mm dishes. Aspirate medium from dish, add 2ml PBS/0.5mM EDTA/0.02% azide and incubate dishes at 37°C for 30 min. to detach cells from dish. Triturate cells vigorously with short
10 pasteur pipet, and collect cells from each dish in a centrifuge tube. Spin 4 min. setting 2.5 (200 x g) (takes 5 min). Resuspend cells in 0.5 -1.) ml PBS/EDTA/azide/5% FBS and add antibodies. Incubate at least 30 min. on ice. Add an equal volume of
15 PBS/EDTA/azide, layer carefully on 3 ml PBS/EDTA/azide/2% Ficoll, and spin 4 min. at setting 2.5. Aspirate supernatant in one smooth movement. Take up cells in 0.5ml PBS/EDTA/azide and add aliquots to antibody-coated dishes containing 3ml PBS/EDTA/azida/5% FBS by pipetting
20 through 100 micron Nylon mesh (Tetko). Add cells from at most two 60mm dishes to one 60mm antibody-coated plate. Let sit at room temperature 1-3 hours. Remove excess cells not adhering to dish by gentle washing with PBS/5% serum or with medium. 2 or 3 washes of 3ml are usually
25 sufficient.

c. Hirt Supernatant. A preferred variant of the method of Hirt, J. Molec. Biol. 26:365-369 (1967), is as follows: Add 0.4 ml 0.6% SDS, 10mM EDTA to panned
30 plate. Let sit 20 minutes (can be as little as 1 min. if there are practically no cells on the plate). Pipet viscous mixture into microfuge tube. Add 0.1ml 5M NaCl, mix, put on ice at least 5 hrs. Keeping the mixture as

-37-

cold as possible seems to improve the quality of the Hirt. Spin 4 min., remove supernatant carefully, phenol extract (twice if the first interface is not clean), add 10ug linear polyacrylamide (or other carrier), fill tube to top with EtOH, precipitate, and resuspend in 0.1ml. Add 3 volumes EtOH/NaOAc, reprecipitate and resuspend in 0.1 ml. Transform into MC1061/p3, preferably using the high efficiency protocol hereinafter described. If the DNA volume exceeds 2% of the competent cell aliquot, the transformation efficiency will suffer. 5% gives the same number of colonies as 2.5% (efficiency is halved).

It is preferred for this aspect of the present invention to use "blockers" in the incubation medium. Blockers assure that non-specific proteins, proteases, or antibodies present do not cross-link with or destroy the antibodies present on the substrate or on the host cell surface, to yield false positive or false negative results. Selection of blockers can substantially improve the specificity of the immunoselection step of the present invention. A number of non-specific monoclonal antibodies, for example, of the same class or subclass (isotype) as those used in the immunoselection step (e.g., IgG₁, IgG₂A, IgGm, etc.) can be used as blockers. Blocker concentration (normally 1-100ug/ul) is important to maintain the proper sensitivity yet inhibit unwanted interference. Those of skill also will recognize that the buffer system used for incubation may be selected to optimize blocking action and decrease non-specific binding.

A population of cells to be panned for those expressing the target cell surface antigen is first detached from its cell culture dish (harvested) without

-38-

trypsin. The cells then are exposed to a first antibody, which may be polyclonal or monoclonal, directed against the antigen of interest or against a family of related antigens. At this initial stage, a single antibody or a group of antibodies may be used, the choice depending upon the nature of the target antigen, its anticipated frequency, and other variables that will be apparent to those of skill. Target antigens expressed on the surfaces of host cells will form an antigen-antibody complex.

The cells subsequently are placed in close apposition to a substrate, such as a culture dish, filter disc, or the like, which previously has been coated with a second antibody or group of antibodies. This second antibody will be directed against the first antibody, and its choice will be a matter of ordinary skill dictated by, for example, the animal in which the first antibody was raised. For example, if the first antibody was raised in mice, the second antibody might be directed against mouse immunoglobulins, raised in goats or sheep. Cells expressing the target antigen will adhere to the substrate via the complex formed between the antigen, the first antibody, and the second antibody. Adherent cells then may be separated from nonadherent cells by washing. DNA encoding the target antigen is prepared from adherent cells by known methods, such as that of Hirt, J. Molec. Biol. 26:365-369 (1967). This DNA may be transformed into E. coli or other suitable host cells for further rounds of fusion and selection, to achieve the desired degree of enrichment.

In the usual case, the initial rounds of immunoselection will employ a panel of first antibodies

-39-

directed against an epitope or group of epitopes common to the family of antigens to which the target antigen belongs. This will be sufficient to narrow the number of clones for future rounds quite significantly. Two such rounds usually will be found adequate, but the number of rounds may vary as mentioned above. Thereafter, a single round of selection may be performed employing a single first antibody or a group of first antibodies recognizing only the target antigen.

By "substrate" is meant a solid surface to which antibodies may be bound for immunoselection according to the present invention. Known suitable substrates include glass, polystyrene, polypropylene, dextran, nylon, and other materials. Tubes, beads, microtiter plates, bacteriological culture dishes, and the like formed from or coated with such materials may be used. Antibodies may be covalently or physically bound to the substrate by known techniques, such as covalent bonding via an amide or ester linkage, or by absorption. Those skilled in the art will know many other suitable substrates and methods for immobilizing antibodies thereupon, or will be able to ascertain such substrates and methods using no more than routine experimentation.

The choice of host tissue culture cells for use according to the present invention preferably should be such as to avoid the situation in which the antibodies used for panning recognize determinants on untransfected cells. Thus, while COS cells are preferred for transient expression of certain surface antigens, more preferred are murine WOP cells. Of the latter, WOP 3027 cells are even more preferred. WOP cells allow virtually all antibodies to be used, since cross-reactions between

-40-

murine antibodies and murine cell surface determinants are rare.

The insert size of the recombinant DNA molecule should be chosen to maximize the likelihood of obtaining an entire coding sequence. Those of skill will know various methods by which a preliminary determination of optimal insert size for a given gene may be determined.

Vector construction and cDNA insertion

Vectors suitable for expression of cDNA in mammalian tissue culture cells may be constructed by known methods. Preferred for the purposes of the present invention is an expression vector containing the SV40 origin. The vector may contain a naturally derived or synthetic transcription origin, and the SV40 early region promoter. Even more preferred is a chimeric promoter composed of human cytomegalovirus immediate early enhancer sequences. Various "enhancer sequences" also may be used with SV40 vectors. These are described, for example, by Banerji *et al.*, Cell 27:299-308 (1981); Levinson *et al.*, Nature 295:568-572 (1982); and Conrad *et al.*, Mol. Cell. Biol. 2:949-965 (1982).

Insertion of cDNA into the vectors of the present invention can occur, for example, by homopolymeric tailing with terminal transferase. However, homopolymeric tracts located 5' to cDNA inserts may inhibit in vitro and in vivo expression. Thus, preferred for purposes of the present invention is the use of inverted identical cleavage sites separated by a short replaceable DNA segment. Such inverted identical cleavage sites, preferably employing the BstXI restriction endonuclease, may be used in parallel with cDNA synthetic

-41-

oligonucleotides, giving the same termini as the replaceable segment of the vector. In this manner, the cDNA cannot ligate to itself, but can ligate to the vector. This allows the most efficient use of both cDNA
05 and vector.

Another embodiment of the present invention is the above-described efficient oligonucleotide-based strategy to promote cDNA insertion into the vector. The piH3M vector of the present invention is preferred, and employs
10 the inverted endonuclease sites. This vector may contain an SV40 origin of replication, but a more preferred form contains an M13 origin. This vector, containing the M13 origin, allows high level expression in COS cells of coding sequences placed under its control. Also, the
15 small size and particular arrangement of sequences in the plasmid permit high level replication in COS cells.

By "cell surface antigen" is meant any protein that is transported through the intracellular membrane system to the cell surface. Such antigens normally are anchored
20 to the cell surface membrane through a carboxyl terminal domain containing hydrophobic amino acids that lie in the lipid bilayer of the membrane, and there exert their biological and antigenic effects. Antigens such as those of T-lymphocytes are particularly suited for gene cloning
25 by the method of the present invention. However, cell surface antigens of any cells may be cloned according to the present method. Moreover, proteins not normally expressed on the cell surface may admit of cloning according to the present method by, for example, using
30 fluorescence activated cell sorting (FACS) to enrich for fixed cells expressing intracellular antigens.

-42-

By "substantially pure" is meant any antigen of the present invention, or any gene encoding any such antigen, which is essentially free of other antigens or genes, respectively, or of other contaminants with which it might normally be found in nature, and as such exists in a form not found in nature. By "functional derivative" is meant the "fragments," "variants," "analogs," or "chemical derivatives" of a molecule. A "fragment" of a molecule, such as any of the antigens of the present invention, is meant to refer to any polypeptide subset of the molecule. A "variant" of such molecules is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule, or a fragment thereof. An "analog" of a molecule is meant to refer to a non-natural molecule substantially similar to either the entire molecule or a fragment thereof.

A molecule is said to be "substantially similar" to another molecule if the sequence of amino acids in both molecules is substantially the same, and if both molecules possess a similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants as that term is used herein even if one of the molecules contains additional amino acid residues not found in the other, or if the sequence of amino acid residues is not identical. As used herein, a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the

-43-

molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Penn. (1980).

05 Similarly, a "functional derivative" of a gene of any of the antigens of the present invention is meant to include "fragments," "variants," or "analogues" of the gene, which may be "substantially similar" in nucleotide sequence, and which encode a molecule possessing similar
10 activity.

 The substantially pure antigens that have been expressed by methods of the present invention may be used in immunodiagnostic assay methods well known to those of skill, including radio-immunoassays (RIAs), enzyme
15 immunoassays (EIAs) and enzyme-linked immunosorbent assays (ELISAs). The substantially pure proteins of the present invention, in soluble form, may be administered alone or in combination with other antigens of the present invention, or with other agents, including
20 lymphokines and monokines or drugs, for the treatment of immune-related diseases and disorders in animals, including humans. As examples of such disorders that may benefit from treatment with the substantially pure proteins of the present invention may be mentioned immune
25 deficiency diseases, diseases of immediate type hypersensitivity, asthma, hypersensitivity pneumonitis, immune-complex disease, vasculitis, systemic lupus erythematosus, rheumatoid arthritis, immunopathogenic renal injury, acute and chronic inflammation, hemolytic
30 anemias, platelet disorders, plasma and other cell neoplasms, amyloidosis, parasitic diseases, multiple sclerosis, Guillain-Barre syndrome, acute and subacute

-44-

myopathic paralysis, myasthenia gravis, immune endocrinopathies, and tissue and organ transplant rejection, all as described in Petersdorf et al., eds., Harrison's Principles of Internal Medicine, supra. See
05 also Weir, ed., supra; Boguslaski et al., eds., supra; and Holborow et al., eds., supra.

When used for immunotherapy, the antigens of the present invention may be unlabeled or labeled with a therapeutic agent. Examples of therapeutic agents which
10 can be coupled to the antigens of the invention for immunotherapy are drugs, radioisotopes, lectins, and toxins.

The dose ranges for the administration of the antigens of the present invention are those large enough
15 to produce the desired immunotherapeutic effect, but not so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage employed will vary with the age, condition, sex, and extent of the disease in the
20 patient. Counterindications (if any), immune tolerance and other variables also will affect the proper dosage. Administration may be parenteral, by injection or by gradual perfusion over time. Administration also may be intravenous, intraparenteral, intramuscular,
25 subcutaneous, or intradermal.

Preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents include
30 propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic and aqueous solutions, emulsions, or suspensions,

-45-

including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient
05 replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives also may be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like. Such preparations, and the
10 manner and method of making them, are known and described, for example, in Remington's Pharmaceutical Science, 16th ed., supra.

The antigens of the present invention also may be prepared as medicaments or pharmaceutical compositions
15 comprising the antigens, either alone or in combination with other antigens or other agents such as lymphokines, monokines, and drugs, the medicaments being used for therapy of animal, including human, immune-related indications.

20 Although the antigens of the present invention may be administered alone, it is preferred that they be administered as a pharmaceutical composition. The compositions of the present invention comprise at least one antigen or its pharmaceutically acceptable salt,
25 together with one or more acceptable carriers and optionally other therapeutic agents. By "acceptable" is meant that the agent or carrier be compatible with other ingredients of the composition and not injurious to the patient. Compositions include those suitable for oral,
30 rectal, nasal, topical (including buccal and sublingual), vaginal, or parenteral administration. The compositions conveniently may be presented in unit dosage form, and

-46-

may be prepared by methods well known in the pharmaceutical arts. Such methods include bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, compositions are prepared by uniformly and intimately bringing
05 into association the active ingredient with liquid carriers or finely divided solid carriers, or both, and shaping the product formed thereby, if required.

Orally administered pharmaceutical compositions
10 according to the present invention may be in any convenient form, including capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient. Powders or granules also are possible, as well as solution or suspension in aqueous or nonaqueous liquids,
15 or oil-in-water liquid emulsions, or water-in-oil liquid emulsions. The active ingredient also may be presented as a bolus, electuary or paste.

Having now described the invention, the same will be more fully understood by reference to the following
20 examples, which are not intended in any way to limit the scope of the invention.

EXAMPLE I Isolation, Molecular Cloning, and Structure of the Human CD2 Antigen

The cDNA expression vector piH3

25 A COS cell expression vector was constructed from piSV (Little et al., Mol. Biol. Med. 1:473-488 (1983)) by inserting a synthetic transcription unit between the suppressor tRNA gene and the SV40 origin. The transcription unit consisted of a chimeric promoter composed
30 of human cytomegalovirus AD169 immediately early enhancer

-47-

sequences fused to the HIV LTR -67 to +80 sequences. Immediately downstream from the LTR +80 sequence was inserted a polylinker containing two BstXI sites separated by a 350bp stuffer; the BstXI sites were flanked by
05 XbaI sites, which could also be used to excise the insert. Downstream from the polylinker were placed the SV40 small t antigen splice and early region polyadenylation signals derived from pSV2. The nucleotide sequence of the vector is shown in Figure 1.

10 cDNA library construction

RNA was prepared from HPB-ALL cells by the guanidinium thiocyanate/CsCl method, as described above. PolyA⁺ RNA was prepared from total RNA by oligo dT selection. Maniatis et al, Molecular Cloning: A Laboratory Manual, supra. cDNA was synthesized by the method of Gubler and Hoffman (Gene 25:263-269 (1982)). BstXI adaptors were ligated to the cDNA, and the reaction products fractionated by centrifugation through a 5ml-20% potassium acetate gradient containing 1mM EDTA for 3
15 hours at 50krpm in a SW55 rotor. 0.5ml fractions were collected manually through a syringe needle or butterfly inserted just above the curve of the tube. Individual fractions were ethanol-precipitated after addition of linear polyacrylamide (Strauss and Varshavsky, Cell
25 37:889-901 (1984)) to 20 ug/ml. Fractions containing cDNA larger than 700bp were pooled and ligated to gradient purified BstXI digested pIH3 vector.

The ligated DNA was transformed into E. coli MC1061/p3 made competent by the following protocol: The
30 desired strain was streaked out on an LB plate. The next day a single colony was inoculated into 20ml TYM broth

-48-

(recipes below) in a 250ml flask. The cells were grown to midlog phase (OD_{600} about 0.2-0.8), poured into a 21 flask containing 100ml TYM, and vigorously agitated until cells grew to 0.5-0.9 OD , then diluted again to 500ml in the same vessel. When the cells grew to OD_{600} 0.6, the flask was placed in ice-water, and shaken gently to assure rapid cooling. When the culture was cool, it was spun at 4.2k rpm for 15 minutes (J6). The supernatant was poured off and the pellet resuspended in about 100ml cold TfB I (below) by gentle shaking on ice. Thereafter, it was respun in the same bottle at 4.2krpm for 8 minutes (J6). The supernatant was poured off and the pellet resuspended in 20 ml cold TfB II by gentle shaking on ice. 0.1 to 0.5 ml aliquots were placed in prechilled microfuge tubes, frozen in liquid nitrogen, and stored at -70°C . For transformation, an aliquot was removed, thawed at room temperature until just melting, and placed on ice. DNA was added, let sit on ice 15-30 minutes, and incubated at 37°C for 5 minutes (6 minutes for 0.5ml aliquots). Thereafter the DNA-containing suspensions were diluted 1:10 in LB and grown for 90 minutes before plating or applying antibiotic selection. Alternatively, the heat-pulsed transformation mix was plated directly on antibiotic plates onto which a thin (4-5ml) layer of antibiotic-free LB agar was poured just before plating.

Media and Buffers: TYM: 2% Bacto-Tryptone, 0.5% Yeast Extract, 0.1M NaCl, 10mM MgSO_4 (can be added before autoclaving). TfB I: 30mM KOAc, 50mM MnCl_2 , 100mM KCl, 10mM CaCl_2 , 15% (v/v) glycerol. TfB II: 10mM Na-MOPS, pH 7.0, 75 mM CaCl_2 , 10mM KCl, 15% glycerol.

-49-

Recovery of cDNA clones by panning

Bacteriological culture dishes (Falcon 1007) were prepared for panning by coating with an affinity purified sheep anti-mouse IgG antibody as described by Wysocki and Sato (Proc. Natl. Acad. Sci. USA 75:2844-2848 (1978)), except that dishes were washed with 0.15M NaCl from a wash bottle instead of PBS, and unreacted sites were blocked by overnight incubation in PBS containing 1mg/ml BSA. Dishes were typically prepared in large batches and stored frozen, after aspiration of the PBS/BSA. In the first round of screening, 24 6cm dishes of 50% confluent COS cells were transfected by protoplast fusion according to the method of Sandri-Goldrin et al., Mol. Cell Biol. 1:743-752 (1981). 72 hours post fusion the cells were detached by incubation in PBS/1mM EDTA/.02% sodium azide at 37°C for 30 minutes. The detached cells were pooled, centrifuged, and resuspended in cold PBS/EDTA/5% Fetal Bovine Serum containing monoclonal antibodies, usually as ascites at 1:1000 dilution, but also as commercial reagents at the concentrations suggested by the manufactures. After 1 hour on ice, the cells were diluted with 1:1 with PBS/EDTA/azide and layered on 10ml of PBS/EDTA/azide containing 2% Ficoll 400. After centrifugation (400xg, 5 minutes), the supernatant was carefully aspirated, the pellet resuspended in a small amount of PBS/EDTA/5% FBS, and the cells distributed into panning plates containing 3 ml of PBS/EDTA/5% FBS. The plates were then treated essentially as described by Wysocki and Sato. Proc. Natl. Acad. Sci. USA 75:2844-2848 (1978). Episomal DNA was recovered from the adherent cells by the Hirt (J. Mol. Biol. 26:365-269 (1967)) procedure and transformed into MC1061/p3.

-50-

Cell lines and cell culture

COS cell clone M6 cells were propagated in Dulbecco's modified Eagle's medium supplemented with 10% calf serum and gentamycin sulfate at 15ug/ml (DME/10% calf serum). Cells were split the day before transfection in 6 cm dishes at approximately 1:8 ratio from stock plates kept as dense as possible without overtly affronting the cells. T cell lines were grown in Iscove's modification of Dulbecco's medium (IMDM) containing gentamycin as above, and either NuSerum (Collaborative Research) or fetal bovine serum at 10%.

COS cell transfection for immunofluorescence studies

COS cells at 50% confluence in 6 cm dishes were transfected in a volume of 1.5ml with a cocktail consisting of DME or IMDM medium containing 10% NuSerum (Collaborative Research), 400ug/ml DEAE Dextran, 10uM chloroquine diphosphate, and 1ug/ml DNA. After 4 hours at 37°C (or earlier if the cells appeared ill), the transfection mix was removed and the cells were treated with 10% DMSO in PBS for 2 minutes. Sussman and Milman, Cell Biol. 4:1641-1643 (1984). Cells were then returned to DME/10% calf serum for 48 to 72 hours to allow expression.

Immunoprecipitations, Northern and Southern

T cells were labeled by lactoperoxidase treatment, lysed, and immunoprecipitated by the procedure of Clark and Einfeld (Leukocyte Typing II, Vol. II, pp. 155-167 (1986)), using commercially available goat anti-mouse IgG agarose beads (Cooper Biomedical). COS cells were transfected by DEAE Dextran method and trypsinized and

-51-

passed without dilution into new plates 24 hours after transfection. 36 hours later, cells were detached by exposure to PBS/EDTA as above, centrifuged, and labeled by the lactoperoxidate method. A cleared lysate was
05 prepared as for the T cell immunoprecipitations, except that the lysis buffer contained 1mM PMSF, and incubation with the primary antibody was carried out for only 2 hours at 4°C. Eluted samples were fractionated on discontinuous 11.25% polyacrylamide gels using the buffer
10 system of Laemmli (Nature 227:680-685 (1970)).

Northern blot analysis was carried out essentially as described (Maniatis et al., Molecular Cloning, a Laboratory Manual (1982)), except that DMSO was omitted from the loading buffer, denaturation was at 70°C for 5
15 minutes, and the gel contained 0.6% formaldehyde rather than 6%. The gel was stained in two volumes of water containing 1µg/ml ethidium bromide, photographed, and transferred to nylon (GeneScreen, DuPont) in the staining liquor. The transferred RNA was irradiated by exposure
20 to a germicidal lamp through Saran Wrap (Church and Gilbert, Proc. Natl. Acad. Sci. USA 8:1991-1995 (1984)) for 5 minutes at a flux (measured at 254nm) of 0.22mW/cm². Southern blot analysis was carried out by alkaline transfer to nylon (GeneScreen, DuPont) as
25 described by Reed and Mann (Nucl. Acids Res. 13:7207-7221 (1986)). Hybridization probes were prepared by the method of Hu and Messing (Gene 18:271-277 (1982)), and blots were prehybridized in SDS/phosphate buffer (Church and Gilbert, Proc. Natl. Acad. Sci. USA 8:1991-1995
30 (1984)) containing 10 DNA microgram equivalents of M13 mp19 phage.

-52-

Erythrocyte Rosetting

Erythrocytes were prepared from whole blood by three centrifugations in PBS. COS cells were transfected in 6 cm dishes with CD2 or other surface antigen expression clones by the DEAE method. 48 to 72 hours posttransfection, the medium was aspirated and 2ml of PBS/5% FDS/azide was added to each plate, followed by 0.4ml of the appropriate erythrocyte samples as 20% suspensions in PBS. After 1 hour at room temperature, the nonadherent erythrocytes were gently washed off, and the plates examined.

A cDNA encoding CD2 antigen determinants was isolated in the following manner: cDNA was prepared from RNA extracted from the human T Cell tumor line HPB-ALL and inserted into the SV40 origin-based expression vector pIH3 as described above. A cDNA library of approximately 3×10^5 recombinants was constructed, and the library was introduced into COS cells by protoplast fusion. Three days later the cells were detached by exposure to EDTA and treated with a pool of monoclonal antibodies, including three (OKT11, Leu5b, and Coulter T11) directed against CD2 determinants. The antibody-treated cells were distributed into dishes coated with an affinity purified sheep anti-mouse IgG antibody, allowed to attach, and separated from the nonadherent cells by gentle washing. This method of enrichment is known in the immunological literature (Mage et al., J. Immunol. Methods 15:47-56 (1977)).

The resulting colonies were pooled, fused into COS cells, and subjected to a second round of panning as before. In the third round, a portion of the detached cells was treated with a mixture of three monoclonal

-53-

antibodies specific for CD2, and a Hirt supernatant was again generated and transformed into E. coli. DNA was prepared from eight of the resulting colonies and transfected into COS cells. After three days, surface
05 expression of the CD2 antigen was detected by indirect immunofluorescence in six of eight transfected dishes. Restriction enzyme digestion of the corresponding plasmid DNAs revealed a 1.5kb insert in all six isolates.

One of the six clones was prepared in larger quantities for further analysis. Following transfection into
10 COS cells, indirect immunofluorescence analysis with a partial panel of antibodies provided by the Third International Workshop on Leukocyte Differentiation Antigens showed that all of the antibodies provided gave positive
15 reactions with the exception of one sample which also failed to react with phytohemagglutinin-activated T lymphocytes. Among the 17 antibodies tested were at least eight distinguishable groups defined by their differing patterns of reactivity with lymphocytes of
20 various primate species. Jonker and Nooij, Leukocyte Typing II, Vol. I, pp. 373-387 (1986).

cDNA sequence analysis

The CD2 cDNA insert was subcloned into M13 mp19 (Vieira and Messing, Gene 19:259-268 (1982)) in both
25 orientations, and the sequence determined by the dideoxynucleotide method (Figure 2). Sanger et al., Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977). An open reading frame was observed to extend 360 residues from an ATG triplet satisfying the consensus criteria of Kozak
30 (Microbiol. Rev.: 1-47:45 (1983)) for translational initiation codons (Figure 1). The predicted amino acid

-54-

sequence evokes an integral membrane protein with a single membrane spanning hydrophobic anchor terminating in a rather large intracytoplasmic domain. Comparison of the N-terminal amino sequence with the matrix of signal sequence residue frequencies constructed by von Heijne (Nucl. Acids Res. 14:4683-4690 (1986)) suggests that mature CD2 peptide is formed by cleavage of a precursor peptide between the 19th (Ser) and 20th (Lys) residues.

A surprising and unexpected feature of this sequence is the presence of a potential N-linked glycosylation site just proximal to the proposed cleavage site. The resulting polypeptide backbone has a predicted molecular weight of 38.9kd divided into an external domain of mass 21.9kb and a cytoplasmic domain of mass 14.6kd. Three N-linked glycosylation sites are present in the extracellular domain.

The membrane spanning domain comprises 26 unchanged residues of predominantly hydrophobic character. In the nine residues immediately following are seven basic residues, either lysines or arginines. The appearance of predominantly hydrophobic residues followed by basic residues is a common organizational feature of transmembrane proteins bearing carboxyl-terminal anchors.

Another surprising feature of the transmembrane domain is the appearance of a cys-gly-gly-gly, a beta turn motif (Chou and Fasman, Annual Review of Biochemistry, 47:251-276 (1978)), flanked by hydrophobic residues (which are frequently found flanking beta turns). Because only 20 residues arrayed in an alpha helix are theoretically needed to traverse the 3nm membrane bilayer (Tanford, Science, 200:1012-1018 (1978)), and as few as 14 hydrophobic residues can allow

-55-

insertion and export of an integral membrane protein (Adams and Rose, Cell, 41:1007-1015 (1985)), the trans-membrane segment of the CD2 antigen may contain a bend or kink.

05 The rather large size of the cytoplasmic domain leaves open the possibility that CD2 possesses an intrinsic enzymatic activity. The cytoplasmic domain is very rich in prolines and contains three sites with high turn probability.

10 Comparison of the amino acid sequence with the NBRF database revealed no substantive homologies with other proteins. In particular, no homology with the T cell receptor alpha or beta chains was observed, ruling out the suggestion that CD2 is a primordial T cell receptor.

15 Milanese et al., Science, 231:1118-1122 (1986).

Just inside the cytoplasmic face of the protein is a run of basic proteins followed by a serine residue, a pattern found at the same location in both the EGF receptor and the class I histocompatibility genes, and in
20 each case a known site for either in vivo (EGF) and in vitro (HLA) phosphorylation by protein kinase C or cyclic AMP-dependent protein kinase, respectively. Hunter et al., Nature, 311:480-482 (1984); Davis and Czech (1985); Guild and Strominger (1984). A similar site is found in
25 the intracytoplasmic domain of the interleukin 2 receptor, and is phosphorylated in vivo by protein kinase C. Leonard et al., Nature, 311:626-631 (1984); Nikaido et al., Nature, 311:631-635 (1984); Shackelford and Trowbridge, J. Biol. Chem., 259:11706-_____ (1984).

-56-

Immunoprecipitation of CD2 antigen expressed by transfected cells

COS cells were transfected with the CD2 expression plasmid and surface labeled with ^{125}I by the lactoperoxidase method 60 hours post-transfection. A cell lysate was prepared, and portions were incubated either with monoclonal anti-CD2 antibody (OKT11) or with an extraneous (OKT4; anti-CD4) antibody for 2 hours at 4°C . Sepharose-bound anti-mouse antibody was added, and after several washing steps, the adsorbed proteins were eluted and electrophoresed through a 11.25% acrylamide gel together with similarly prepared immunoprecipitates from phytohemagglutinin-activated T lymphocytes, the cDNA donor line HPB-ALL, or a long-term T cell line generated in this laboratory. Autoradiography demonstrated a prominent band of immunoreactive material precipitated from transfected COS cells by the anti-CD2 antibody, but not by the control. The calculated mean molecular weight of the COS cell material was 51kd, compared to a mean molecular weight of 54kd for the T blast and T cell line material; the antigen from HPB-ALL cells was found to have a molecular weight of approximately 61kd. The observed differences in size were attributed to different patterns of glycosylation in the different cell types. A minor band of apparent molecular weight 38kd was present in material immunoprecipitated from COS cells but not from T cells or HPB-ALL cells. The size of this species agrees within experimental error with the predicted molecular weight of mature unglycosylated peptide, 39kd.

30 COS cells expressing CD2 form rosettes with sheep erythrocytes

COS cells transfected with the CD2 expression clone

-57-

were treated for 1 hour with purified MT910 (IgG, kappa) anti-CD2 antibody (Rieber et al., Leukocyte Typing II, Vol. I, pp. 233-242 (1986)) at a concentration of 1ug/ml, or with purified MB40.5 (IgG1, kappa; Kawata et al., J. Exp. Med., 160:633-651 (1984)) antibody at the same concentration. MB40.5 recognizes a monomorphic HLA-ABC determinant and cross-reacts with African Green Monkey histocompatibility antigens; it was chosen because it represents an isotype-matched antibody recognizing a surface antigen of approximately the same abundance as the CD2 antigen expressed by transfected cells. Sheep erythrocyte rosettes were observed in the presence of MB40.5, but not of MT910. Rosette inhibition was also observed with OKT11 antibody, and not with various other control antibodies.

Transfected COS cells form rosettes with other animal erythrocytes

In addition to sheep erythrocytes, human T cells are known to form rosettes with horse, pig, dog, goat, and rabbit, but not mouse or rat erythrocytes. Johansen et al., J. Allergy Clin. Immunol., 54:86-94 (1974); Amiot et al. in, A. Bernard et al., eds., Leucocyte Typing, Springer, publisher, New York, N.Y., pp. 281-293 (1984); Nalet and Fournier, Cell. Immunol., 96:126-136 (1985). Autorosettes between human erythrocytes and human thymocytes (Baxley et al., Clin. Exp. Immunol., 15:385-393 (1973)) have also been reported. COS cells transfected with the CD2 expression clone were treated with either MT910 or with the control antibody, MB40.5, and exposed to erythrocytes from the species above.

-58-

Rosettes were observed with horse, pig, dog, goat, sheep, rabbit, and human erythrocytes, but not with mouse or rat erythrocytes. Rosette formation was blocked by pretreatment of transfected COS cells with MT910, but not
05 with MB40.5. In these experiments, it was noticed that horse erythrocytes formed unusually dense rosettes, and that goat erythrocytes formed rather sparse rosettes, possibly because their small size made them more susceptible to washing. Mouse erythrocytes showed weak
10 spontaneous binding to the culture dish as well as to MT910 and MB40.5 pretreated cells, while rat erythrocytes showed no detectable binding of any sort.

Binding of human erythrocytes is blocked by LFA3 antibody

Because it has been suggested on the basis of
15 antibody blocking studies that LFA3 is the target structure for the CD2 antigen (Shaw *et al.*, *Nature*, 323:262-264 (1986)), the ability of anti-LFA3 antibody to prevent rosette formation was investigated. Transfected cells were exposed to human erythrocytes pretreated for 2
20 hours with either anti-LFA3 (IgG1, kappa) as ascites at 1:1000 dilution, or with a 10ug/ml concentration of each of four isotype-matched nonagglutinating antibodies directed against human erythrocyte antigens as prevalent or more prevalent than LFA3:G10/B11 and D10, anti-K14
25 antigen, D6, anti-Wr^b antigen; and F7/B9, anti-k antigen. Nichols *et al.*, *Vox Sang*, in press. The erythrocytes were washed free of excess LFA3 antibody, but were allowed to form rosettes in the presence of the control antibodies to guard against possible loss of antibody
30 blocking power by desorption. Rosette formation was

-59-

observed in the presence of all four control antibodies, but not with erythrocytes pretreated with anti-LFA3.

COS cells expressing other T cell antigens do not form rosettes

05 A number of clones were isolated by the same
expression technique used to clone CD2 and characterized
to varying degrees by antibody reactivity, nucleic acid
restriction and sequence analysis, and immunoprecipitation.
10 Representative clones were transfected into COS
cells and analyzed for ability to sustain rosette
formation. The CD1a, CD1b, CD1c, CD4, CD5, CD6, CD6,
CD8, and CD28 (Tp44) clones did not form rosettes with
human erythrocytes.

RNA blot analysis

15 Equal amounts of total RNA prepared from cell types
expressing or lacking CD2 antigen were electrophoresed
through denaturing agarose gels and transferred to nylon.
Hybridization of the transferred RNA with a strand
selective probe (Hu and Messing, Gene, 17:271-277 (1982))
20 prepared from an M13 clone containing a CD2 cDNA insert
revealed the presence of prominent 1.65 and 1.3 kb
transcripts present in RNA derived from thymocyte,
activated T cell, and senescent T cell populations.
Lesser amounts were found in RNA extracted from the cDNA
25 donor line, HPB-ALL and less still from MOLT4; barely
detectable levels were recorded in RNA from the HSB-2
line. No reactivity was observed with RNA from Namalwa
(Burkitt lymphoma), U937 (histiocytic leukemia), HuT-78
(Adult T cell leukemia), PEER (T cell leukemia), or
30 Jurkat clone J3R7 (T cell leukemia) lines. The pattern

-60-

of reactivity conformed well with the known or measured pattern of expression of CD2 antigen, which was absent or undetectable on the Namalwa, *937, HuT-78, J3R7, PEER, and HSB-2 cell lines, weakly present on MOLT4, more
05 strongly present on EPB-ALL, and most strongly present on activated T cells. Thymocytes are also known to express high levels of CD2 antigen.

Examination of the sequence of the cDNA clone suggested that the 1.3kb RNA might arise by formation of
10 an alternate 3' end distal to the canonical polyadenylation signal AATAAA at position 1085 in the cDNA sequence. To test this notion, RNA from HPB-ALL and activated T cells was subjected to Northern blot analysis and hybridized either with a complete cDNA probe, or with
15 a probe derived from the 3' portion of the cDNA distal to nucleotide 1131. The latter probe reacted only with the 1.65kb species, while the former showed the same reactivity pattern observed in Figure 5. This result is consistent with the suggested origin of the 1.3kb
20 transcript.

In both activated and senescent T cell RNA preparations, a weakly hybridizing transcript of approximately 0.75kb was detected. At present the origin of this RNA is unknown.

25 Genomic organization of the CD2 gene

Southern blot analysis of genomic DNA from placenta, peripheral blood lymphocytes, T cells, HeLa cells, or the tumor lines used in the RNA analysis above showed identical BamHI digest patterns, indicating that
30 rearrangement is not involved in the normal expression of the CD2 gene during development. Similarly, no gross

-61-

genomic alteration underlies the failure of the examined T cell tumor lines to express CD2 antigen. Restriction analysis of total genomic DNA with a number of other enzymes, as well as preliminary results with an incomplete collection of 1 phage recombinants bearing the CD2 sequence, shows that the gene is divided into at least four exons.

EXAMPLE II Isolation and Molecular Cloning of
Human LFA-3 Antigen

The previous example shows that cDNAs encoding surface antigens, such as the CD2 antigen, can be isolated by the transient expression system of the present invention, in which COS cells transfected with cDNA libraries are allowed to attach to ("panned" on) antibody-coated plates. Plasmid DNA is recovered from cells adhering to the plates, transformed into E. coli, and the process is repeated, usually twice, to isolate the desired clone. Although powerful, this approach cannot be used when the monoclonal antibodies used for panning recognize determinants on the untransfected cells. This appears to be the case for anti-LFA3 monoclonal TS2/9. However, a similar transient expression system based on polyoma virus replication-competent cells should allow almost all monoclonals to be used, since the probability of cross reaction between murine antibodies and murine cell surface determinants should usually be small.

A new expression vector, CDM8 (Figure 3) was created from the COS cell vector piH3M described previously. The new vector differs by the inclusion of a deleted version

-62-

of a mutant polyoma virus early region selected for high efficiency expression in both murine and monkey cells, by the replacement of substantially all of the human immunodeficiency promoter region with the cognate sequences of the human cytomegalovirus immediate early promoter, and by inclusion of a bacteriophage T7 promoter between the eukaryotic promoter and the site of cDNA insertion. Expression in COS cells of chloramphenicol acetyltransferase by all of the vectors was equivalent.

10 A library of 1.9×10^6 recombinants having inserts greater than 0.8kb in size was prepared in the CDM8 vector from a microgram of poly A+ RNA isolated from the human lymphoblastoid cell line JY. The library was introduced into WOP cells (NIH 3T3 cells transfected with polyoma origin deletion DNA) by spheroplast fusion, and subjected to three rounds of panning and reintroduction into E. coli as described in Example I.

A clone encoding the LFA-3 antigen was identified by indirect immunofluorescence of transfected WOP cells, amplified and sequenced (Figure 4). Within the 874 bp insert, an open reading frame of 237 residues originates at a methionine codon closely corresponding to the consensus sequence suggested by Kozak, Microbiol. Rev., 47:1-45 (1983). The reading frame terminates in a series of hydrophobic residues lacking the characteristic basic anchoring residues of internal membrane proteins, but sharing features with known phosphatidylinositol-linked superficial membrane proteins. The features include clustered serine or threonine residues in a hydrophilic region immediately preceding the hydrophobic domain, and the presence of serines and threonines in the hydrophobic portion.

-63-

The amino acid sequence predicted from the nucleotide sequence of the LFA-3 clone was compared to the NBRF database, and no significant homologies were uncovered; the most significant scores were to the HIV envelope protein. Within the 200 residues comprising the presumed mature protein are 6 N-linked glycosylation sites, and 5 tandem serine or tandem threonine residues that frequently appear in O-linked glycosylated proteins. Ten cysteine residues appear in the complete sequence, 6 of which are distributed in the latter half of the mature protein, and one of which falls in the carboxy-terminal hydrophobic domain. Although esterification of cysteine thiols to fatty acids is a common occurrence in integral membrane proteins, and may play an alternate role in membrane anchoring of LFA-3, two examples are known of cysteine residues within or at the margin of the hydrophobic region of phosphatidylinositol linked proteins.

The predicted sequence suggests that the known manipulations for increasing erythrocyte adhesion to T cells may find direct physical explanation in the structure of the LFA-3 molecule. Aminoethylisothiuronium bromide, the thiourea adduct of bromoethylamine, undergoes spontaneous rearrangement to mercaptoethylguanidine at alkaline pH. The latter likely gains access to disulfide bonds inaccessible to less chaotropic reducing agents and may thereby reduce and promote the unfolding of the LFA-3 molecule. Similarly, neuraminidase may decrease steric interference by the many carbohydrate chains on the molecule.

RNA and DNA blot hybridization analysis showed that the LFA-3 gene shares no closely related sequences in the

-64-

genome, and encodes a single RNA species of about 1 kb in length. Cell lines that express large amounts of surface LFA-3 have greater amounts of LFA-3 RNA than those that express small or nondetectable amounts.

05 Radioimmunoprecipitation of the antigen expressed in transfected COS and murine cells shows a broad band of approximately 50kd mean molecular mass, similar to that found in JY cells.

10 EXAMPLE III Isolation and Molecular Cloning of the
Human CD28 cDNA Antigen

 The previous examples illustrate the monoclonal antibody-based technique of the present invention for enrichment of cDNAs encoding surface antigens. In the present example, a method of constructing plasmid
15 expression libraries is described which allows the enrichment technique to be fully exploited. The method of the present invention for making plasmid expression libraries is of general use for expression cloning.

 The antibody selection technique of the present
20 invention has also been applied to isolate a cDNA clone encoding the CD28 antigen. The antigen shares substantial homology with members of the immunoglobulin superfamily and forms a dimer structure on the surface of transfected COS cells similar to the dimer structure
25 found on T lymphocytes.

Preparation of cDNA Libraries. Poly(A)+ RNA was prepared from the human T-cell tumor line HPB-ALL by oligo(dT) cellulose chromatography of total RNA isolated by the guanidinium thiocyanate method (Chirgwin, J.M. et al.,

-65-

Biochemistry, 18:5294-5299 (1979)). cDNA was prepared by a protocol based on the method of Gubler and Hoffman (Gubler, U. et al., Gene, 25:263-269 (1982)). 4ug of mRNA was heated to approximately 100°C in a 1.5 ml centrifuge tube for 30 seconds, quenched on ice, and the volume adjusted to 70ul with RNase-free water. To this were added 20ul of buffer (0.25 M Tris pH 8.8 (8.2 at 42°C), 0.25 M KCl, 30 mM MgCl₂), 2ul of RNase inhibitor (Boehringer 36 u/ul), 1ul of 1M DTT, 1ul of 5ug/ul of oligo dT (Collaborative Research), 2ul of 25 mM each deoxynucleoside triphosphate (US Biochemicals), and 4ul of reverse transcriptase (Life Sciences, 24 u/ul). After 40 minutes at 42°C, the reaction was terminated by heating to 70°C for 10 minutes. To the reaction mix was then added 320ul of RNase free water, 80ul of buffer (0.1 M Tris pH 7.5, 25 mM MgCl₂, 0.5 M KCl, 0.25 mg/ml BSA, and 50 mM DTT), 25 units of DNA Polymerase I (Boehringer), and 4 units of RNase H (BRL). After 1 hour at 15°C and 1 hour at 22°C, 20 ul of 0.5M EDTA pH 8.0 were added, the reaction mixture was extracted with phenol, NaCl was added to 0.5 M, linear polyacrylamide (carrier; Strauss, F. et al., Cell, 37:889-901 (1984)) was added to 20 ug/ml, and the tube was filled with ethanol. After centrifugation for 2-3 minutes at 12,000 x g, the tube was removed, vortexed to dislodge precipitate spread on the wall of the tube, and respun for 1 minute.

Unpurified oligonucleotides having the sequence CTCTAAG and CTTAGAGCACA were dissolved at a concentration of 1 mg/ml, MgSO₄ was added to 10 mM, and the DNA precipitated by adding 5 volumes of ETOH. The pellet was rinsed with 70% ETOH and resuspended in TE at

-66-

a concentration of 1 mg/ml. 25 ul of the resuspended oligonucleotides were phosphorylated by the addition of 3 ul of buffer (0.5 M Tris pH 7.5, 10 mM ATP, 20 mM DTT, mM spermidine, 1 mg/ml BSA, and 10 mM $MgCl_2$) and 20 units of polynucleotide kinase followed by incubation at 37°C overnight.

3 ul of the 12-mer and 2 ul of the 8-mer phosphorylated oligonucleotides were added to the cDNA prepared as above in a 300 ul reaction mixture containing 6 mM Tris pH 7.5, 6 mM $MgCl_2$, 5 mM NaCl, 0.35 mg/ml BSA, 7 mM mercaptoethanol, 0.1 mM ATP, 2 mM DTT, 1 mM spermidine and 400 units T4 DNA ligase (New England BioLabs) at 15°C overnight. 10 ul of 0.5 M EDTA were added, the reaction was phenol extracted, ethanol precipitated, resuspended in a volume of 100 ul and layered on a 5 ml gradient of 5-20% potassium acetate in 1 mM EDTA, 1 ug/ml ethidium bromide. The gradient was spun 3 hours at 50,000 rpm (SW55 rotor) and fractionated manually, collecting three approximately 0.5 ml fractions followed by six approximately 0.25 ml fractions in microcentrifuge tubes by means of a butterfly infusion set inserted just above the curve of the tube. Linear polyacrylamide was added to 20 ug/ml, the tubes were filled with ethanol, chilled, spun, vortexed and respun as above. The precipitate was washed with 70% ethanol, dried, and resuspended in 10 ul. 1 ul of the last 6 fractions was run on a gel to determine which fractions to pool, and material less than 1kb in size was typically discarded. Remaining fractions were pooled and ligated to the vector.

The complete sequence and derivation of the vector is shown in Figure 5. The vector was prepared for

-67-

cloning by digestion with BstXI and fractionation on 5-20% potassium acetate gradients as described for the cDNA. The appropriate band was collected by syringe under 300 nm UV light and ethanol precipitated as above.

05 cDNA and vector were titrated in test ligations. Usually 1-2 ug of purified vector were used for the cDNA from 4 ug of poly A+ RNA. The ligation reactions were composed as described for the adaptor addition above. The ligation reactions were transformed into MC1061/p3 cells

10 made competent as described above. The transformation efficiency for supercoiled vector was $3-5 \times 10^8$ colonies/ug.

Recovery and characterization of the CD28 clone. Panning of the library was carried out as described herein above,

15 using purified antibody 9.3 (DuPont) at a concentration of 1 ug/ml in the antibody cocktail. The methods used for COS cell transfection, radioimmunoprecipitation, RNA and DNA blot hybridization, and DNA sequencing were all as described herein above.

20 To isolate the CD28 cDNA, a large plasmid cDNA library was constructed in a high efficiency expression vector containing an SV40 origin of replication. A preferred version of the vector, containing an M13 origin, is shown in Figure 6. Three features of the

25 vector make it particularly suitable for this use: (i) the eukaryotic transcription unit allows high level expression in COS cells of coding sequences placed under its control; (ii) The small size and particular arrangement of sequences in the plasmid permit high level

30 replication in COS cells; and (iii) the presence of two identical BstXI sites in inverted orientation and

-68-

separated by a short replaceable fragment allows the use of an efficient oligonucleotide-based strategy to promote cDNA insertion in the vector.

05 The BstXI cleavage site, CCAN'₅NTGG, creates a four
base 3' extension which varies from site to site. A
vector was created in which two identical sites were
placed in inverted orientation with respect to each
other, and separated by a short replaceable segment of
DNA. Digestion with BstXI followed by removal of the
10 replaceable segment yielded a vector molecule capable of
ligating to fragments having the same ends as the
replaceable segment, but not to itself. In parallel,
cDNA synthetic oligonucleotides were employed that give
the same termini as the replaceable segment. The cDNA
15 then could not ligate to itself, but could ligate to the
vector. In this way, both cDNA and vector were used as
efficiently as possible.

Tailing with terminal transferase achieves the same
end, but with less convenience and less overall
20 efficiency. Moreover, homopolymer tracts located 5' to
cDNA inserts have been reported to inhibit expression in
vitro and in vivo (Yokota, T., et al., Nucl. Acids Res.
14:1511-1524 (1986); Riedel, H., EMBO J. 3:1477-1483
(1985)). Similar approaches based on the use of
25 partially filled restriction sites to favor insertion of
genomic DNAs (Zabarovsky, E.R., et al., Gene 42:119-123
(1986)) and cDNAs (Yang, Y., et al., Cell 47:3-10 (1986))
recently have been reported. These approaches give 2 or
3 base complementary termini, which usually ligate less
30 efficiently than the 4 base extensions reported here.

Although the cloning scheme of the present invention
does not result in a directional insertion of the cDNA,

-69-

the ability to make large libraries easily, coupled with a powerful selection procedure, makes directional insertion unnecessary. The library construction efficiencies observed according to the present invention, between 0.5 and 2×10^6 recombinants per ug of mRNA, with less than 1% background and an insert size greater than 1kb, compared favorably with those described for phage vectors lambda gt10 (7.5×10^5 /ug of mRNA) and lambda gt11 (1.5×10^6 /ug of mRNA) (Huynh, T., et al., In: DNA Cloning Vol. I, A Practical Approach, Glover, D.M. (ed.), IRL Press, Oxford (1985), pp. 49-78); but the resulting clones were more convenient to manipulate.

Surface antigen cDNAs can be isolated from these libraries using the antibody enrichment method of the present invention. In this method, the library is introduced into COS cells (for example, by spheroplast or protoplast fusion), where it replicates and expresses its inserts. The cells are harvested by detaching without trypsin, treated with monoclonal antibodies specific for the surface antigens desired, and distributed in dishes coated with affinity purified antibody to mouse immunoglobulins. Cells expressing surface antigen adhere, and the remaining cells can be washed away. From the adherent cells, a Hirt fraction is prepared (Hirt, B., J. Molec. Biol. 26:365-369 (1967)), and the resulting DNA transformed back into E. coli for further rounds of fusion and selection. Typically, after two rounds of selection with monoclonal antibodies recognizing different surface antigens, a single round of selection is performed with a single antibody, or pool of antibodies recognizing the same antigen.

-70-

Isolation of a CD28 cDNA. The CD28 cDNA was isolated from a library of about 3×10^5 recombinants prepared from cDNA from 0.8ug of poly A⁺ RNA using an earlier version of the protocol described in the Materials and Methods. The library was screened for CD28 (and other surface antigen) cDNA clones by the method outlined above. After the third transfection, COS cells were panned with the 9.3 antibody alone. A Hirt supernatant was prepared from the adherent cells and transformed into E. coli. Plasmid DNA was isolated from eight colonies and transfected individually into COS cell cultures. The presence of the DC28 antigen was detected in three of eight transfected cultures by indirect immunofluorescence. All three plasmid DNAs contained an insert of about 1.5 kb.

cDNA sequence analysis. The CD28 cDNA encodes a long open reading frame of 220 residues having the typical features of an integral membrane protein (Figure 17). Removal of a predicted (von Heijne, Nucl. Acids Res. 14:4683-4690 (1986)) N-terminal signal sequence gives a mature protein of 202 residues comprising an extracellular domain with five potential N-linked glycosylation sites (Asn-X-Ser/Thr), a 27-amino acid hydrophobic membrane spanning domain, and a 41-amino acid cytoplasmic domain. Comparison of the amino acid sequence of CD28 with the National Biomedical Research Foundation database (Version 10.0) revealed substantial homology with mouse and rabbit immunoglobulin heavy-chain variable regions over a domain spanning almost the entire extracellular portion of CD28. Within this domain two cysteine residues in the homology blocks Leu-(Ser or

-71-

Thr)-Cys and Tyr-(Tyr or Phe)-Cys are shared by CD28, CD4, CD8, immunoglobulin heavy- and light-chain variable sequences and related molecules with approximately the same spacing (Maddon et al., Annu. Rev. Biochem. 48:961-997 (1979)).

CD28 cDNA directs the production of a homodimer in transfected COS cells. Immunoprecipitation of CD28 antigen from transfected COS cells was carried out using the monoclonal antibody 9.3 (Hansen, J.A., et al., Immunogenetics 10:247-260 (1980)). The material obtained from COS cells migrated with a molecular weight of 74kd under nonreducing conditions and 39 kd under reducing conditions, a pattern consistent with homodimer formation. Under the same conditions activated T cells give bands with molecular weights of 87 and 44kd, and HPB-ALL cells give bands of 92 and 50 kd, under nonreducing and reducing conditions respectively. The variation in molecular weight of the material obtained from different cell types arises as a result of differing glycosylation patterns characteristic of each type. Similar results were observed with other leukocyte surface antigens (Seed et al., Proc. Natl. Acad. Sci USA 87 (1987)). The nucleotide sequence of the CD28 cDNA predicts a mature protein with molecule weight of 23 kd, much smaller than observed in these experiments, and probably attributable to utilization of the 5 N-linked glycosylation sites predicted by the amino acid sequence.

RNA blot analysis. Equal amounts of total RNA prepared from cell types expressing or lacking CS28 were subjected to RNA blot analysis as described hereinabove. Four

-72-

bands with molecular weights of 3.7, 3.5, 1.5, and 1.3 kb were visible in lanes containing RNA thymocytes, T blasts, senescent T cells, and the T cell leukemia cell lines PEER and HPB-ALL. No bands were detected in lanes containing RNA prepared from the cell lines U937 (histiocytic leukemia), HuT-78 (Adult T cell leukemia), Jurkat (T cell leukemia), Namalwa (Burkitt lymphoma), MOLT4, and HSB-2, all of which do not express CD28. The 1.5 kb transcript presumably corresponds to the isolated cDNA, and the 3.7 and 3.5 kb species reflect incomplete splicing or alternative polyadenylation site utilization. The 1.3 kb transcript may terminate at an unconventional polyadenylation signal, since there is no obvious candidate in the sequence.

The CD28 gene is not rearranged. DNA blot analysis (Seed et al., Proc. Natl. Acad. Sci USA 87 (1987)) of genomic DNA from placenta, peripheral blood lymphocytes, T cells, HeLa cells, or the tumor lines used in the RNA blot analysis above showed identical Dra 1 digest patterns indicating that rearrangement is not involved in the normal expression of the CD28 gene during development. Similarly, no gross genomic rearrangement underlies the failure of the examined T-cell tumor lines to express CD28 antigen. It may be inferred from the Dra 1 fragment pattern that the CD28 gene contains at least two introns.

EXAMPLE IV Isolation and Molecular Cloning of Two
 Human CD7 Antigen cDNAs

The CD7 cluster of antibodies (Palker, et al., Leukocyte Typing II, Springer-verlag, New York, 303-313

-73-

(1985)) recognized a 40 kd glycoprotein (gp40) on the surface of peripheral blood T cells and thymocytes. Early studies with anti-CD7 antibodies showed that CD7⁺ T cells enhance immunoglobulin (Ig) synthesis by B cells (Miroshima et al., J. Immunol. 129:1091-1098 (1982)), suppress B cell Ig synthesis when stimulated with Concanavalin A (Haynes et al. Proc. Natl. Acad. Sci. U.S.A. 76:5829-5833 (1979)) and are the precursors of the cytotoxic T cells generated in mixed lymphocytic culture (Morishima et al., J. Immunol. 129:1091-1098 (1982)). Furthermore, CD7 has been found to be the most reliable marker for the identification of T cell acute lymphoblastic leukemia (Link et al., Blood 62:722-728 (1983)). As such, studies have been carried out, in which cytotoxins coupled to the anti-CD7 antibody 3A1 were used to purge bone marrow prior to reinfusion to avoid early relapse in autologous bone marrow transplants or as prophylaxis against graft vs. host disease in allogenic bone marrow transplants (Ramakrishnan et al., J. Immunol. 135:3616-3622 (1985)). Similarly, anti-CD7 antibodies also show promise as immunosuppressive agents in the treatment of allograft rejections (Raftery et al., Transpl. Proc., 17:2737-2739 (1985)) which is in accord with the recent observation that the anti-CD7 antibody 7G5 significantly inhibits the primary mixed lymphocyte reaction (Lazarovits et al. Leukocyte Typing III. Oxford Univ. Press, Oxford (1987)).

At present the physiological role of CD7 is not understood. It is known that anti-CD7 antibodies are not mitogenic, and do not block the T cells' response to PHA, or tetanus toxoid (Palker et al. Leukocyte Typing . Springer-verlag, New York, 303-313 (1985)). Some have

-74-

noted that expression of CD7 in thymocytes occurs prior to the onset of T cell receptor beta-chain rearrangement (Pittaluga *et al.*, *Blood*, 68:134-139 (1986)) and have pointed to a possible role for CD7 in this rearrangement and subsequent expression of the T cell receptor. It is clear that the cloning of the CD7 antigen would further efforts to understand its role in T cell physiology. Nucleotide sequencing and preliminary characterization of two cDNAs encoding the CD7 antigen was carried out according to the method of the present invention. Prompted by the recent suggestion that CD7 may be, or be part of, the T cell IgM receptor (Sandrin *et al.*, *Leukocyte Typing III*. Oxford Univ. Press, Oxford (1987)), the ability of COS cells expressing CD7 to bind IgM or IgM immune complexes was evaluated. The results do not support the simple notion that CD7 itself is an IgM receptor.

Preparation of cDNA library and recovery and characterization of CD7 clones

Preparation of an HPB-ALL cDNA library in the expression vector pIH3 was carried out as described herein. Panning of the library was carried out according to the method of the present invention, using purified anti-CD7 antibody Leu9 (Becton Dickinson) and antibody 7G5 as ascites fluid was diluted 1/1000. Methods for cell transfection, radioimmunoprecipitation, DNA and RNA blot hybridization and DNA sequencing were all as described herein.

IgM and IgG binding by COS cells transfected with CD7 and CDw32

Human IgM, IgG, and IgA antibodies, affinity

-75-

purified FITC conjugated goat anti-human immunoglobulins antibodies (anti-Ig(G+M+A)), washed and preserved bovine red blood cells, and IgG and IgM fractions of rabbit anti-bovine red blood cell antibodies were purchased from
05 Cooper Biomedical (Malverne, PA). COS cells were transfected by the DEAE Dextran method with cDNAs encoding the CD7, CDw32, and CD28 surface antigens. 48 hours after transfection the cells were washed with PBS/0.5% BSA and incubated with either human IgM, IgG or
10 IgA antibodies at a concentration of 1ug/ml, at 4°C for 2 hours. Subsequently the cells were washed with PBS/0.5% BSA and incubated for 30 minutes at 4°C with FITC conjugated rabbit anti-human immunoglobulins. After washing the cells were examined with a fluorescence
15 microscope. The experiments were also performed in the presence of 0.1% azide with the same results.

Bovine erythrocytes for rosette assays were prepared as described by Ercolani et al., J. Immunol. 127:2044-2051 (1981). Briefly, a 2% suspension of bovine
20 erythrocytes was washed with PBS/0.5% BSA and treated with subagglutinating amounts of either IgG or the IgM fraction of rabbit anti-bovine erythrocyte antibodies at 4°C for 1 hour. Erythrocytes were then washed twice with PBS/0.5% BSA and adjusted to a 2% solution. 2 ml of
25 antibody-coated erythrocytes were layered on 60mm dishes containing COS cells which had been transfected 48 hours earlier with either CD7, CD32 or CD28 by the DEAE Dextran method. The dishes were then centrifuged at 150 X g at 4°C for 15 minutes. After an additional 45 minute
30 incubation at 4°C, the plates were gently washed 5 times with 5 mls of PBS/0.5% BSA, and the COS cells were

-76-

examined for rosette formation. These experiments were also performed in the presence of 0.1% sodium azide without alteration of the results.

05 Formation of T cell rosettes with antibody-coated erythrocytes

Peripheral blood lymphocytes were obtained from heparinized blood by centrifugation at 4°C over a Ficoll-Hypaque gradient at 400 x g for 30 minutes. Leukocytes at the interface were washed two times with
10 PBS. The leukocytes were adjusted to 10Y7 cells/ml in IMDM/10% Fetal Bovine Serum (FBS) and incubated in tissue culture dishes at 37°C for 30 minutes. Nonadherent cells were transferred to new dishes, and PHA was added to
15 day the cells were washed with PBS and placed in fresh IMDM/10%FBS.

Rosette assays were performed three days later. Cells were washed with PBS/0.5% BSA, and a 10 ul suspension of 2% Ig-coated erythrocytes prepared as
20 described above was added to 10 ul of PBS/0.5% BSA containing 5×10^6 cells/ml. The mixtures were placed in Falcon round bottom 96 well plates and centrifuged at 150 X g for 15 min at 4°C. After an additional incubation of 45 min at 4°C pellets were resuspended with 10 ul of
25 PBS/0.5% BSA, and the rosettes scored by phase contrast microscopy. The experiments were carried out in both the presence and absence of 0.1% sodium azide with no detectable difference.

Isolation of cDNAs encoding the human CD7 antigen.

30 To isolate CD7 cDNAs, a large plasmid library was constructed in the expression vector H3M as describe

SUBSTITUTE SHEET

-77-

hereinabove. The library was introduced into COS cells by spheroplast fusion, and allowed to replicate and express its inserts. The COS cells were harvested by detaching without trypsin 48 to 72 hours after
05 transfection, treated with monoclonal antibodies specific for surface antigens believed to be encoded in the library, and distributed in dishes coated with affinity purified anti-mouse antibody as described herein. Under these conditions, cells expressing surface antigen adhere
10 and the remaining cells can be washed away.

A Hirt (Hirt, J. Mol. Biol., 26:365-369 (1967)) fraction was prepared from adherent cells, and the resulting DNA transformed back into E. coli for further rounds of fusion and selection. In the third round of
15 selection the detached cells were treated with a mixture of monoclonal antibodies specific for CD7 (765 and Leu9), and a Hirt supernatant was again generated and transformed into E. coli. After transformation of the DNA into E. coli 8 colonies were picked, and the plasmid
20 DNA prepared from them by an alkaline miniprep procedure (Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1982)). DNA was prepared from 8 resulting colonies and transfected into COS cells. After 3 days, surface
25 expression of the CD7 antigen was detected by indirect immunofluorescence in 7 of 8 transfected dishes. Restriction enzyme digest of the corresponding plasmid DNAs revealed two species. One contained a 1.2 kb insert, and the other a 1.3 kb insert.

-78-

CD7 cDNA sequence analysis

Both isolates were sequenced by the dideoxynucleotide method. The 1.2 kb cDNA encodes a long open reading frame of 240 residues having the typical features of an integral membrane protein. The initial assignment of the signal sequence cleavage site by the method of von Heijne (Nucl. Acids Res. 14:4683-4690 (1986)) was at the 18th residue. It later was determined, however, that the homology with immunoglobulin variable regions would better predict the mature terminus at residue 26; this assignment would also correlate well with the position of the intron as discussed below and as shown in Figure 8. Removal of the predicted N-terminal signal sequence gives a mature protein of 215 residues with a predicted molecular mass of 23kd. In the extracellular domain are two N-linked glycosylation sites (Asn-X-Ser Thr), in agreement with the results of Sutherland *et al.* (J. Immunol. 133:327-333 (1984)), who also showed the presence of O-linked glycans and covalently associated palmitic acid on the mature protein. In the 27 amino acid hydrophobic membrane spanning domain is a single cysteine residue which may be the site of fatty acylation (Rose *et al.*, Proc. Natl. Acad. Sci. USA 81:2050-2054 (1984); Kaufman *et al.*, J. Biol. Chem. 259:7230-7238 (1984)). The length of the cytoplasmic domain, 39 residues, is in good agreement with the 30-40 amino acids predicted by protease digestion of the CD7 precursor in rough microsomal membrane fractions (Sutherland *et al.*, J. Immunol. 133:327-333 (1984)).

Sequence analysis of the 1.7 kb clone (Figure 8) revealed the presence of an intron located 121 bp from the 5' end. The 411 bp intron contains stop codons in

-79-

all three reading frames and is located just downstream of the secretory signal sequence, as is frequently observed for secreted or surface proteins. Both the 5' and 3' ends of the intron conform to the splice donor/acceptor consensus AAG GTRAGA/.../Y₆₋₁₁NYAG A (Mount, Nucl. Acids Res. 10:459-472 (1982)). Because both the 1.2 and 1.7 kb clones express CD7 antigen equally well in COS cells, the intron must be excised in COS cells fairly efficiently.

Comparison of the amino acid sequence with the National Biomedical Research Foundation database revealed substantial homology with human and mouse immunoglobulin kappa chain and T-cell receptor gamma chain variable regions over almost the entire extracellular portion of the molecule. Two cysteine residues shared in approximately equal spacing by all three structures fall in the conserved sequences Ile-Thr-Cys and Tyr-X-Cys. In kappa chain variable regions these cysteins form a disulfide bridge. The presence of at least one intrastrand disulfide bond in the CD7 structure has previously been proposed by Sutherland et al. (J. Immunol. 133:327-333 (1984)), who noted that immunoprecipitation of CD7 gave rise to a band with an apparent molecular mass of 40 kd under reducing conditions and 38 kd under nonreducing conditions.

Based on the homology with immunoglobulin V-regions, it is predicted that CD7 contains a disulfide bond linking Cys 23 and Cys 89. A second disulfide bond, linking Cys 10 and Cys 117, has been proposed, based on the structural similarity between CD7 and Thy-1. The extracellular domains of both Thy-1 and CD7 have 4 cysteine residues, in roughly homologous positions. The

-80-

4 cysteine residues, in roughly homologous positions. The 4 cysteine residues of Thy-1 are joined in two internal disulfide bridges between Cys 9-111 and Cys 19-85 (Williams *et al.*, *Science* 216:696-703 (1982)). In
05 Thy-1, Cys 111 forms an amide bond with the ethanolamine moiety of a substituted phosphatidylinositol, and is thus the last residue of the mature molecule (Tse *et al.*,
Science 230:1003-1008 (1985)). In CD7, Cys 117 is followed by four repeats of a sequence whose consensus is
10 Xaa-Pro-Pro-Xaa-Ala-Ser-Ala-Leu-Pro, and which, it is proposed, plays the role of a stalk projecting the V-like domain away from the surface of the cell.

In addition to the homologies shown in Figure 20 and mentioned above, the extracellular domain of CD7 has
15 significant homology with both chains of the rat CD8 heterodimer (Johnson *et al.*, *Nature* 323:74-76 (1986)), and the myelin P₀ protein (Lemke *et al.*, *Cell* 40:501-508 (1985)).

20 CD7 directs the production of a 40 kd protein in transfected COS cells

Immunoprecipitation of CD7 antigen from transfected COS cells was carried out as described herein using monoclonal antibody 7G5 (Lazarovits *et al.*, *Leukocyte Typing III*, Oxford Univ. Press, publisher, Oxford,
25 England (1987)). The material obtained from COS cells migrated with as a broad band with molecular weight of 40 kd under reducing conditions. Under the same conditions HPB-ALL cells (the cDNA donor line) and activated T cells gave bands with molecular widths of 41 and 39 kd
30 respectively. In both the COS cell and HPB-ALL lane a faint band with molecular weight of 30 kd was also

-81-

observed, possibly corresponding to a partially glycosylated precursor (Sutherland, D.R., et al., J. Immunol. 133:327-333 (1984)).

RNA blot analysis

- 05 Equal amounts of total RNA prepared from cell types expressing or lacking CD7 were subjected to Northern blot analysis as described herein. A single 1.3 kb species was visible in lanes containing RNA from thymocytes, activated T cells, resting T cells, and the T cell
- 10 leukemia lines HuT-78, HPB-ALL, Jurkat J3R7, HSB-2 and PEER. With the exception of the PEER cell line, none of the T cell tumors showed significant overexpression of CD7 transcripts. CD7 RNA was detected in all of the thymus-derived cells, but not in RNA from U937
- 15 (histiocytic leukemia) and Namalwa (Burkitt Lymphoma) cells. No band corresponding to the 1.7 kb cDNA could be detected, suggesting that this species is artificially enriched during the cloning or library amplification process.
- 20 Enrichment during amplification seems unlikely because the 12 kb cDNA clone propagates as well in E. coli as the 1.7 kb clone. However, immediately upstream and downstream from the site of insertion of the intron are sequences that could form an interrupted stem and
- 25 loop structure. Eight of the 10 basepairs of the potential stem are GC pairs, perhaps giving the structure sufficient stability to interfere with elongation of the cDNA first strand. The presence of the intron greatly separates the two halves of the stem, potentially
- 30 eliminating the structure via unfavorable loop entropy and allowing efficient first strand synthesis.

-82-

The CD7 gene is not rearranged

Southern blot analysis of genomic DNA from placenta, peripheral blood lymphocytes, T cells, HeLa cells, or the tumor lines used in the RNA blot analysis above showed
05 identical Dra 1 digest patterns. Thus, the CD7 gene is not grossly altered during development, and the high level of expression in the PEER cell line is not the consequence of a substantial genomic rearrangement.

COS cells expressing CD7 do not bind IgM

10 Human peripheral blood T lymphocytes express receptors for IgM antibodies (FcRu: Moretta et al., Eur. J. Immunol. 5:565-569 (1975); McConnell et al., Immunol. 30:835-837 (1976)). Recently it has been reported that CD7 might play a role in IgM binding by T cells (Sandrin
15 et al., Leukocyte Typing III, Oxford Univ. Press, publisher, Oxford, England (1987)). L cells, normally CD7⁻ and FcRu⁻, become CD7⁺ and FcRu⁺ when transfected with a 16 kb genomic fragment encoding the CD7 antigen (Sandrin et al., Leukocyte Typing III, Oxford Univ.
20 Press, publisher, Oxford, England (1987)). Furthermore, IgM binding to CD7-positive cells can be blocked by the anti-CD7 monoclonal antibody Huly-m2 (Thurlow et al., Transplantation 38:143-147 (1984)), and IgM columns bind a 37 kd protein from radiolabeled lysates of peripheral
25 blood T lymphocytes (Sandrin et al., Leukocyte Typing III, Oxford Univ. Press, publisher, Oxford, England (1987)).

Accordingly, COS cells expressing CD7 were tested for their ability to bind IgM. IgM receptor activity was
30 assayed either by direct binding (Hardin et al., Proc. Natl. Acad. Sci. USA 76:912-914 (1979)) or by a rosette

-83-

assay with ox erythrocytes coated with an IgM fraction of rabbit anti-bovine red cell serum as described by Ercolani *et al.* J. Immunol. 127:2044-2051 (1981)). Cells expressing CD7 neither bound human IgM nor formed
05 rosettes with IgM-coated erythrocytes. Under the same conditions, COS cells transfected with a cDNA encoding the human IgG receptor CDw32 bound IgG directly and formed rosettes with IgG-coated erythrocytes. Erythrocytes coated with IgM or IgG antibodies also
10 adhered to a fraction of peripheral blood lymphocytes as reported (Moretta *et al.*, Eur. J. Immunol. 5:565-569 (1975)).

These results do not support the notion that the CD7 antigen is by itself an IgM receptor, although they do
15 not exclude the possibility that COS cells suppress IgM binding activity in some manner, or that CD7 is part of, or modified to become, an IgM receptor. That CD7 is not by itself an IgM receptor is supported by the observation that a number of CD7⁺ T cell lines are FcRu-(Sandrin *et al.*, Leukocyte Typing III, Oxford Univ. Press, publisher,
20 Oxford, England (1987)).

EXAMPLE V Isolation and Molecular Cloning of the
 Human CDw32 Antigen

A cDNA encoding the human CDw32 antigen, a human
25 receptor for immunoglobulin G constant domains (Fc receptor), was isolated by the method of the present invention, by virtue of its affinity for its ligand, IgG. The sequence of the isolated clone is most closely related to the murine beta 2 Fc receptor, but has
30 diverged completely in the portion encoding the

-84-

cytoplasmic domain. The receptor expressed in COS cells shows a preference for IgG₁ among IgG subtypes, and no affinity for IgM, IgA or IgE.

To isolate the Fc receptor clone, cDNA libraries
05 were prepared from tumor cell lines or from a human tumor and transfected into COS cells. After 48 hours, the cells were treated with mouse or human IgG antibodies, and allowed to settle on dishes coated with
affinity-purified sheep anti-mouse IgG or goat anti-human
10 IgG antibodies. After lysis, DNA recovery, and transformation in E. coli, the cycle was repeated for two more rounds. Although no positive clones were isolated from the tumor line libraries, a cDNA clone encoding an Fc receptor was isolated from a library prepared from a
15 human adrenal tumor. It has been discovered that many tumors are heavily infiltrated by macrophages and lymphocytes. Thus, tumor RNA may be a productive source in general for transcripts of human macrophages.

By indirect immunofluorescence assay, the human
20 receptor expressed on COS cells bound all mouse and human IgGs with relatively low affinity (10^{-7} M), and a clear discrimination was noted among human antibodies for IgG₁. Human IgM, IgA₁, IgA₂, and IgE did not bind, nor did murine IgM or IgA. As expected, human Fc, but not Fab
25 fragments, bound to the transfected cells. Among monoclonal antibodies donated to the Third International Workshop on Leukocyte Differentiation Antigens, three gave strong positive immunofluorescence: two (out of two) recognizing the Fc Receptor CDw32 determinant, and
30 one (out of four) recognizing the CD23 (B cell IgE Fc receptor) determinant. Monoclonals recognizing the T cell/Macrophage Fc receptor antigen CD16 gave only weak

-85-

immunofluorescence comparable to that shown by control ascites.

Radioimmunoprecipitation of transfected COS cells with CDw32 antibodies showed the presence of a single
05 40kd species, comparable in size to the antigen recognized on the surface of the myeloid CDw32⁺ line HL-60, and to the less abundant antigen present on the histiocytic leukemia line U937. This result reinforces the notion that the isolated receptor is CDw32, as the
10 CD16 receptor is reported to be substantially larger (60-70kd).

The nucleotide sequence of the isolated receptor (Figure 9) is highly homologous to that of members of the recently isolated murine receptor family, and most
15 closely related to the murine beta₂ receptor by nucleic acid homology. Surprisingly, the murine beta₂ receptor is found on T and B lymphocytes and macrophages, while the alpha receptor is restricted to macrophages; in the human system, CDw32 (shown here to be beta₂-like) is
20 restricted to macrophages while another Fc receptor (CD16) is found on lymphocytes and macrophages. The human sequence appears to have diverged from the mouse sequence by insertion of approximately 1kb of DNA a few bases 3' to the junction between the transmembrane and
25 cytoplasmic domains. The junctions of the insertion site do not show obvious relationships to splice donor and acceptor sequences. Comparison of the human and murine peptide sequences showed that the peptide sequence diverges at the end of the transmembrane domain, before
30 the nucleotide sequence diverges, suggesting the existence of a selective pressure favoring the creation of a different cytoplasmic domain.

-86-

RNA blot analysis showed that myeloid but not lymphocytic cell lines expressed RNA homologous to the CDW32 probe. DNA blot analysis showed multiple bands consistent with the existence of a small multigene family.

EXAMPLE VI Isolation and Molecular Cloning of Two
cDNA Clones Encoding the B Lymphocyte-
specific CD20 (B1, Bp35) Antigen

Recent studies suggest that the pan B cell antigen CD20 (B1, Bp35) plays an important role in B cell activation. Monoclonal antibodies (mAb) to CD20 induce different cellular responses depending on the antibody used and the stage of differentiation or activation of the target B cells. The monoclonal antibody 1F5 activates resting B cells by initiating the transition from the G_0 to the G_1 phase of the cell cycle, and induces dense tonsillar B cells to proliferate (Clark et al., Proc. Natl. Acad. Sci USA 82:1766 (1985); Clark and Shu, J. Immunol. 138:720 (1987)). However, 1F5 does not induce an increase in cytoplasmic free calcium and does not induce circulating B cells to proliferate (Rabinovitch et al., In: Leukocyte Typing III (McMichael, Ed.), p. 435, Oxford University Press (1987))/ Other anti-Cd20 mAbs, such as B1, have been shown to block B cell activation (Tedder et al., J. Immunol. 135:973 (1985)) and both 1F5 and B1 can inhibit B cell differentiation (Golay et al., J. Immunol. 135:3795 (1985)). Recently it has been suggested that phosphorylation and internalization of CD20 may be necessary steps for B cell entry into the G_1 phase of the

-87-

cell cycle (Valentine et al., In: Leukocyte Typing III (McMichael, Ed.), p. 440, Oxford University Press (1987)). In the present example, two CD20 cDNA clones were isolated and expressed using the methods of the
05 present invention.

Preparation of cDNA Library and Recovery of cDNA Clones
by Panning

Poly (A)⁺ RNA was prepared from the human Burkitt cell line Daudi by oligo (dT) cellulose chromatography of
10 total RNA isolated by procedures described herein. cDNA preparation and expression library construction were carried out as described.

Anti CD20 mAbs 1F5, 2H7, B1, L27, G28-2, 93-1B3, B-C1, and NU-B2 were obtained from the International
15 Leukocyte Typing Workshop (Valentine et al., In: Leukocyte Typing III (McMichael, Ed.), p. 440, Oxford University Press (1987)). Purified mAbs were used at a concentration of 1ug/ml and ascites were used at a dilution of 1:1000. Panning was done according to the
20 present method. In the first round of screening, eight 10cm dishes of 50% confluent COS cells were transfected by the DEAE-Dextran method. Subsequent screening cycles were performed by spheroplast fusion.

Immunoprecipitation, Sequencing, RNA and DNA Blot
25 Hybridization

B cell lines CESS and Daudi were metabolically labeled with ³⁵S-methionine and ³⁵S-cysteine for 6h at 37°C. COS cells transfected by the DEAE-Dextran method were similarly labeled 36 hours post-transfection. The

-88-

labeled cells were incubated with the B1 mAb (Coulter) at 4°C for 1h, washed in PBS, and lysed with 0.5% NP-40, 0.1% SDS, 0.05% deoxycholate and 1mM PMSF in PBS. After centrifuging (13000xg, 5 min.), the lysate was incubated
05 with fixed S. aureus cells (Calbiochem) for 1 hr at 4°C. The S.aureus cells were pelleted, washed 5 times with 1%NP-40/PBS, eluted and electrophoresed through 12.5% polyacrylamide gels.

DNA and RNA blot analysis and hybridization probe
10 preparation were carried out as described. Sequencing was done by the method of Sanger et al. Proc. Natl. Acad. Sci. USA 74:5463 (1977)). The nucleotide sequence of the CD20.4 cDNA is represented in Figure 10.

Two cDNA clones, bearing inserts of 1.5 (CD20.4) and
15 1.0 kb (CD20.6), were isolated from a Daudi cell DNA library by panning with a panel of mAbs against CD20. COS cells transfected with either clone reacted with all members of the panel of antibodies. Immunoprecipitation of the cDNA-enclosed protein from transfected COS cells
20 showed two bands of 32 and 30kd reminiscent of the 37 and 35kd bands observed in different B cell subsets and lines (Valentine et al., "Structure and Function of the B Cell Specific 35-37kDa CD20 Protein," In: Leukocyte Typing III, A. McMichael et al., eds., Oxford University Press,
25 p. 440 (1987)). It has been the experience of the present inventors that the molecular masses of surface antigens expressed in COS cells are consistently smaller than those of their native counterparts. This may be due to differences in glycosylation.

30 Both cDNA clones have the same coding sequence, and differ only in the 3' untranslated region. The insert in clone CD20.6 has a short polyA tail and lacks a consensus

-89-

polyadenylation signal, while the insert in CD20.4 lacks a polyA tail and extends 431bp beyond the 3' terminus in CD20.6 (Fig. 10A).

RNA blot analysis showed that three transcripts of 3.8, 3.0 and 1.5 kb were present in B cells but absent from other cell types, in agreement with the known pattern of antibody reactivity (Clark *et al.*, Proc. Natl. Acad. Sci. USA 82:1766 (1985); Clark *et al.*, J. Immunol. 138:720 (1987); Tedder *et al.*, J. Immunol. 135:973 (1985); Golay *et al.*, J. Immunol. 135:3795 (1985)). It appears likely that the CD20.6 clone is derived from the 1.5 kb transcript or possibly from an even shorter, undetectable species. Because the CD20.4 clone lacks a poly(A)⁺ tail, its source cannot be inferred at present.

DNA blot analysis showed that the CD20 genomic sequences are not rearranged during development and are not amplified in the cell lines examined. A restriction fragment length polymorphism was observed in a DNA sample obtained from placenta.

The amino acid sequence predicted by the cDNA contains 297 residues and has a molecular mass of 33,097 daltons. The sequence contains three major hydrophobic stretches involving residues 51-103, 117-141 and 183-203 (Fig.10). Two other notable characteristics are the absence of an amino-terminal signal peptide and the presence of a highly charged carboxy-terminal domain. A polyclonal anti-CD20 antibody that recognized the last 18 residues of the carboxy-terminus reacts with lysates of cells expressing CD20 but not with intact cells, suggesting that the CD20 carboxy terminus is located within the cytoplasm. Since there is no amino-terminal signal peptide, it is likely that the amino-terminus is

-90-

also intracellular, and that the first hydrophobic region acts as an internal membrane insertion signal (Zerial et al., EMBO J. 5:1543 (1986)). The first hydrophobic region is composed of 53 residues and is therefore long enough to span the membrane twice if organized as an alpha helix. Because there are two remaining hydrophobic regions, the intracellular side. Alternatively, the carboxy-terminus requires that the first hydrophobic domain exit the membrane on the intracellular side.

Alternatively, the carboxy-terminal antibody may only recognize epitopes exposed by detergent treatment allowing the carboxy-terminus to be extracellular and forcing the first hydrophobic domain to exit the membrane on the extracellular side. The sequence contains 2 potential N-glycosylation sites (Asn-Xaa-Ser/Thr, where Xaa cannot be Pro (Bause, Biochem. J. 209:331 (1983)) at positions 9 and 293, but neither of these is expected to be used if located in intracellular domains of the molecule. The difference in molecular mass between CD20 expressed on COS cells and on B cells is therefore presumably due to O-linked glycosylation, although other forms of post-translational modification are not excluded. If the carboxy-terminus is intracellular, the only extracellular domain would lie between residues 142 and 182. This region is rich in serine and threonine residues which might support O-glycosylation.

The observation of two protein species in COS cells cannot be explained by alternate splice formation because the cDNA sequence does not contain any promising splice donor or acceptor sequences (Shapiro et al., Nucl. Acids Res. 15:7155 (1987)). A difference in glycosylation or alternate translational initiation site selection may

SUBSTITUTE SHEET

-91-

account for the two species observed. Initiation at either the first or the second ATG gives protein molecular masses of 33.1 and 30.8 kd respectively, in good agreement with the sizes observed in COS cells.

05 Neither ATG is embedded in the consensus sequence proposed by Kozak (Nucl. Acids Res. 12:857 (1984)). Use of alternate initiation sites has been reported for several proteins (Kozak, Nucl. Acids Res. 12:857 (1984)).

Comparison of the peptide sequence with the
10 sequences in the National Biomedical Research Foundation database showed no significant homology by the FASTP rapid sequence alignment algorithm. Because the bulk of the protein appears to be confined to the interior of the membrane and the cell, it seems plausible that it may
15 play a role in transducing signals from other transmembrane proteins to the cell interior. Consistent with this role is the relatively hydrophilic nature of the hydrophobic regions which might allow hydrogen bond interactions with the transmembrane portions of other
20 proteins.

EXAMPLE VII Isolation and Molecular Cloning of ICAM,
 An Adhesion Ligand of LFA-1

Antigen-specific cell contacts in the immune system are strengthened by antigen-non-specific interactions
25 mediated in part by lymphocyte function associated or LFA antigens (Springer, T.A., et al., Annu. Rev. Immunol. 5:223-252 (1987); Anderson, D.C., et al., Annu. Rev. Medicine 5:175-194 (1987)). The LFA-1 antigen, a major receptor of T cells, B cells and granulocytes (Rothlein,
30 R., et al., Exp. Med. 163:1132-1149 (1987)), is involved

-92-

in cytolytic conjugate formation, antibody-dependent killing by NK cells and granulocytes, and helper T cell interactions. LFA-1 has been placed in the integrin family of cell surface receptors by virtue of the high sequence similarity between the LFA-1 and integrin beta chains (Kishimoto, T.K., et al., Cell 48:681-690 (1987); Hynes, R.O. Cell 48:549-554 (1987)). The adhesion ligands of the integrin family are glycoproteins bearing the Arg-Gly-Asp (RGD) sequence motif, e.g., fibronectin, fibrinogen, vitronectin and von Willebrand factor (Ruoslahti, E., et al., Cell 44:517-518 (1987)).

In this example, the Intercellular Adhesion Molecule-1 (ICAM-1), a ligand for LFA-1 (Rothlein, R., et al., J. Immunol. 137:1270-1275 (1986); Dustin, M.L., et al., J. Immunol. 137:245-254 (1986)), was cloned according to the methods of the present invention. ICAM contains no RGD motifs, and instead is homologous to the neural cell adhesion molecule NCAM (Cunningham, B.A., et al., Science 236:799-806 (1987); Barthels, D., et al., EMBO J. 6:907-914 (1987)). COS cells transfected with the ICAM cDNA clone bind myeloid cells by a specific interaction which can be blocked by monoclonal antibodies directed against either LFA-1 or ICAM-1.

A cDNA library was constructed using RNA prepared from HL60 cells induced with phorbol myristyl acetate (PMA). The library was transfected into COS cells and cells expressing surface antigens were recovered according to the methods of the present invention by panning with the anti-ICAM monoclonal antibodies (mAbs) 8F5 and 84H10 (McMichael, A.J., et al., eds., Leukocyte Typing III. White Cell Differentiation Antigens, Oxford University Press (1987)). Episomal DNA was recovered

-93-

from the panned cells and the expression-panning cycle repeated a further 2 times to obtain a cDNA clone designated pICAM-1.

COS cells transfected with pICAM-1 gave positive surface immunofluorescence reactions with three anti-ICAM-1 antibodies: 8F5; 84H10; and RR-1. Immunoprecipitation of pICAM-1-transfected COS cells with the mAb 84H10 gave a band of molecular mass 100kD. 30). A slightly larger protein of 110 kD was precipitated from HL60 cells induced for 48 hours with either phorbol myristyl acetate (PMA), gamma-interferon (gammaIFN), tumour necrosis factor (TNF), or interleukin-1 beta (IL-1 beta), but was absent from uninduced cells. The smaller molecular mass of ICAM-1 expressed in COS cells is consistent with the lower molecular masses observed for other surface antigens expressed in COS cells.

RNA blot analysis showed 2 species of 3.2 kb and 1.9 kb present in HL60 cells stimulated with either PMA, gamma IFN, TNF or IL-1 gamma, but absent in uninduced cells. Thus, the expression of ICAM-1 is regulated by a number of cytokines, apparently at the level of transcription. Similar species were present in B cells (JY and Raji), T cells (Peer and T blasts) and Lymphokine Activated Killer cells (LAK). The structure of these ICAM-1 transcripts and their relationship to the pICAM-1 cDNA remains to be established. Blot hybridization of genomic DNA from placenta revealed a pattern consistent with a single copy gene.

To investigate whether pICAM-1 encodes a functional cell adhesion molecule, COS cells expressing ICAM-1 were tested for their ability to bind HL60 cells. After 30 minutes at 37°C in the presence of Mg^{2+} , HL60 cells

SUBSTITUTE SHEET

-94-

strongly adhered to the ICAM-expressing COS cells, but not to mock transfected cells. The specificity of this adhesion was demonstrated by preincubating the ICAM-1 expressing COS cells with mAb 84H10. All HL60 binding was abolished under these conditions. An isotype matched monoclonal antibody, W6/32, which recognizes a monomorphic HLA-ABC related determinant of approximately equal abundance to ICAM-1 on transfected COS cells, had no effect on the adhesion. Similarly, preincubation of the HL60 cells with either 84H10 or W6/32 did not inhibit binding.

To determine if LFA-1 was acting as the receptor for ICAM-1 in this system, HL60 cells were pretreated with antibodies against the beta chain of LFA-1 (CD18 (McMichael, A.J., et al., eds., Leukocyte Typing III. White Cell Differentiation Antigens, Oxford University Press (1987))) and then subjected to the binding assay. All adhesion to ICAM-expressing COS cells was blocked. Pretreatment of COS cells with the CD18 antibodies had no effect on the adhesion. This provides direct evidence that ICAM-1 is indeed acting as an adhesion ligand for LFA-1.

The sequence of the pICAM-1 cDNA insert consists of 1846 nucleotides (Fig. 11). The predicted peptide sequence of 532 residues has the typical features of a transmembrane protein including a putative signal sequence, which may be cleaved between glycine-25 and asparagine-26 (von Heijne, G., Nucl. Acids Res. 14:4683-4690 (1986)), and a single 25 residue membrane-spanning domain terminating in a short, highly charged cytoplasmic domain. The extracellular domain contains seven potential N-linked glycosylation sites

-95-

which could adequately explain the difference in size between the deglycosylated precursor (55 kD) and the final product (90-115 kD) (Dustin, M.L., et al., J. Immunol. 137:245-254 (1986)). Differential use of these putative glycosylation sites could also explain the heterogeneous molecular mass of ICAM-1 observed in different cell types (Dustin, M.L., et al., J. Immunol. 137:245-254 (1986)).

LFA-1 is a member of the integrin family of cell surface receptors (Kishimoto, T.K., et al., Cell 48:681-690 (1987); Hynes, R.O., Cell 48:549-554 (1987)). The tripeptide motif Arg-Gly-Asp (RGD) is a common feature of the ligands for this family, e.g., fibronectin, fibrinogen, vitronectin and von Willebrand factor, and is crucial for ligand-receptor interaction (Ruoslahti, E., et al., Cell 44:517-518 (1987)). However, ICAM-1 contains no RGD motifs, bearing instead a single RGE sequence at position 152. A search of the National Biomedical Research Foundation (Dayhoff, M.O., et al., Methods Enzymol. 91:524-545 (1983)) (NBRF) database revealed no significant similarities to other proteins. However, a comparison to a laboratory database containing recently published surface proteins did reveal a surprising and significant similarity between ICAM-1 and the neural cell adhesion molecule NCAM-1 (Cunningham, B.A., et al., Scienc 236:799-806 (1987); Barthels, D., et al., EMBO J. 6:907-914 (1987)). The optimal alignment score obtained using the NBRF ALIGN program is 8 standard deviations above the mean score obtained from 500 random permutations of the sequences. The probability of the spontaneous occurrence of an equal or higher score is approximately 10^{-9} .

-96-

Using a database of known immunoglobulin related sequences, it has been shown that ICAM-1 may be divided into five Ig domains (28-112, 115-206, 217-310, 312-391, and 399-477) each of which shows significant similarity with other members of the Ig superfamily (Williams, A.F., Immunol. Today 8:298-3-3 (1987)). For example, domain I is similar to CD3 whilst domains IV and V are similar to domains of myelin associated glycoprotein (Arguint, M., et al., Proc. Natl. Acad. Sci. USA 84:600-604 (1987)) and carcinoembryonic antigen (Beauchemin, N., et al., Mol. Cell. Biol. 7:3221-3230 (1987)). All five Ig domains of NCAM align with the Ig segments in ICAM, and the principal contribution to the similarity comes from domains II and III of ICAM. Finally, the T cell-specific adhesion molecule CD2 shows roughly the same similarity to NCAM as does ICAM, but ICAM and CD2 are only weakly related. Thus, some precursor of NCAM is ancestral to both ICAM and CD2.

The availability of a functional ICAM-1 cDNA will allow a better assessment of the role of ICAM-1/LFA-1 mediated adhesion in antigen-specific leukocyte function, including T-cell mediated killing, T-helper responses and antibody-dependent cell mediated killing.

EXAMPLE VIII Isolation and Molecular Cloning of the
Human CD19, CD20, CD22, CDW32a, CDW32b,
and CD40 Antigens

The rapid immunoselection cloning method of the present invention was applied to isolate and clone the CD19, CD20, CD22, CDW32a, CDW32b, and CD40 antigens. The nucleotide sequence of CD19 is shown in Figure 12. The

SUBSTITUTE SHEET

-97-

nucleotide sequence of CD20 is shown in Figure 13. The
nucleotide sequence of CD22 is shown in Figure 14. The
nucleotide sequence of CDw32a is shown in Figure 15. The
nucleotide sequence of CDw32b is shown in Figure 16. The
05 nucleotide sequence of CD40 is shown in Figure 17.

Equivalents

Those skilled in the art will recognize or be able
to ascertain, using no more than routine experimentation,
many equivalents to the specific embodiments of the
10 invention described herein. Such equivalents are
intended to be encompassed within the scope of this
invention.

CLAIMS

1. A method for cloning a cDNA encoding a cell surface antigen, comprising:
 - (a) preparing a cDNA library;
 - (b) introducing said cDNA library into mammalian tissue culture cells;
 - (c) culturing said cells under conditions allowing expression of said cell surface antigen by said cells;
 - (d) exposing said cells to a first antibody directed against said cell surface antigen selected from the group consisting of CD1a, CD1b, CD1c, CD6, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, FcRIa, FcRIb, TLIa, and Lev-8;
 - (e) thereafter exposing said cells to a substrate coated with a second antibody directed against said first antibody, thereby causing said cells to adhere to said substrate; and
 - (f) separating adherent from non-adherent cells.
2. The method of claim 1 wherein said cDNA library is prepared from RNA extracted from a human cell line.
3. The method of claim 2, wherein said cell line is selected from the group consisting of HPB-ALL and JY.
4. The method of claim 1, wherein said cDNA library is prepared from RNA extracted from human tumor cells.
5. The method of claim 4, wherein said human tumor cell is a human adrenal tumor cell.

6. A cloned cDNA segment encoding a cell surface antigen selected from the group consisting of CD1a, CD1b, CD1c, CD6, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, FcRIa, FcRIb, TLIa, and Lev-8, or a functional derivative thereof.
7. A substantially pure protein selected from the group consisting of CD1a, CD1b, CD1c, CD6, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, FcRIa, FcRIb, TLIa, and Lev-8, or a functional derivative thereof.
8. Substantially pure CDw32a antigen, or a functional derivative thereof.
9. Substantially pure CDw32b antigen, or a functional derivative thereof.
10. Substantially pure CD20 antigen, or a functional derivative thereof.
11. Substantially pure CD19 antigen, or a functional derivative thereof.
12. Substantially pure CD22 antigen, or a functional derivative thereof.
13. Substantially pure CD22 antigen, or a functional derivative thereof.
14. Substantially pure CD40 antigen, or a functional derivative thereof.

15. Substantially pure cDNA comprising the nucleotide sequence shown in Figure 15, or a functional derivative thereof.
16. Substantially pure cDNA comprising the nucleotide sequence shown in Figure 16, or a functional derivative thereof.
17. Substantially pure cDNA comprising the nucleotide sequence shown in Figure 13, or a functional derivative thereof.
18. Substantially pure cDNA comprising the nucleotide sequence shown in Figure 12, or a functional derivative thereof.
19. Substantially pure cDNA comprising the nucleotide sequence shown in Figure 14, or a functional derivative thereof.
20. Substantially pure cDNA comprising the nucleotide sequence shown in Figure 11, or a functional derivative thereof.
21. Substantially pure cDNA comprising the nucleotide sequence shown in Figure 17, or a functional derivative thereof.
22. Substantially pure protein having the amino acid sequence shown in Figure 10, or a functional derivative thereof.
23. Substantially pure protein having the amino acid sequence shown in Figure 11, or a functional derivative thereof.

24. A pharmaceutical composition comprising substantially pure cell surface antigen, said cell surface antigen present in soluble form or in the form of an acceptable salt.
25. A pharmaceutical composition of claim 57 additionally comprising an acceptable carrier.
26. A pharmaceutical composition of claim 25, wherein the cell surface antigen is selected from the group consisting of CD1a, CD1b, CD1c, CD6, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43, ICAM, FcRIa, FcRIb, TLIa, and Lev-8, or a functional derivative of said cell surface antigen.
27. A pharmaceutical composition of claim 26, additionally comprising a therapeutic agent.
28. An immunotherapeutic agent, comprising substantially pure cell surface protein, an acceptable carrier and a therapeutic agent.
29. A kit useful for immunodiagnostic assay, comprising substantially pure cell surface antigen in soluble form and a containing means.

1 GGCCTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT
51 TTGTTTGCCG GATCAAGAGC TACCAACTCT TTTTCCGAAG GAACTGGCTT
101 CAGCAGAGCG CAGATACCAA ATACTGTCCT TCTAGTGTAG CCGTAGTTAG
151 GCCACCACTT CAAGAACTCT GTAGCACCGC CTACATACCT CGCTCTGCTA
201 ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC GATAAGTCGT GTCTTACCGG
251 GTTGGACTCA AGACGATAGT TACCGGATAA GGCGCAGCGG TCGGGCTGAA
301 CGGGGGGTTC GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA
351 CTGAGATACC TACAGCGTGA GCTATGAGAA AGCGCCACGC TTCCCGAAGG
401 GAGAAAGGCG GACAGGTATC CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC
451 GCACGAGGGA GCTTCCAGGG GGAAACGCCT GGTATCTTTA TAGTCCTGTC
501 GGGTTTCGCC ACCTCTGACT TGAGCGTCGA TTTTGTGAT GCTCGTCAGG
551 GGGGCGGAGC CTATGGAAAA ACGCCAGCAA CGCCGAATTA cgcgcgtCTT
601 TCTCAACGTA AACTTTTACA GCGGCGCGTC ATTTGATATG ATGCGCCCCG
651 CTTCCCGATA AGGGAGCAGG CCAGTAAAAG CATTACCCGT GGTGGGGTTC
701 CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA
751 GGTTCAATC CTTCCCCAC CACCATCACT TTCAAAGTC CGAAAGAATC
801 TGCTCCCTGC TTGTGTGTTG GAGGTCGCTG AGTAGTGGC GAGTAAATTT
851 TAAGCTACAA CAAGGCAAGG CTTGACCGAC AATTGCATGA AGAATCTGCT
901 TAGGGTTAGG CGTTTTGCGC TGCTTCGCGA TGTACGGGCC AGATATACGC
951 GTTGACATTG ATTATTGACT AGTTATTAAT AGTAATCAAT TACGGGGTCA
1001 TTAGTTCATA GCCCATATAT GGAGTTCGC GTTACATAAC TTACGGTAAA
1051 TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG ACGTCAATAA
1101 TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA
1151 TGGGTGGACT ATTTACGGTA AACTGCCAC TTGGCAGTAC ATCAAGTGTA
1201 TCATATGCCA AGTACGCCCC CTATTGACGT CAATGACGGT AAATGGCCCG
1251 CCTGGCATTG TGCCAGTAC ATGACCTTAT GGGACTTTCC TACTTGGCAG
1301 TACATCTACG TATTAGTCAT CGCTATTACC ATGGTGATGC GGTTTTGGCA
1351 GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA TTTCCAAGTC
1401 TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG
1451 GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG
1501 AATTCCTGGG CGGGACTGGG GAGTGGCGAG CCCTCAGATG CTGCATATAA
1551 GCAGCTGCTT TTTGCCTGTA CTGGGTCTCT CTGGTTAGAC CAGATCTGAG
1601 CCTGGGAGCT CTCTGGCTAA CTAGAGAACC CACTGCTTAA GCCTCAATAA
1651 AGCTTCTAGA GATCCCTCGA CCTCGAGGGA TCTTCCATAC CTACCAGTTC

FIG. 1.

1701 TCGGCCTGCA GGTGCGGCC GCGACTCTAG AGGATCTTTG TGAAGGAACC
1751 TTACTTCTGT GGTGTGACAT AATTGGACAA ACTACCTACA GAGATTTAAA
1801 GCTCTAAGGT AAATATAAAA TTTTAAAGTG TATAATGTGT TAAACTACTG
1851 ATTCTAATTG TTTGTGTATT TTAGATTCCA ACCTATGGAA CTGATGAATG
1901 GGAGCAGTGG TGAATGCCT TTAATGAGGA AAACCTGTTT TGCTCAGAAG
1951 AAATGCCATC TAGTGATGAT GAGGCTACTG CTGACTCTCA ACATTCTACT
2001 CCTCCAAAAA AGAAGAGAAA GGTAGAAGAC CCCAAGGACT TTCCTTCAGA
2051 ATTGCTAAGT TTTTGTAGTC ATGCTGTGTT TAGTAATAGA ACTCTTGCTT
2101 GCTTTGCTAT TTACACCACA AAGGAAAAAG CTGCACTGCT ATACAAGAAA
2151 ATTATGGAAA AATATTCTGT AACCTTTATA AGTAGGCATA ACAGTTATAA
2201 TCATAACATA CTGTTTTTTC TTA CTCCACA CAGGCATAGA GTGTCTGCTA
2251 TTAATAACTA TGCTCAAAAA TTGTGTACCT TTAGCTTTTT AATTTGTAAA
2301 GGGGTTAATA AGGAATATTT GATGTATAGT GCCTTGACTA GAGATCATAA
2351 TCAGCCATAC CACATTTGTA GAGGTTTTAC TTGCTTTAAA AAACCTCCCA
2401 CACCTCCCC TGAACCTGAA ACATAAAATG AATGCAATTG TTGTTGTAA
2451 CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT AGCATCACAA
2501 ATTTACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG TGGTTTGTC
2551 AAATCATCA ATGTATCTTA TCATGTCTGG ATCCTGTGGA ATGTGTGTCA
2601 GTTAGGGTGT GGAAAGTCCC CAGGCTCCCC AGCAGGCAGA AGTATGCAAA
2651 GCATGCATCT CAATTAGTCA GCAACCAGGT GTGGAAAGTC CCCAGGCTCC
2701 CCAGCAGGCA GAAGTATGCA AAGCATGCAT CTCAATTAGT CAGCAACCAT
2751 AGTCCCGCCC CTAATCCGC CCATCCCGCC CCTAACTCCG CCCAGTCCG
2801 CCCATTCTCC GCCCCATGGC TGAATAATTT TTTTATTTA TGCAGAGGCC
2851 GAGGCCGCCT CGGCCTCTGA GCTATTCCAG AAGTAGTGAG GAGGCTTTTT
2901 TGGAGGCCTA GGCTTTTGCA AAAAGCTAAT TC

FIG. 1. (CONT.)

SUBSTITUTE SHEET

3/33

CCTAAGATGAGCTTTCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCT (60)
 METSERPHEPROCYSLYSPHEVALALASERPHELEULEUILEPHEASNVALSER
 TCCAAAGGTGCAGTCTCCAAGAGATTACGAATGCCTTGAAACCTGGGGTGCCTTGGGT (120)
 SERLYSGLYALAVALSERLYSGLUILETHRASNALALEUGLUTHRTRPGLYALALEUGLY
 1
 20 CAGGACATCAACTTGGACAATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAA (180)
 GLNASPILEASNLEUASPPILEPROSERPHEGLNMETSERASPPASPPILEASPPILELYS
 TGGGAAAAAATTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTC (240)
 40 TRPGLULYSTHRSERASPLYSLYSILEALAGLNPHARGLYSGLULYSGLUTHRPHE
 AAGGAAAAAGATACATATAAGCTATTTAAAAATGGAACCTCTGAAAATTAAGCATCTGAAG (300)
 60 LYSGLULYSASPTHRTRYLYSLEUPHELYSASNGLYTHRLEULYSILELYSHISLEULYS
 ---CHO---
 80 ACCGATGATCAGGATATCTACAAGGTATCAATATATGATACAAAAGGAAAAATGTGTTG (360)
 THRASPASPGLNASPILETYRLYSVALSERILETYRASPTHRLYSGLYLYSASNVALLEU
 GAAAAAATAATTTGATTTGAAGATTCAAGAGAGGGTCTCAAAACCAAAGATCTCCTGGACT (420)
 100 GLULYSILEPHEASPLEULYSILEGLNGLUARGVALSERLYSPROLYSILESERTRPTHR
 TGTATCAACACAACCTGACCTGTGAGGTAAATGAATGGAACCTGACCCCGAATTAAACCTG (480)
 120 CYSILEASNTHRTHRLEUTHRCYSGLUVALMETASNGLYTHRASPProGLULEUASNLEU
 ---CHO--- ---CHO---
 140 TATCAAGATGGGAAACATCTAAAACCTTCTCAGAGGGTCATCACACAAAGTGGACCACC (540)
 TYRGLNASPGLYLYSHISLEULYSLEUSERGLNARGVALILETHRHISLYSTRPTHRTHR
 AGCCTGAGTGCAAATTCAGTGCACAGCAGGGAACAAAGTCAGCAAGGAATCCAGTGTC (600)
 160 SERLEUSERALALYSPELYSCYSTHRALAGLYASNLYSVALSERLYSGLUSERSERVAL
 GAGCCTGTGAGCTGTCCAGAGAAAGGTCTGGACATCTATCTCATCATTGGCATATGTGGA (660)
 180 GLUProVALSERCYSProGLULYSGLYLEUASPPILETYRLEUILEILEGLYILECYSGLY
 GGAGGCAGCCTCTTGATGGTCTTTGTGGCACTGCTCGTTTTCTATATCACAAAAGGAAA (720)
 200 GLYGLYSERLEULEUMETVALPHEVALALALEULEUVALPHETYRILETHRLYSARGLYS
 -----TM-----
 220 AACAGAGGAGTCGGAGAAATGATGAGGAGCTGGAGACAAGAGCCACAGAGTAGCTACT (780)
 LYSGLNARGSERARGARGASNAPGLUGLULEUGLUTHRARGALAHISARGVALALATHR
 GAAGAAAGGGGCCGAAGCCCAACAAATTCAGCTTCAACCCCTCAGAAATCCAGCAACT (840)
 240 GLUGLUARGGLYARGLYSProGLNGLNILEProALASERTHRProGLNASNProALATHR
 TCCCAACATCCTCCTCCACACCTGGTCAATCGTTCCAGGCACCTAGTCAATCGTCCCCCG (900)
 260 SERGLNHISProProProProGLYHISARGSERGLNALAProSERHISARGProPro
 CCTCCTGGAACCCGTGTTCAAGCACCAGCCTCAGAAGAGGCCTCCTGCTCCGTGGGCACA (960)
 280 ProProGLYHISARGVALGLNHISGLNProGLNLYSARGProProALAProSERGLYTHR

FIG. 2.

4/33

300 CAAGTTCACĈAGCAGAAAGĈCCCGCCCTĈCCAGACCTĈGAGTTCAGCĈAAAACCTCCĈ (1020)
GLNVALHISGLNGLNLYSGLYPROPROLEUPROARGPROARGVALGLNPROLYSPROPRO

320 CATGGGGCAGCAGAAAACĈATTGTCCCTĈTCTCTAATTAAAAAGATĈGAAACTGTCTĈ (1080)
HISGLYALAĈLAGLUĈASN SERLEUSERPROSERSERĈSNĈEND

TTTTCAATAĈAAAGCACTGTĈGGATTTCTGĈCCTCCTGATGTĈGCATATCCĈGTACTTCCATĈ (1140)

AGGTGTTTTĈTGTGTGCAGĈACATTGTCAĈCTCCTGAGGĈTGTGGGCAĈAGCCACCTĈTĈ (1200)

GCATCTTCGĈACTCAGCCAĈGTGGTCAACĈATCTGGAGTTĈTTTGGTCTCĈTĈCAGAGAGCTĈ (1260)

CATCACACCĈGTAAGGAGAĈGCAATATAĈGTGTGATTGCĈAGAATGGTAĈAGGACCGAGĈ (1320)

ACAGAAATCĈTAGAGATTTĈTTGTCCCCTĈTĈCAGGTCATGTĈGTAGATGCĈGATAAATCAAGĈ (1380)

TGATTGGTGTĈGCCTGGGTCTĈCACTACAAGĈAGCCTATCTGĈCTTAAGAGACTCTGGAGTTĈTĈ (1440)

CTTATGTGCCCTGGTGGACĈATTGCCACĈATCCTGTGAĈGTAAAAGTGAĈATAAAAGCTĈTĈ (1500)

TGAC (1504)

FIG. 2. (CONT.)

SUBSTITUTE SHEET

1 G C C C G A G A G C C A T G G T T G C T G G G A G C G A C G G G G C C C T G G G G C T C T C A G C G T G G T C G C T G C A C T G C T T T G G T T C A T C 90
 1 MetValAlaGlySerAspAlaGlyArgAlaLeuGlyValLeuSerValValCysLeuLeuHisCysPheGlyPheIle 26
 91 A G C T G T T T T C C C A A C A A A T A T A T G G T G T G T A T G G A A T G T A A C T T T C C A T G T A C C A A G C A A T G T G C C T T T A A A A G A G A G G T C C T A T G G 180
 27 SerCysPheSerGlnGlnIleTyrGlyValValTyrGlyAsnValThrPheHisValProSerAsnValProLeuLysGluValLeuTrp 56
 ---CHO---
 181 A A A A A C A A A A G G A T A A A G T T G C A G A A C T G C A A A A T T C T G A A T T C A G A G C T T T C T C A T C T T T A A A A A T A G G G T T T A T T T A G A C A C T G T G 270
 57 LysLysGlnLysAspLysValAlaGluLeuGluAsnSerGluPheArgAlaPheSerSerPheLysAsnArgValTyrLeuAspThrVal 86
 271 T C A G G T A G C C T C A C T A T A C A A C T T A A C A T C A T C A G A T G A G A T G A A T G G A A T G C C A A A T A T T A C T G A T A C C A T G A A G T T C 360
 87 SerGlySerLeuThrIleTyrAsnLeuThrSerSerAspGluAspGluTyrGluMetGluSerProAsnIleThrAspThrMetLysPhe 116
 ---CHO---
 361 T T T C T T T A T G T G C T T C A G T C T C T T C C A C A C T A A C T T G T G C A T G A C T A A T G G A G C A T T G A A G T C C A A T G C A T G A T A C C A G A G 450
 117 PheLeuTyrValLeuGluSerLeuProSerProThrLeuThrCysAlaLeuThrAsnGlySerIleGluValGlnCysMetIleProGlu 146
 ---CHO---
 451 C A T T A C A A C A G C C A T C G A G G A C T T A T A T G T A C T C A T G G G A T T G T C C T A T G G A G C A A T G T A A C G T A A C T C A A C C A G T A T A T A T T T A A G 540
 147 HisTyrAsnSerHisArgGlyLeuIleMetTyrSerTrpAspCysProMetGluGlnCysLysArgAsnSerThrSerIleTyrPheLys 176
 ---CHO---
 541 A T G G A A A A T G A T C T T C C A C A A A A A T A C A G T G T A C T C T T A G C A A T C C A T T A T T A A I A C A A C A T C A T C A A T T T T G A C A A C C T G T A T C 630
 177 MetGluAsnAspLeuProGlnLysIleGlnCysThrLeuSerSerAsnProLeuPheAsnThrThrSerSerIleIleLeuThrThrCysIle 206
 ---CHO---
 631 C C A A G C A G C G T C A T T C A A G A C A C A G A T A T G C A C T T A T A C C C A T A C C A T T A G C A G I A A T T A C A A C A T G T A T T G T G T A T A T G A A T G T T 720
 207 ProSerSerGlyHisSerArgHisArgTyrAlaLeuIleProIleProLeuAlaValIleThrThrCysIleValIleLeuTyrMetAsnVal 236
 =====
 721 C T T T A A T T G A G A G A C A A T T C T T C A T T T T T A G G T A T T C T G A A A T G T G A C A G A A A C C A C A G A C A C A A C T C C A A T T G A T T G G I A A C A G 810
 237 LeuEnd
 ===
 811 A A G A T G A G A C A C A C A G C A T A A C T A A A T A T T T A A A A A C T A A A A G C C A T C T G A T T T C A T T 874

FIG. 4A.

SUBSTITUTE SHEET

6/33




FIG. 3.




FIG. 4B.

7/33




FIG. 5.




FIG. 10B.

8/33

1 GCGTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT
51 TTGTTTGCCG GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAAGTGGCT
101 TCAGCAGAGC GCAGATACCA AATACTGTCC TTCTAGTGTA GCCGTAGTTA
151 GGCCACCACT TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT
201 AATCCTGTTA CCAGTGGCTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG
251 GGTGGACTC AAGACGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA
301 ACGGGGGGTT CGTGACACACA GCCCAGCTTG GAGCGAACGA CCTACACCGA
351 ACTGAGATAC CTACAGCGTG AGCATTGAGA AAGCGCCACG CTTCCCGAAG
401 GGAGAAAGGC GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG
451 CGCACGAGGG AGCTTCCAGG GGGAAACGCC TGGTATCTTT ATAGTCCTGT
501 CGGGTTTCGC CACCTCTGAC TTGAGCGTCG ATTTTGTGA TGCTCGTCAG
551 GGGGGCGGAG CCTATGGAAA AACGCCAGCA ACGCAAGCTA GCTTCTAGCT
601 AGAAATTGTA AACGTTAATA TTTTGTTAAA ATTCGCGTTA AATTTTGT
651 AAATCAGCTC ATTTTAAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT
701 AAATCAAAG AATAGCCCGA GATAGGGTTG AGTGTTGTTT CAGTTTGGAA
751 CAAGAGTCCA CTATTAAAGA ACGTGGACTC CAACGTCAAA GGGCGAAAAA
801 CCGTCTATCA GGGCGATGGC CGCCCACTAC GTGAACCATC ACCCAAATCA
851 AGTTTTTTGG GGTGAGGTG CCGTAAAGCA CTAAATCGGA ACCCTAAAGG
901 GAGCCCCCGA TTTAGAGCTT GACGGGGAAA GCCGGCGAAC GTGGCGAGAA
951 AGGAAGGGAA GAAAGCGAAA GGAGCGGGCG CTAGGGCGCT GGCAAGTGTA
1001 GCGGTCACGC TGCGCGTAAC CACCACACCC GCCGCGCTTA ATGCGCCGCT
1051 ACAGGGCGCG TACTATGGTT GCTTTGACGA GCACGTATAA CGTGCTTTCC

FIG. 6. (page 1)

SUBSTITUTE SHEET

9/33

1101 TCGTTGGAAT CAGAGCGGGA GCTAAACAGG AGGCCGATTA AAGGGATTTT
1151 AGACAGGAAC GGTACGCCAG CTGGATCACC GCGGTCTTTC TCAACGTAAC
1201 ACTTTACAGC GGCGCGTCAT TTGATATGAT GCGCCCCGCT TCCCGATAAG
1251 GGAGCAGGCC AGTAAAAGCA TTACCCGTGG TGGGGTTCCC GAGCGGCCAA
1301 AGGGAGCAGA CTCTAAATCT GCCGTCATCG ACTTCGAAGG TTCGAATCCT
1351 TCCCCACCA CCATCACTTT CAAAAGTCCG AAAGAATCTG CTCCTGCTT
1401 GTGTGTTGGA GGTCGCTGAG TAGTGCGCGA GTAAAATTTA AGCTACAACA
1451 AGGCAAGGCT TGACCGACAA TTGCATGAAG AATCTGCTTA GGGTTAGGCG
1501 TTTTGCCTG CTTCGCGATG TACGGGCCAG ATATACGCGT TGACATTGAT
1551 TATTGACTAG TTATTAATAG TAATCAATTA CGGGGTCATT AGTTCATAGC
1601 CCATATATGG AGTTCGCGT TACATAACTT ACGGTAAATG GCCCGCCTGG
1651 CTGACCGCCC AACGACCCCC GCCCATTGAC GTCAATAATG ACGTATGTTC
1701 CCATAGTAAC GCCAATAGGG ACTTTCCATT GACGTCAATG GGTGGACTAT
1751 TTACGGTAAA CTGCCCCTT GGCAGTACAT CAAGTGTATC ATATGCCAAG
1801 TACGCCCCCT ATTGACGTCA ATGACGGTAA ATGGCCCGCC TGGCATTATG
1851 CCCAGTACAT GACCTTATGG GACTTTCCTA CTTGGCAGTA CATCTACGTA
1901 TTAGTCATCG CTATTACCAT GGTGATGCGG TTTTGGCAGT ACATCAATGG
1951 GCGTGGATAG CGGTTTGACT CACGGGGATT TCCAAGTCTC CACCCATTG
2001 ACGTCAATGG GAGTTTGTTT TGGCACCAAA ATCAACGGGA CTTTCACAAA
2051 TGTCGTAACA ACTCCGCCCC ATTGACGCAA ATGGGCGGAA TTCCTGGGCG
2101 GGACTGGGGA GTGGCGAGCC CTCAGATGCT GCATATAAGC AGCTGCTTTT
2151 TGCCTGTACT GGGTCTCTCT GGTTAGACCA GATCTGAGCC TGGGAGCTCT
2201 CTGGCTAACT AGAGAACCCA CTGCTTAAGC CTCAATAAAG CTTCTAGAGA
2251 TCCCTCGACC TCGAGATCCA TTGTGCTGGC GCGGATTCTT TATCACTGAT

FIG. 6. (page 2)

SUBSTITUTE SHEET

10/33

2301 AAGTTGGTGG ACATATTATG TTTATCAGTG ATAAAGTGTC AAGCATGACA
2351 AAGTTGCAGC CGAATACAGT GATCCGTGCC GCCCTAGACC TGTTGAACGA
2401 GGTCCGGCGTA GACGGTCTGA CGACACGCAA ACTGGCGGAA CGGTTGGGGG
2451 TTCAGCAGCC GGCGCTTTAC TGGCACTTCA GGAACAAGCG GGCGCTGCTC
2501 GACGCACTGG CCGAAGCCAT GCTGGCGGAG AATCATAGCA CTTCGGTGCC
2551 GAGAGCCGAC GACGACTGGC GCTCATTTCT GACTGGGAAT GCCCGCAGCT
2601 TCAGGCAGGC GCTGCTCGCC TACCGCCAGC ACAATGGATC TCGAGGGATC
2651 TTCCATACCT ACCAGTTCTG CGCCTGCAGG TCGCGGCCGC GACTCTAGAG
2701 GATCTTTGTG AAGGAACCTT ACTTCTGTGG TGTGACATAA TTGGACAAAC
2751 TACCTACAGA GATTTAAAGC TCTAAGGTAA ATATAAAATT TTTAAGTGTA
2801 TAATGTGTTA AACTACTGAT TCTAATTGTT TGTGTATTTT AGATTCCAAC
2851 CTATGGAAC TATGAATGGG AGCAGTGGTG GAATGCCTTT AATGAGGAAA
2901 ACCTGTTTTG CTCAGAAGAA ATGCCATCTA GTGATGATGA GGCTACTGCT
2951 GACTCTCAAC ATTCTACTCC TCCAAAAAAG AAGAGAAAGG TAGAAGACCC
3001 CAAGGACTTT CCTTCAGAAT TGCTAAGTTT TTTGAGTCAT GCTGTGTTTA
3051 GTAATAGAAÇ TCTTGCTTGC TTTGCTATTT ACACCACAAA GGAAAAAGCT
3101 GCACTGCTAT ACAAGAAAAT TATGGAAAAA TATTCTGTAA CCTTTATAAG
3151 TAGGCATAAC AGTTATAATC ATAACATACT GTTTTTTCTT ACTCCACACA
3201 GGCATAGAGT GTCTGCTATT AATAACTATG CTCAAAAATT GTGTACCTTT
3251 AGCTTTTTTAA TTTGTAAAGG GGTTAATAAG GAATAATTGA TGTATAGTGC
3301 CTTGACTAGA GATCATAATC AGCCATACCA CATTTGTAGA GGTTTTACTT
3351 GCTTTAAAAA ACCTCCCACA CCTCCCCCTG AACCTGAAAC ATAAATGAA
3401 TGCAATTGTT GTTGTTAACT TGTTTATTGC AGCTTATAAT GGTTACAAAT
3451 AAAGCAATAG CATCACAAAT TTCACAAATA AAGCATTTTT TCACTGCAT

FIG. 6. (page 3)

SUBSTITUTE SHEET

11/33

3501 TCTAGTTGTG GTTTGTCCAA ACTCATCAAT GTATCTTATC ATGTCTGGAT
3551 CCTGTGGAAT GTGTGTCAGT TAGGGTGTGG AAAGTCCCCA GGCTCCCCAG
3601 CAGGCAGAAG TATGCAAAGC ATGCATCTCA ATTAGTCAGC AACCAGGTGT
3651 GGAAAGTCCC CAGGCTCCCC AGCAGGCAGA AGTATGCAAA GCATGCATCT
3701 CAATTAGTCA GCAACCATAG TCCCGCCCT AACTCCGCCC ATCCCGCCCC
3751 TAACTCCGCC CAGTTCCGCC CATTCTCCGC CCCATGGCTG ACTAATTTTT
3801 TTTATTTATG CAGAGGCCGA GGCCGCCTCG GCCTCTGAGC TATTCCAGAA
3851 GTAGTGAGGA GGCTTTTTTG GAGGCCTAGG CTTTGTCAAA AAGCTAATTC

FIG. 6. (page 4)

12/33

AGACTCTCAGGCCTTGGCAGGTGCGTCTTTTCAGTTCCCCTCACACTTCGGGTTCTCGGG (60)
 GAGGAGGGGCTGGAACCCTAGCCCATCGTCAGGACAAAGATGCTCAGGCTGCTCTTGGCT (120)
 METLEUARGLEULEULEUALA
 -18
 CTCAACTTATTCCCTTCAATTCAAGTAACAGGAAACAAGATTTTGGTGAAGCAGTCGCC (180)
 LEUASNLEUPHEPROSERILEGLNVALTHRGLYASNLYSILELEUVALLYSGLNSERPRO
 +1
 10 ATGCTTGTAAGCTACGACAATGCGGTCAACCTTAGCTGCAAGTATTCCTACAATCTCTTC (240)
 METLEUVALALATYRASPASNALAVASNLEUSERCYSLYSTYRSERTYRASNLEUPHE
 ---CHO---
 30 TCAAGGGAGTTCCGGGCATCCCTTCACAAAGGACTGGATAGTGCTGTGGAGTCTGTGTT (300)
 SERARGGLUPHEARGALASERLEUHLISLYSGLYLEUASPSEALAVAGLUVALCYSVAL
 GTATATGGGAATTACTCCCAGCAGCTTCAGGTTTACTCAAAAACGGGGTTCAACTGTGAT (360)
 50 VALTYRGLYASNTYRSEGLNGLNLEUGLNVALTYRSERLYSTHRLYPHEASNCYSASP
 ---CHO---
 70 GGGAAATTGGGCAATGAATCAGTGACATTCTACCTCCAGAAATTTGTATGTTAACCAAACA (420)
 GLYLYSLEUGLYASNGLUSERVALTHRPHETYLEUGLNASNLEUTYRVALASNGLNTHR
 ---CHO---
 90 GATATTTACTTCTGCAAAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAG (480)
 ASPILETYRPHECYSLYSILEGLUVALMETTYRPROPROPROTYRLEUASPASNGLULYS
 AGCAATGGAACCATTATCCATGTGAAAGGAAACACCTTTGTCCAAGTCCCTATTTCCC (540)
 110 SERASNGLYTHRILEILEHISVALLYSGLYLYSHISLEUCYSPROSERPROLEUPHEPRO.
 ---CHO---
 130 GGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTGGTGGAGTCTGGCTTGCTATAGC (600)
 GLYPROSERLYSPROPHETRPVALLEUVALVALVALGLYGLYVALLEUALACYSTYRSE
 -----TM-----
 150 TTGCTAGTAACAGTGGCCTTTATTATTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTG (660)
 LEULEUVALTHRVALALAPHEILEILEPHETRPVALARGSERLYSARGSERARGLEULEU

 170 CACAGTGACTACATGAACATGACTCCCCGCCGCCCGGGCCACCCGCAAGCATTACCA (720)
 HISSERASPTYRMETASNMETTHRPROARGARGPROGLYPROTHRARGLYSHISTYRGLN
 CCCTATGCCCAECACGCGACTTCGAGCCTATCGCTCCTGACACGGACGCTATCCAGA (780)
 190 PROTYRALAPROPROARGASPPHEALAALATYRARGSEREND
 202
 AGCCAGCCGGCTGGCAGCCCCCATCTGCTCAATATCACTGCTCTGGATAGGAAATGACCG (840)
 CCATCTCCAGCCGCCACCTCAGCCCCTGTTGGGCCACCAATGCCAATTTTCTCGAGTG (900)
 ACTAGACCAATATCAAGATCATTTTGAGACTCTGAAATGAAGTAAAGAGATTTCTGT (960)
 GACAGGCCAAGTCTTACAGTGCCATGGCCACATTCCAACTTACCATGTACTTAGTGACT (1020)
 TGACTGAGAAGTTAGGGTAGAAAACAAAAGGGAGTGGAATCTGGGAGCCTCTTCCCTTT (1080)

FIG. 7.

SUBSTITUTE SHEET

13/33

CTCACTCACCTGCACATCTCAGTCAAGCAAAGTGTGGTATCCACAGACATTTTAGTTGCA (1140)
GAAGAAAGGCTAGGAAATCATTCCCTTTTGGTTAAATGGGTGTTAATCTTTTGGTTAGTG (1200)
GGTTAAACGGGGTAAGTTAAGTAGGGGGAGGGATAGGAAGACATATTTAAAAACCATT (1260)
AAACACTGTCTCCCACTCATGAAATGAGCCACGTAGTTCCTATTTAATGCTGTTTTCTT (1320)
TAGTTTAGAAATACATAGACATTGTCTTTTATGAATTCTGATCATATTTAGTCATTTTGA (1380)
CCAAATGAGGGATTTGGTCAAATGAGGGATTCCCTCAAAGCAATATCAGGTAAACCAAGT (1440)
TGCTTTCCTCACTCCCTGTGATGAGACTTCAGTGTTAATGTTTACAATATACTTTCGAAA (1500)
GAATAAAATAGTTC (1514)

FIG. 7. (CONT.)

14/33

TAGACCCAGAGAGGCTCAGCTGCACTCGCCGGCTGGGAGAGCTGGGTGTGGGGAACATG (60)
 MET
 GCCGGGCTCCGAGGCTCCTGCTGCTGCCCTGCTTCTGGCGCTGGCTCGCGGCTGCCT (120)
 ALAGLYPROPROARGLEULEULEULEUPROLEULEULEUÅLALEUÅLAARGGLYLEUPRO
 GGGGCCCTGGCTGCCAAGGTAAGAGCTTCCAGGCTCTCCATGGCCACAGCTCCGGAGC (180)
 GLYÅLALEUÅLAALAGLN /
 TCTCCCTGCCCATGAGCTCAGAGCCCCAGTCTGAGCCACAGCACAGCCCCAGGAAGC (240)
 GGGTGGGTGCTGAGCGGCTCCAGTGTCTGAGGACTCATTTAAGAGAAGGAAAAAGGT (300)
 GGACCCGGTGGGAGTGGCAGGGGCTGTCCAGGCAGGGCCGCTGCTTTGGGAGGAAGAA (360)
 CCCACAGTCTCGGAACACGAGGACAGCACCTCCCCAACACCACAGCCGGTGCCAGATC (420)
 TGCTCCATGCCCCGTAAGGACCGTGTCTTTGGCGACATGTCAGCCCTGGGCTGTCTCAG (480)
 GGCCCCACCATCCCCACCACTGTCCCCTGCAGGGAGGACATTCTGTCTTCTGGCCA (540)
 ACTGATGGTGACAGCCAGGTCTCCAGAGGTGAGCAGTCTCCCACTGCACGACTGT (600)
 GLUVALGLNGLNSERPROHISCYSTHRTHRVA
 CCCCCTGGGAGCCTCCGTCAACATCACCTGCTCCACCAGCGGGGGCTGCGTGGGATCTA (660)
 LPROVALGLYALASERVALASNILETHRCYSSERTHRSEGLYGLYLEUARGGLYLETY
 ---CHO---
 CCTGAGGACGCTCGGGCCACAGCCCCAAGACATCATTTACTACGAGGACGGGTGGTGCC (720)
 RLEUARGGLNLEUGLYPROGLNPROGLNASPILEILETYRTYRGLUASPGLYVALVALPR
 CACTACGGAACAGACGGTTCGGGGCCGCACTGACTTCTCAGGGTCCCAGGACAACCTGAC (780)
 OTHRTHRASPARGARGPHEARGLYARGILEASPPHESERGLYSERGLNASPNLEUTH
 ---CHO---
 TATCACCATGCACCGCCTGCAGCTGTGCGACACTGGCACCTACACCTGCCAGGCCATCAC (840)
 RILETHRMETHISARGLEUGLNLEUSERASPTHRGLYTHRTYRTHRCYSGLNALAILETH
 GGAGGTCAAATGTCTACGGCTCCGGCACCTGGTCTGGTGACAGAGGAACAGTCCCAAGG (900)
 RGLUVALASNVALTYRGLYSERGLYTHRLEUVALLEUVALTHRGLUGLUGLNSERGLNGL
 ATGGCACAGATGCTCGGACGCCCCACCAAGGGCTCTGCCCTCCCTGCCCCACCGACAGG (960)
 YTRPHISARGCYSERASPALAPROPROARGALASERÅLALEUPROÅLAPROPROTHRGL
 CTCCGCCCTCCCTGACCCGACAGACAGCCTCTGCCCTCCCTGACCCGCCAGCAGCCTCTGC (1020)
 YSERÅLALEUPROASPPROGLNTHRALASERÅLALEUPROASPPROPROÅLAALASERÅL
 CCTCCCTGCGGCCCTGGCGGTGATCTCCTCCTCCTCGGGCTGGGCCTGGGGGTGGCGTG (1080)
 ÅLEUPROÅLAALÅLEUÅLAVALILESERPHELEULEUGLYLEUGLYLEUGLYVALÅLACY
 -----TM-----*

FIG. 8.

TGTGCTGGCGAGGACACAGATAAAGAACTGTGCTCGTGGCGGGATAAGAATTCGGCGGC (1140)
SVALLEU~~ALA~~ARGTHRGLNILELYSLYSLEUCYSSERTRPARGASPLYASNSER~~ALA~~AL

ATGTGTGGTGTACGAGGACATGTCGCACAGCCGCTGCAACACGCTGTCTCCCCCAACCA (1200)
ACYSVALVALTYRGLUASPMETSERHISSE~~R~~ARGCYSASNTHRLEUSERSERPROASNGL
GTACCAGTGACCCAGTGGGCCCCCTGCACGTCCCGCCTGTGGTCCCCCAGCACCTTCCCT (1260)
NTYRGLNEND
GCCCCACCATGCCCCCACCCCTGCCACACCCCTCACCTGCTGTCTCCACGGCTGCA~~G~~ (1320)
CAGAGTTTG~~A~~AGGGCCCAGCCGTGCCAGCTCCAAGCAGACACACAGGCAGTGGCCAGGC (1380)
CCCACGGTGCTTCTCAGTGGACAATGATGCCTCCTCCGGGAAGCCTTCCCTGCCCAGCCC (1440)
ACGCCGCCACCGGGAGGAAGCCTGACTGTCTTTGGCTGCATCTCCCGACCATGGCCAAG (1500)
GAGGGCTTTTCTGTGGGATGGGCCTGGCA~~G~~CGGCCCTCTCCTGTCAGTGCCGGCCAC~~C~~ (1560)
CACCAGCAGGCCCCCAACCC~~C~~CAGGCAGCCCGGCAGAGGACGGGAGGAGACCAGTCCCC~~C~~ (1620)
ACCCAGCCGTACCAGAAATAAAGGCTTCTGTGCTTCAAAAAAAAA (1665)

FIG. 8. (CONT.)

16/33

CCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTT (60)
 METSERGLNASNVALCYS⁻²⁹PROARGASNLEUTRPLEULEUGLNPROLEUTHRVALL
 TGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCAAAGGCTGTGCTGAAAC (120)
 EULEULEULEUALASERALAASP^{-1 +1}SERGLNALAALAALAPROPROLYSALAVALLEULYS
 10 TTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGG (180)
 EUGLUPROPROTRP^{*}ILEASNVALLEUGLNGLUASP^{*}SERVALTHRLEUTHRCYSGNLGLYA
 30 CTCGCAGCCCTGAGAGCGACTCCATTCACTGGTTCCACAATGGGAATCTCATTCCCACCC (240)
 LAARGSERPROGLUSERASP^{*}SERILEGLNTRPPHEHISASNGLYASNLEUILEPROTHR
 50 ACACGCAGCC^{*}CAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCC (300)
 ISTHRGLNPROSERTYRARGPHELYSALAASNASNASP^{*}SERGLYGLUTYRTHRCYSG
 70 AGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTTTCGAATGGCTGG (360)
 LNTHRGLYGLNTHRSERLEUSERASPPROVALHISLEUTHRVALLEUSERGLUTRPLEUV
 90 TGCTCCAGACCCCTCACCTGGAGTTCAGGAGGGAGAAACCATCATGCTGAGGTGCCACA (420)
 ALLEUGLNTHRPROHISLEUGLUPHEGLNGLUGLYGLUTHRIEMETLEUARGCYSHISS
 110 GCTGGAAGGACAAGCCTCTGGTCAAGGTCAATTCTTCCAGAATGGAAAATCCCAGAAAT (480)
 ERTRPLYSASPLYS^{*}PROLEUVALLYSVALTHRPHEPHEGLNASNGLYLYSSERGLNLYSP
 130 TCTCCCGTTTGGATCCCACCTTCTCCATCCACAAGCAAACACAGTCAAGTGGTGATT (540)
 HESERARGLEUASPPROTHRPHE⁻⁻⁻SERILEPROGLNALAASN⁻⁻⁻HISSERHIS⁻⁻⁻GLYASPT
 150 ACCACTGCA^{*}CAGGAAACATAGGCTACAGCTGTTCTCATCCAAGCCTGTGACCATCACTG (600)
 YRHIS^{*}CYSTHRGLYASNILEGLYTYRTHRLEUPHESER^{*}SERLYSPROVALTHRIETHRV
 170 TCCAAGTGCC^{*}CAGCATGGG^{*}CAGCTCTTCA^{*}CAATGGGGA^{*}TTCATTGTGGCTGTGGTCATTG (660)
 ALGLNVALPROSERMETGLYSERSERSER^{*}PROMETGLYILEILEVALALAV^{*}ALILEA
 190 CGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTACTGCAGGAAAAAGC (720)
 LATHRALAVALALAILEVALALAALAVALVALALALEUILETYRCYSARGLYSLYSA
 210 GGATTTTMCAGCCAATTCCACTGATCCTGTGAAGGCTGCCAATTTGAGCCACCTGGACGTC (780)
 RGILESERALAASN^{*}SERTHRASPPROVALLYSALAALAGLN^{*}PHEGLUPROPROGLYARGG
 230 AAATGATTGCCATCAGAAAGAGACAACTGAAGAAACCAACAATGACTATGAAACAGCTG (840)
 LNMETILEALAILEARGLYSARGGLNLEUGLUGLUTHRASNASN^{*}ASPTYRGLUTHRALAA
 250 ACGGCGGCTACATGACTCTGAACCCAGGGCACCTACTGACGATGATAAAAACATCTACC (900)
 SPGLYGLYTYRMETTHRLEUASNPROARGALAPROTHRASPASP^{*}PLYSASNILETYRL

FIG. 9.

270 TGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAAAGAGTAACGTTATGCCATG (960)
EUTHRELEUPROPROASNASPHISVALASNSEASNASNEND
TGGTCATACTCTCAGCTTGCTGAGTGGATGACAAAAGAGGGGAATTGTTAAAGGAAAAT (1020)
TTAAATGGAGACTGGAAAAATCCTGAGCAACAAAACCACTGGCCCTTAGAAATAGCTT (1080)
TAACTTTGCTTAAACTACAACACAAGCAAACTTCACGGGGTCATACTACATACAAGCA (1140)
TAAGCAAACTTAACTTGGATCATTTCTGGTAAATGCTTATGTTAGAAAATAGACAACCC (1200)
CAGCCAATCACAAGCAGCCTACTAACATAATAATTAGGTGACTAGGGACTTCTAAGAAGA (1260)
TACCTACCCCAAAAAACAATTATGTAATGAAAACCAACCGATTGCCTTATTTTGCTT (1320)
CCACATTTTCCCAATAAATACTTGCCTGTGACATTTTGCCTACTGGAACAATAAATTCAT (1380)
GAATTGCGCTCAGATTTTCTTTAACAATCTTTTTTTTTTTTACAGAGTCTCAATCTG (1440)
TTACCCAGGCTGGAGTGCAGTGGTGCTATCTTGGCTCACTGCAAACCCGCTCCCAGGT (1500)
TAAGCGATTCTCATGCCTCAGCCTCCCAGTAGCTGGGATTAGAGGCATGTGCCATCATA (1560)
CCAGCTAATTTTGTATTTTATTTTTTTTTTTTAGTAGAGACAGGGTTTCGCAATGT (1620)
GGCCAGGCCGATCTCGAACTTCTGGCTCTAGCGATCTGCCCGCTCGGCTCCCAAAGT (1680)
GCTGGGATGACCAGCATCAGCCCCAATGTCCAGCCTCTTAAACATCTTCCTTCTATGCC (1740)
CTCTCTGTGGATCCCTACTGCTGGTTTCTGCCTTCTCCAATGCTGAGAACAAAATCACCTA (1800)
TCACTGCTTATGCAGTCGGAAGCTCCAGAGAACAAGAGCCCAATTAACAGAACAC (1860)
TTAAGTCTCATTGTTTTGCCTTGGGATTGAGAAGAGAATTAGAGAGGTGAGGATCTGG (1920)
TATTTCTGGACTAAATTCCTTGGGGAAGACGAAGGGATGCTGCAGTCCAAAAGAG (1980)
AGGACTCTTCAGAGTCATCTACCTGAGTCCCAAAGCTCCCTGTCCTGAAGCCACAGAC (2040)
AATATGGTCCCAAATGACTGACTGCACCTTCTGTGCCTCAGCCGTTCTTGACATCAAGAA (2100)
TCTTCTGTTCCACATCCACACAGCCAATAACAATTAGTCAACCACTGTTATTAACAGATG (2160)
TAGCAACATGAGAAACGCTTATGTTACAGGTTACATGAGAGCAATCATGTAAGTCTATA (2220)
GACTTCAGAAATGTTAAAAATAGACTAACCTCTAACAACAATTAAAGTGATTGTTTCA (2280)
GGTGAAAAA (2290)

FIG. 9. (CONT.)

SUBSTITUTE SHEET

```

1  AAAGACAACTGCACCCACTGAACTCCGACGCTAGCATCCAAATCAGCCCTTGAGATTGAGGCTTGAGAGACTCAGGAGTTTGGAGAGC
91  AAAATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCTCCGGCAGAGCCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCA
1   Met Thr Thr Pro Arg Asn Ser Val Asn Gly Thr Phe Pro Ala Glu Pro Met Lys Gly Pro Ile Ala Met Gln Ser Gly Pro Lys Pro
   ---CHD---
181 CTCTTCAGGAGGATGTCCTTCACTGGTGGGCCCCACGCAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAAT
30  Leu Phe Arg Arg Met Ser Ser Leu Val Gly Pro Thr Gln Ser Phe Phe Met Arg Glu Ser Lys Thr Leu Gly Ala Val Gln Ile Met Asn
   =====
271 GGGCTCTTCCACATTGCCCTGGGGGTCTTCTGATGATCCAGCAGGATCTATGCACCCATCTGTGACTGTGTGGTACCCCTCTCTGG
60  Gly Leu Phe His Ile Ala Leu Gly Gly Leu Leu Met Ile Pro Ala Gly Ile Tyr Ala Pro Ile Cys Val Thr Val Trp Tyr Pro Leu Trp
   =====
361 GGAGGCATTATGTATATTATTCGCGATCACTCCTGGCAGCAACGAGAAACCTCCAGGAAGTGTTGGTCAAAGGAAATGATAATG
90  Gly Gly Ile Met Tyr Ile Ile Ser Gly Ser Leu Leu Ala Ala Thr Glu Lys Asn Ser Arg Lys Cys Leu Val Lys Gly Lys Met Ile Met
   =====
451 AATTCAITGAGCCICTTTGCTGCCATTTCTGGAATGATTCCTTCAATCATGGACATACTTAATAATTTCCCATTTTAAAAATG
120 Asn Ser Leu Ser Leu Phe Ala Ala Ile Ser Gly Met Ile Leu Ser Ile Met Asp Ile Leu Asn Ile Lys Ile Ser His Phe Leu Lys Met
   =====
541 GAGAGCTCGAATTTATTAGAGCTCACACACCATATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAACCTCCCATCT
150 Glu Ser Leu Asn Phe Ile Arg Ala His Thr Pro Tyr Ile Asn Ile Tyr Asn Cys Glu Pro Ala Asn Pro Ser Glu Lys Asn Ser Pro Ser
   =====
631 ACCCAATACTGTTACAGCATACAATCTCTGTCTTGGGCATTTTGTGATGCTGATCTTTGCCCTTCTTCCAGGAACCTTGTAATAGCT
180 Thr Gln Tyr Cys Tyr Ser Ile Gln Ser Leu Phe Leu Gly Ile Leu Ser Val Met Leu Ile Phe Ala Phe Phe Gln Glu Leu Val Ile Ala
   =====

```

FIG. 10A.

721 GGCATCGTTGAGAAATGAATGGAAAGAACGTGCTCCAGACCCAAATCTAACATAGTTCTCTCTCAGCAGAAAGAAAAAGAACAGACT
210 GlyIleValGluAsnGluTrpLysArgThrCysSerArgProLysSerAsnIleValLeuLeuSerAlaGluLysLysGluGlnThr

811 ATTGAAATAAAGAAGAAGTGGTGGCTAACTGAACATCTTCCCAACCAAAGAAATGAAGAAGACATTGAAATTATTCCAATCCAAGAA
240 IleGluIleLysGluGluValValGlyLeuThrGluThrSerSerGlnProLysAsnGluGluAspIleGluIleIleProIleGlnGlu

901 GAGGAAGAAGAAGAACAGAGACGAACCTTCCAGAACCTCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAAGTG
270 GluGluGluGluThrGluThrAsnPheProGluProProGlnAspGlnGluSerSerProIleGluAsnAspSerSerProEnd 297
---CHD---

991 ATTTCCTCTGTTTTCTGTTTCCTTTTTTAAACATTAGTGTTCATAGCTTCCAAGAGACATGCTGACTTTTCATTTCTTGAGGTACTCTGCA
*

1081 CATACGCACCACATCTCTATCTGGCCTTTGCAIGGAGTGACCATAGCTCCTTCTCTCTTACATTGAATGTAGAGAAATGTAGCCATTGTAG

1171 CAGCTTGTTGTACGCTTCTTCTTTTGAGCAACTTCTTACACTGAAGAAAGGCAGAAATGAGTGCTTCAGAATGTGATTTCTCTACTAA

1261 CCTGTTCTTGATAGGCTTTTTAGTATAGTATTTTTTTTTTGTCATTTTCTCCATCAGCAACCAGGGAGACTGCACCTGATGGAAAAGAT

1351 ATATGACTGCTTCATGACATTCCTAAACTATCTTTTTTTTATCCACATCTACGTTTTTGGTGGAGTCCCTTTTATCATCTCTTAAACA

1441 ATGATGCAAAAGGCCTTAGAGCACAAATGGAICT 1474

SEQUENCE OF THE INVENTION

FIG. 10A. (CONT.)

20/33

1 CTCAGCTCGCTATGGCTCCAGAGCCCCGGCGCTGCCGACTCCTGGTCTCGGGCTCTGTTCCCA
 MetAlaProSerSerProArgProAlaLeuProAlaLeuValLeuLeuGlyAlaLeuPhePro
 (-25)
 GGACCTGGCAATGCCAGACATCTGTGTCCTCCCTCAAAAGTC
 GlyProGlyAsnAlaGlnThrSerValSerProSerLysVal
 (+1)
 121 ATCTGCCCCGGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTTGTTGGGCATAGAGACC
 IleLeuProArgGlyGlySerValLeuValThrCysSerThrSerCysAspGlnProLysLeuLeuGlyIleGluThr
 (+11)
 CCGTTGCCTAAAAGGAGTTGCTCCTGCTGGGAACAACCGG
 ProLeuProLysLysGluLeuLeuProGlyAsnAsnArg
 (+51)
 241 AAGGTGATGAAGTGAAGCAATGTGCAAGAGATAGCCAACTGCTATTCAAACTGCCCTGATGGGCAGTCAACA
 LysValTyrGluLeuSerAsnValGlnGluAspSerGlnProMetCysTyrSerAsnCysProAspGlyGlnSerThr
 GCTAAACCTTCCTCACCGTGTACTGGACTCCAGAACGGGTG
 AlaLysThrPheLeuThrValTyrTrpThrProGluArgVal
 (+91)
 361 GAACTGGCACCCCTCCCTCTTGGCAGCCAGTGGCAAGAACCTTACCCCTACGCTGCCAGGTGGAGGTGGGCACCCC
 GluLeuAlaProLeuProSerTrpGlnProValGlyLysAsnLeuThrLeuArgCysGlnValGluGlyGlyAlaPro
 ---CHO---
 CGGGCCAACCTCACCGTGGTGTCTCGTGGGAGAGGAG
 ArgAlaAsnLeuThrValValLeuLeuArgGlyGluLysGlu
 -----(+131)
 481 CTGAACGGGAGCAGCTGTGGGGAGCCCCGCTGAGGTCACGACACCGGTGCTGGTGAGGAGATCACCATGGAGCC
 LeuLysArgGluProAlaValGlyGluProAlaGluValThrThrValLeuValArgArgAspHisGlyAla
 AATTCTCGTCCGCACTGAAGTGGACCTGGGCCCCCAAGGG
 AsnPheSerCysArgThrGluLeuAspLeuArgProGlnGly
 ---CHO---
 601 CTGGAGCTGTTTGAGAACACCTCGGCCCTACAGCTCCAGACCTTTGTCCTGCCAGCGACTCCCCCACTTGTC
 LeuGluLeuPheGluAsnThrSerAlaProTyrGlnLeuGlnThrPheValLeuProAlaThrProProGlnLeuVal
 ---CHO---
 AGCCCCGGGCTCCTAGAGGTGGACACGCGGGGACCGTGGTC
 SerProArgValLeuGluValAspThrGlnGlyThrValVal
 (+211)

FIG. 11. (page I)

21/33

- 721 TGTTCCTGGACGGGCTGTCCAGTCTCGAGGCCAGGTCCACCTGGCAGTGGGGACCAGAGGTTGAACCCACAC
CysSerLeuAspGlyLeuPheProValSerGluAlaGlnValHisLeuAlaLeuGlyAspGlnArgLeuAsnProThr
GTCACCTATGGCAACGACTCCTTCTCGGCCAAGGCCTCAGTC
ValThrTyrGlyAsnAspSerPheSerAlaLysAlaSerVal
---CHO--- (+251)
- 841 AGTGTACCGCAGAGGACGAGGCCACCCAGCGGTGACGTGTGCAGTAATACTGGGGAACAGAGCCAGGACACTG
SerValThrAlaGluAspGluGlyThrGlnArgLeuThrCysAlaValIleLeuGlyAsnGlnSerGlnGluThrLeu
CAGACAGTGACCATCTACAGCTTTCGGCGCCCAACGTGATT
GlnThrValThrIleTyrSerPheProAlaProAsnValIle
---CHO--- (+291)
- 981 CTGACGAAGCCAGAGGTCTCAGAAGGGACCCAGGTGACAGTGAGTGAGGCCACCCCTAGAGCCAAAGGTGACGCTG
LeuThrLysProGluValSerGluGlyThrGluValThrValLysCysGluAlaHisProArgAlaLysValThrLeu
AATGGGGTTCCAGCCCGCCAGCCACTGGGCCCGAGGCCAGCTC
AsnGlyValProAlaGlnProLeuGlyProArgAlaGlnLeu
---CHO--- (+331)
- 1081 CTGCTGAAGGCCACCCAGAGGACAACGGCGCAGCTTCTCTGCTCTGCAACCCCTGGAGGTGGCCGCCAGCTTATA
LeuLeuLysAlaThrProGluAspAsnGlyArgSerPheSerCysSerAlaThrLeuGluValAlaGlyGlnLeuIle
CACAAAGAACCCAGACCCGGGAGCTTCGTGTCCTGTATGGCCCC
HisLysAsnGlnThrArgGluLeuArgValLeuTyrGlyPro
---CHO--- (+371)
- 1201 CGACTGGACGAGAGGGATTGTCCGGGAACTGGACGTGGCCAGAAATTCACGAGACTCCAATGTGCCAGGCTTGG
ArgLeuAspGluArgAspCysProGlyAsnTrpThrTrpProGluAsnSerGlnGlnThrProMetCysGlnAlaTrp
GGAAACCCATTGCCCGAGCTCAAGTGTCTAAAGGATGGCACT
GlyAsnProLeuProGluLeuLysCysLeuLysAspGlyThr
---CHO--- (+411)
- 1321 TTCCCACTGCCCCATCGGGGAATCAGTGACTGTCTCAGATCTTGAGGGCACCTACCTCTGTGGGCCAGGACACT
PheProLeuProIleGlyGluSerValThrValThrArgAspLeuGluGlyThrTyrLeuCysArgAlaArgSerThr
CAAGGGAGGTACCCCGCAGGTGACCGTGAATGTGCTCTCC
GlnGlyGluValThrArgGluValThrValAsnValLeuSer
---CHO--- (+451)

FIG. 11. (page 2)

SEQUENCE LISTING

22/33

1441 CCCC GTATGAGATTGTCATCATCACTGTGGTAGCAGCCGAGTCATAATGGCACTGCAGGCCCTCAGCACGTACCTC
ProArgTyrGluIleValIleIleThrValValAlaAlaValIleMetGlyThrAlaGlyLeuSerThrTyrLeu
-----TM-----
TATAACCGCCAGCGGAAGATCAAGAAATACAGACTACAACAG
TyrAsnArgGlnArgLysIleLysLysTyrArgLeuGlnGln
--- (+491)
1581 GCCCAAAAGGGACCCCCCATGAAACCGAACAACACAGCCAGCCCTCCCTGAACCTATCCCGGACAGGGCCTCTTCCT
AlaGlnLysGlyThrProMetLysProAsnThrGlnAlaThrProPro
(+507)
CGGCCCTTCCCATATTGGTGGCAGTGGTGCCACACTGAACAGA

1681 GTGAAGACATATGCCATGCAGCTACACCTACCGGCCCTGGACGCCGGAGGACAGGGCATTGTCCTCAGTCAGATAC
1801 GGCCACGCATCTGATCTGTAGTCACATGACTAAGCCAAAGGAAGG
AACAGCATTGGGGCCATGGTACCTGCACACCTAAACACTA

FIG. II. (page 3)

23/33

1 ..GGAGAGTC TGACCACCAT GCCACCTCCT CGCCTCCTCT TCTTCCTCCT
51 CTTTCCTCACC CCCATGGAAG TCAGGCCCGA GGAACCTCTA GTGGTGAAGG
101 TGGAAGAGGG AGATAACGCT GTGCTGCAGT GCCTCAAGGG GACCTCAGAT
151 GGCCCCACTC AGCAGCTGAC CTGGTCTCGG GAGTCCCCGC TTAAACCCTT
201 CTTAAAACTC AGCCTGGGGC TGCCAGGCCT GGAATCCAC ATGAGGCCCC
251 TGGcCATCTG GCTTTTCATC TTCAACGTCT CTCAACAGAT GGGGGGCTTC
301 TACCTGTGCC AGCCGGGGCC CCCCTCTGAG AAGGCCTGGC AGCCTGGCTG
351 GACAGTCAAT GTGGAGGGCA GCGGGGAGCT GTTCCGGTGG AATGTTTCGG
401 ACCTAGGTGG CCTGGGCTGT GGCCTGAAGA ACAGGTCTC AGAGGGCCCC
451 AGTCCCCCTT CCGGGAGCT CATGAGCCCC AAGCTGTATG TGTGGGCCAA
501 AGACCGCCCT GAGATCTGGG AGGGAGAGCC TCCGTGTGTC CCACCGAGGG
551 ACAGCCTGAA CCAGAGCCTC AGCCAGGACC TCACCATGGC CCCTGGCTCC
601 AACTCTGGC TGTCTGTGG GGTACCCCT GACTCTGTGT CCAGGGGCCC
651 CCTCTCCTGG ACCCATGTGC ACCCAAGGG GCCTAAGTCA TTGCTGAGCC
701 TAGAGCTGAA GGACGATCGC CCGCCAGAG ATATGTGGGT AATGGAGACG
751 GGTCTGTTGT TGCCCCGGG CACAGCTCAA GACGCTGGAA AGTATTATTG
801 TCACCGTGGC AACCTGACCA TGTCATTCCA CCTGGAGATC ACTGCTCGGC
851 CAGTACTATG GCACTGGCTG CTGAGGACTG GTGGCTGGAA GGTCTCAGCT
901 GTGACTTTGG CTTATCTGAT CTTCTGCCTG TGTTCCCTTG TGGGCATTCT
951 TCATCTTCAA AGAGCCCTGG TCCTGAGGAG GAAAAGAAAG CGAATGACTG
1001 ACCCCACCAG GAGATTCTTC AAAGTGACGC CTCCCCAGG AAGCGGGCCC
1051 CAGAACCAGT ACGGGAACGT GCTGTCTCTC CCCACACCCA CCTCAGGCCT
1101 CGGACGCGCC CAGCGTTGGG CCGCAGGCCT GGGGGGCACT GCCCCGTCTT
1151 ATGGAACCC GAGCAGCGAC GTCCAGGCGG ATGGAGCCTT GGGTCCCCG

FIG. 12.

SUBSTITUTE SHEET

1201 AGCCGCCGGG AGTGGGCCCA GAAGAAGAGG AAGGGGAGGG CTATGAGGAA
1251 CCTGACAGTG AGGAGGACTC CGAGTTCTAT GAGAACGACT CCAACCTTGG
1301 GCAGGACCAG CTCTCCCAGG ATGGCAGCGG CTACGAGAAC CCTGAGGATG
1351 AGCCCCTGGG TCCTGAGGAT GAAGACTCCT TCTCCAACGC TGAGTCTTAT
1401 GAGAACGAGG ATGAAGAGCT GACCCAGCCG GTCGCCAGGA CAATGGACTT
1451 CCTGAGCCCT CATGGGTCAG CCTGGGACCC CAGCCGGGAA GCAACCTCCC
1501 TGGGGTCCCA GTCCTATGAG GATATGAGAG GAATCCTGTA TGCAGCCCCC
1551 CAGCTCCGCT CCATTCGGGG CCAGCCTGGA CCCAATCATG AGGAAGATGC
1601 AGACTCTTAT GAGAACATGG ATAATCCCGA TGGGCCAGAC CCAGCCTGGG
1651 GAGGAGGGGG CCGCATGGGC ACCTGGAGCA CCAGGTGATC CTCAGGTGGC
1701 CAGCCTGGAT CTCCTCAAGT CCCCAAGATT CACACCTGAC TCTGAAATCT
1751 GAAGACCTCG AGCAGATGAT GCCAACCTCT GGAGCAATGT TGCTTAGGAT
1801 GTGTGCATGT GTGTAAGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT
1851 ATACATGCCA GTGACACTTC CAGTCCCCTT TGTATTCCTT AAATAAACTC
1901 AATGAGCTCT TCCAAAAAAA AAAA

FIG. 12. (CONT.)

SUBSTITUTE SHEET

25/33

1 ACAAAGACAA ACTGCACCCA CTGAACTCCG CAGCTAGCAT CCAAATCAGC
51 CCTTGAGATT TGAGGCCTTG GAGACTCAGG AGTTTTGAGA GCAAAATGAC
101 AACACCCAGA AATTCAGTAA ATGGGACTTT CCCGGCAGAG CCAATGAAAG
151 GCCCTATTGC TATGCAATCT GGTCCAAAAC CACTCTTCAG GAGGATGTCT
201 TCACTGGTGG GCCCCACGCA AAGCTTCTTC ATGAGGGAAT CTAAGACTTT
251 GGGGGCTGTC CAGATTATGA ATGGGCTCTT CCACATTGCC CTGGGGGGTC
301 TTCTGATGAT CCCAGCAGGG ATCTATGCAC CCATCTGTGT GACTGTGTGG
351 TACCCTCTCT GGGGAGGCAT TATGTATATT ATTTCCGGAT CACTCCTGGC
401 AGCAACGGAG AAAAATCCA GGAAGTGTTC GGTCAAAGGA AAAATGATAA
451 TGAATTCATT GAGCCTCTTT GCTGCCATTT CTGGAATGAT TCTTTCAATC
501 ATGGACATAC TTAATATTAA AATTTCCCAT TTTTAAAAA TGGAGAGTCT
551 GAATTTTATT AGAGCTCACA CACCATATAT TAACATATAC AACTGTGAAC
601 CAGCTAATCC CTCTGAGAAA AACTCCCCAT CTACCCAATA CTGTTACAGC
651 ATACAATCTC TGTTCCTGGG CATTTTGTCA GTGATGCTGA TCTTTGCCTT
701 CTTCCAGGAA CTTGTAATAG CTGGCATCGT TGAGAATGAA TGGAAAAGAA
751 CGTGCTCCAG ACCCAAATCT AACATAGTTC TCCTGTCAGC ACAAGAAAAA
801 AAAGAACAGA CTATTGAAAT AAAAGAAGAA GTGGTTGGGC TAACTGAAAC
851 ATCTTCCCAA CCAAAGAATG AAGAAGACAT TGAAATTATT CCAATCCAAG
901 AAGAGGAAGA AGAAGAAACA GAGACGAACT TTCCAGAACC TCCCAAGAT
951 CAGGAATCCT CACCAATAGA AAATGACAGC TCTCCTTAAG TGATTTCTTC
1001 TGTTTTCTGT TTCCTTTTTT AACATTAGT GTTCATAGCT TCCAAGAGAC
1051 ATGCTGACTT TCATTTCTTG AGGTACTCTG CACATACGCA CCACATCTCT

FIG. 13.

SUBSTITUTE SHEET

26/33

1101 ATCTGGCCTT TGCATGGAGT GACCATAGCT CCTTCTCTCT TACATTGAAT
1151 GTAGAGAATG TAGCCATTGT AGCAGCTTGT GTTGTACACG TTCTTCTTTT
1201 GAGCAACTTT CTTACACTGA AGAAAGGCAG AATGAGTGCT TCAGAATGTG
1251 ATTCCTACT AACCTGTTCC TTGGATAGGC TTTT TAGTAT AGTATTTTTT
1301 TTTGTCATTT TCTCCATCAG CAACCAGGGA GACTGCACCT GATGGAAAAG
1351 ATATATGACT GCTTCATGAC ATTCCTAAAC TATCTTTTTT TTATTCCACA
1401 TCTACGTTTT TGGTGGAGTC CCTTTTATC ATCCTTAAAA CAATGATGCA
1451 AAAGGGCTTT AGAGCACAAT GGATCT

FIG. 13. (CONT.)

1 ACGCGGAAAC AGGCTTGCAC CCAGACACGA CACCATGCAT CTCCTCGGCC
51 CCTGGCTCCT GCTCCTGGTT CTAGAATACT TGGCTTTCTC TGA CTCAAGT
101 AAATGGGTTT TTGAGCACCC TGAAACCCTC TACGCCTGGG AGGGGGCCTG
151 CGTCTGGATC CCCTGCACCT ACAGAGCCCT AGATGGTGAC CTGGAAAGCT
201 TCATCCTGTT CCACAATCCT GAGTATAACA AGAACACCTC GAAGTTTGAT
251 GGGACAAGAC TCTATGAAAG CACAAAGGAT GGGAAGGTTC CTTCTGAGCA
301 GAAAAGGGTG CAATTCCTGG GAGACAAGAA TAAGAACTGC AACTGAGTA
351 TCCACCCGGT GCACCTCAAT GACAGTGGTC AGCTGGGGCT GAGGATGGAG
401 TCCAAGACTG AGAAATGGAT GGAACGAATA CACCTCAATG TCTCTGAAAG
451 GCCTTTTCCA CCTCATATCC AGCTCCCTCC AGAAATTCAA GAGTCCCAGG
501 AAGTCACTCT GACCTGCTTG CTGAATTTCT CCTGCTATGG GTATCCGATC
551 CAATTGCAGT GGCTCCTAGA GGGGGTTCCA ATGAGGCAGG CTGCTGTCAC
601 CTCGACCTCC TTGACCATCA AGTCTGTCTT CACCCGGAGC GAGCTCAAGT
651 TCTCCCCACA GTGGAGTCAC CATGGGAAGA TTGTGACCTG CCAGCTTCAG
701 GATGCAGATG GGAAGTTCCT CTCCAATGAC ACGGTGCAGC TGAACGTGAA
751 GCATCCTCCC AAGAAGGTGA CCACAGTGAT TCAAAACCCC ATGCCGATTC
801 GAGAAGGAGA CACAGTGACC CTTTCCTGTA ACTACAATTC CAGTAACCCC
851 AGTGTTACCC GGTATGAATG GAAACCCCAT GGCGCCTGGG AGGAGCCATC
901 GCTTGGGGTG CTGAAGATCC AAAACGTTGG CTGGGACAAC ACAACCATCG
951 CCTGCGCAGC TTGTAATAGT TGGTGCTCGT GGGCCTCCCC TGTCGCCCTG
1001 AATGTCCAGT ATGCCCCCG AGACGTGAGG GTCCGAAAA TCAAGCCCCT
1051 TTCCGAGATT CACTCTGGAA ACTCGGTCAG CCTCCAATGT GACTTCTCAA
1101 GCAGCCACCC CAAAGAAGTC CAGTTCTTCT GGGAGAAAAA TGGCAGGCTT
1151 CTGGGGAAAG AAAGCCAGCT GAATTTTGAC TCCATCTCCC CAGAAGATGC
1201 TGGGAGTTAC AGCTGCTGGG TGAACAACTC CATAGGACAG ACAGCGTCCA
1251 AGGCCTGGAC ACTTGAAGTG CTGTATGCAC CCAGGAGGCT GCGTGTGTCC
1301 ATGAGCCCGG GGGACCAAGT GATGGAGGGG AAGAGTGCAA CCCTGACCTG
1351 TGAGAGCGAC GCCAACCCTC CCGTCTCCA CTACACCTGG TTTGACTGGA
1401 ATAACCAAAG CCTCCCCTAC CACAGCCAGA AGCTGAGATT GGAGCCGGTG
1451 AAGGTCCAGC ACTCGGGTGC CTA CTGGTGC CAGGGGACCA ACAGTGTGGG
1501 CAAGGGCCGT TCGCTCTCA GCACCCTCAC CGTCTACTAT AGCCCGGAGA
1551 CCATCGGCAG GCGAGTGGCT GTGGGACTCG GGTCTGCCT CGCCATCCTC
1601 ATCCTGGCAA TCTGTGGGCT CAAGCTCCAG CGACGTTGGA AGAGGACACA
1651 GAGGCCAGCA GGGGCTTCAG GAGAATTCCA GCGGCCAGAG CTTCTTTGTG

FIG. 14.

SUBSTITUTE SHEET

1701 AGGAATAAAA AGGTTAGAAG GGCCCCCCTC TCTGAAGGCC CCCACTCCCT
1751 GGGATGCTAC AATCCAATGA TGGAAGATGG CATTAGCTAC ACCACCCTGC
1801 GCTTTCCCGA GATGAACATA CCACGAACTG GAGATGCAGA GTCCTCAGAG
1851 ATGCAGAGAC CTCCCCCGGA CTGCGATGAC ACGGTCACCTT ATTCAGCATT
1901 GCACAAGCGC CAAGTGGGCA CTATGAGAAC GTCATTCCAG ATTTTCCAGA
1951 AGATGAGGGG ATTCATTACT CAGAGCTGAT CCAGTTTGGG GTCGGGGAGC
2001 GGCCTCAGGC ACAAGAAAAT GTGGACTATG TGATCCTCAA ACATTGACAT
2051 GGATGGGCTG CAGCAGAGGC ACTGGGGGCA GCGGGGGCCA GGAAGTCCC
2101 CGAGTTT

FIG. 14. (CONT.)

SUBSTITUTE SHEET

1 CCCAAATGTC TCAGAATGTA TGTCCCAGAA ACCTGTGGCT GCTTCAACCA
51 TTGACAGTTT TGCTGCTGCT GGCTTCTGCA GACAGTCAAG CTGCAGCTCC
101 CCCAAAGGCT GTGCTGAAAC TTGAGCCCCC GTGGATCAAC GTGCTCCAGG
151 AGGACTCTGT GACTCTGACA TGCCAGGGGG CTCGCAGCCC TGAGAGCGAC
201 TCCATTCACT GGTTCACAA TGGGAATCTC ATTCCCACCC ACACGCAGCC
251 CAGCTACAGG TTCAAGGCCA ACAACAATGA CAGCGGGGAG TACACGTGCC
301 AGACTGGCCA GACCAGCCTC AGCGACCCTG TGCATCTGAC TGTGCTTTCC
351 GAATGGCTGG TGCTCCAGAC CCCTCACCTG GAGTTCAGG AGGGAGAAAC
401 CATCATGCTG AGGTGCCACA GCTGGAAGGA CAAGCCTCTG GTCAAGGTCA
451 CATTCTTCCA GAATGGAAAA TCCCAGAAAT TCTCCCGTTT GGATCCCACC
501 TTCTCCATCC CACAAGCAAA CCACAGTCAC AGTGGTGATT ACCACTGCAC
551 AGGAAACATA GGCTACACGC TGTTCATC CAAGCCTGTG ACCATCACTG
601 TCCAAGTGCC CAGCATGGGC AGCTCTTCAC CAATGGGGAT CATTGTGGCT
651 GTGGTCATTG CGACTGCTGT AGCAGCCATT GTTGCTGCTG TAGTGGCCTT
701 GATCTACTGC AGGAAAAAGC GGATTTGAGC CAATTCCACT GATCCTGTGA
751 AGGCTGCCCC ATTTGAGCCA CCTGGACGTC AAATGATTGC CATCAGAAAG
801 AGACAACTTG AAGAAACCAA CAATGACTAT GAAACAGCTG ACGGCGGCTA
851 CATGACTCTG AACCCAGGG CACCTACTGA CGATGATAAA AACATCTACC
901 TGA CTCTTCC TCCCAACGAC CATGTCAACA GTAATAACTA AAGAGTAACG
951 TTATGCCATG TGGTCATACT CTCAGCTTGC TGAGTGGATG AAAAAAGAG
1001 GGGAAATTGTT AAAGGAAAAT TTAAATGGAG ACTGGAAAAA TCCTGAGCAA
1051 AAAAAACCAC CTGGCCCTTA GAAATAGCTT TAACTTTGCT TAACTACAA
1101 ACACAAGCAA AACTTCACGG GGTCACTA CATACAAGCA TAAGCAAAAC
1151 TTAAC TTGGA TCATTTCTGG TAAATGCTTA TGTTAGAAAT AAGACAACCC
1201 CAGCCAATCA CAAGCAGCCT ACTAACATAT AATTAGGTGA CTAGGGACTT
1251 TCTAAGAAGA TACCTACCCC CAAAAACAA TTATGTAATT GAAAACCAAC
1301 CGATTGCCTT TATTTTGCTT CCACATTTT CCAATAAATA CTTGCCTGTG
1351 ACATTTTGCC ACTGGAACAC TAAACTTCAT GAATTGCGCC TCAGATTTTT
1401 CCTTTAACAT CTTTTTTTTT TTTGACAGAG TCTCAATCTG TTACCCAGGC
1451 TGGAGTGCAG TGGTGCTATC TTGGCTCACT GCAAACCCGC CTCCCAGGTT
1501 TAAGCGATTC TCATGCCTCA GCCTCCAGT AGCTGGGATT AGAGGCATGT
1551 GCCATCATAC CCAGCTAATT TTTGTATTTT TTATTTTTTT TTTTGTAGTAG
1601 AGACAGGGTT TCGCAATGTT GGCCAGGCCG ATCTCGAACT TCTGGCCTCT
1651 AGCGATCTGC CCGCCTCGGC CTCCCAAAGT GCTGGGATGA CCAGCATCAG

FIG. 15.

SUBSTITUTE SHEET

1701 CCCCAATGTC CAGCCTCTTT AACATCTTCT TTCCTATGCC CTCTCTGTGG
1751 ATCCCTACTG CTGGTTTCTG CTTTCTCCAT GCTGAGAACA AAATCACCTA
1801 TTCCTGCTT ATGCAGTCGG AAGCTCCAGA AGAACAAAGA GCCCAATTAC
1851 CAGAACCACA TTAAGTCTCC ATTGTTTTGC CTTGGGATTT GAGAAGAGAA
1901 TTAGAGAGGT GAGGATCTGG TATTCCTGG ACTAAATTCC CCTTGGGGAA
1951 GACGAAGGGA TGCTGCAGTT CAAAAGAGA AGGACTCTTC CAGAGTCATC
2001 TACCTGAGTC CCAAAGCTCC CTGTCCTGAA AGCCACAGAC AATATGGTCC
2051 CAAATGACTG ACTGCACCTT CTGTGCCTCA GCCGTTCTTG ACATCAAGAA
2101 TCTTCTGTT CACATCCACA CAGCCAATAC AATTAGTCAA ACCACTGTTA
2151 TTAACAGATG TAGCAACATG AGAAACGCTT ATGTTACAGG TTACATGAGA
2201 GCAATCATGT AAGTCTATAT GACTTCAGAA ATGTTAAAAT AGACTAACCT
2251 CTAACAACAA ATTAAAAGTG ATTGTTTCAA GGTGAAAAAA

FIG. 15. (CONT.)

SUBSTITUTE SHEET

1 GCTGTGACTG CTGTGCTCTG GGCGCCACTC GCTCCAGGGA GTGATGGGAA
51 TCCTGTCATT CTTACCTGTC CTTGCCACTG AGAGTGACTG GGCTGACTGC
101 AAGTCCCCC AGCCTTGGGG TCATATGCTT CTGTGGACAG CTGTGCTATC
151 CCTGGCTCCT GTTGCTGGGA CACCTGCAGC TCCCCAAAG GCTGTGCTGA
201 AACTCGAGCC CCAGTGGATC AACGTGCTCC AGGAGGACTC TGTGACTCTG
251 ACATGCCGGG GGA CTACAG CCCTGAGAGC GACTCCATT C AGTGGTTCCA
301 CAATGGGAAT CTCATTCCCA CCCACACGCA GCCCAGCTAC AGGTCAAGG
351 CCAACAACAA TGACAGCGGG GAGTACACGT GCCAGACTGG CCAGACCAGC
401 CTCAGCGACC CTGTGCATCT GACTGTGCTT TCTGGTCAGT GGAGGAAGGC
451 CCCAGGGTGG ACCTGGGAGG GCCAGGACGG ATGAAATCTG CTTTCAGGCA
501 GAGGTTTGCA GGAAAGGGGG GTGGCCTGCT TACTGGGAAG TATCGCTGTG
551 AGTTGCCTCA GCACATATCA GTGGTTGTTT TTGCCTCAGT TCTGATTGAA
601 CAGAAGAAGG TTTCAAGGCC AAAACACAGG AGCCAAGTGT GAGAGAAGCA
651 GAAGGAAATC CCTACTGCAT AAAACCCATT TCCATTTTAA TGGCAGAATT
701 GAAAAGCACA GACCACA ACT GAATCCTAGC CCTGGAAATG ACTCACTATA
751 CAACATGATG AATTCATTTA ACCCTTGAGT TTCCATTTCT TCACCTGCTC
801 CGTGGGGCAC TAACGCCTCC CTCAGAGGCT TCTGGTGAGA ATCAGTGTTC
851 CCCTGCCCCC GCCCCGCCCT CCATGCCCT TCTCCACGTT CCACTGTGC
901 TAGGTGCTCT TCTCTGTCTT TCTCTCCAC CAGCCTGTGG GAAACCTGAG
951 ATGAAAGTCG TGTCTTACCC ATCTTTGTAT TTCCAGCATC TGAACTGGG
1001 CAGAGCTTAA TAAATATTTT GCTGGAGAGG TTGATGATCT TACAAAGCTC
1051 CCATTGAAAG GTGGCTCTCT GTAAAGCAAA GTTACAATGA GATTGTGATG
1101 AACATTGTCC TTGTGGCTTT TCACTTAGTC CCCTCCCTTC ACCTGAAGAG
1151 CAAATTTTCC TCAAAAGTAC ACAGCAAACG AATGACCCAC TGGTGACACT
1201 GTTGCCCTTTA GACCCTGCTG GAAAGAAGCT CCACATTTAT TAACATTCCC
1251 GAAGTAAATT TATCAGGTAG CATTATCAG GTAACATTTG TTGCACATTC
1301 ATGACTTTTC TACTGTCCAC AAAGGCATAT GTCCTTATCA TATGCGGACT
1351 CCTCGGTCAC ACTGGATTCT TCCTCCCTC CTCGACATGG AAGAGATGGC
1401 ATCTTAGGGT CTCTTGTTT CTTCTGCAG AGGCCTGTG GGCAGGAAAA
1451 GGCTGCAGCT GCCTTCCTGG GAGAAGGAGG AGATGAGTGT ATCCTGAACA
1501 CCTATTATGT GCTAGGGGCT ATTGTAGATA CATGACACTA TCATGCTCAT
1551 TTTCACGAAT GAGGAACTG AGGCTCAGAA GACTTAAATT ATTTGCCCAA
1601 GAGTTATAAA TGACAGAGCC AGCATTAGAG TCCAGGACTG TCTGATTTCA
1651 GACCTAAGCT GTTCCCTCTG CACATCGTGT CCCACCAGTA AGGAAGATCT

FIG. 16.

1701 GGGTCTCAGA GCTGAGCCAA GACCTCCCCG GTCCTCTGCG GTTTTTTGTG
1751 TCTTTCAGAG TGGCTGGTGC TCCAGACCCC TCACCTGGAG TTCCAGGAGG
1801 GAGAAACCAT CGTGCTGAGG TGCCACAGCT GGAAGGACAA GCCTCTGGTC
1851 AAGGTCACAT TCTTCCAGAA TGGAAAATCC AAGAAATTTT CCCGTTTCGA
1901 TCCCAACTTC TCCATCCCAC AAGCAAACCA CAGTCACAGT GGTGATTACC
1951 ACTGCACAGG AAACATAGGC TACACGCTGT ACTCATCCAA GCCTGTGACC
2001 ATCACTGTCC AAGCTCCCAG CTCTTCACCG ATGGGGATCA TTGTGGCTGT
2051 GGTCACGGG ATTGCTGTAG CGGCCATTGT TGCTGCTGTA GTGGCCTTGA
2101 TCTACTGCAG GAAAAAGCGG ATTTCAGGTT TGTAGCTCCT CCCGGTCCCT
2151 TTTGTTATCA GTTCCACTT T

FIG. 16. (CONT.)

SUBSTITUTE SHEET




1 GCCTCGCTCG GGC GCCCAGT GGT CCTGCCG CCTGGTCTCA CCTCGCCATG
51 GTTCGTCTGC CTCTGCAGTG CGTCCTCTGG GGCTGCTTGC TGACCGCTGT
101 CCATCCAGAA CCACCCACTG CATGCAGAGA AAAACAGTAC CTAATAAACA
151 GTCAGTGCTG TTCTTTGTGC CAGCCAGGAC AGAAACTGGT GAGTGACTGC
201 ACAGAGTTCA CTGAAACGGA ATGCCTTCCT TCGGGTGAAA GCGAATTCCT
251 AGACACCTGG AACAGAGAGA CACACTGCCA CCAGCACAAA TACTGCGACC
301 CCAACCTAGG GCTTCGGGTC CAGCAGAAGG GCACCTCAGA AACAGACACC
351 ATCTGCACCT GTGAAGAAGG CTGGCACTGT ACGAGTGAGG CCTGTGAGAG
401 CTGTGTCCTG CACCGCTCAT GCTCGCCCGG CTTTGGGGTC AAGCAGATTG
451 CTACAGGGGT TTCTGATACC ATCTGCGAGC CCTGCCCAGT CGGCTTCTTC
501 TCCAATGTGT CATCTGCTTT CGAAAAATGT CACCCTTGGA CAAGCTGTGA
551 GACCAAAGAC CTGGTTGTGC AACAGGCAGGC ACAAACAAGA CTGATGTTGT
601 CTGTGGTCCC CAGGATCGGC TGAGAGCCCT GGTGGTGATC CCCATCATCT
651 TCGGGATCCT GTTTGCCATC CTCTTGGTGC TGGTCTTTAT CAAAAAGGTG
701 GCCAAGAAGC CAACCAATAA GGCCCCCCAC CCCAAGCAGG AACCCCAGGA
751 GATCAATTTT CCCGACGATC TTCCTGGCTC CAACACTGCT GCTCCAGTGC
801 AGGAGACTTT ACATGGATGC CAACCGGTCA CCCAGGAGGA TGGCAAAGAG
851 AGTCGCATCT CAGTGCAGGA GAGACAGTGA GGCTGCACCC ACCCAGGAGT
901 GTGGCCACGT GGGCAAACAG GCAGTTGGCC AGAGAGCCTG GTGCTGCTGC
951 TGCAGGGGTG CAGGCAGAAG CGGGGAGCTA TGCCCAGTCA GTGCCAGCCC
CTC

FIG. 17.

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/02809

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4): C07H 17/02; U.S. C1.: 536/27; 435/17														
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; font-size: small;">Classification System</td> <td style="font-size: small;">Classification Symbols</td> </tr> <tr> <td>U.S.</td> <td>536/27 435/7, 17213 530/380</td> </tr> </table> <div style="text-align: center; font-size: x-small;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U.S.	536/27 435/7, 17213 530/380								
Classification System	Classification Symbols													
U.S.	536/27 435/7, 17213 530/380													
Chemical Abstracts database Keywords: panning, HPB-ALL, JY, human adrenal tumor, CDW32, IgG FC receptor, Fc gamma, R? CD20, CD 19, CD22, ICAM-1, CD40														
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; font-size: x-small;">Category [*]</th> <th style="width: 70%; font-size: x-small;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; font-size: x-small;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td><u>Proceedings of the National Academy of Sciences USA</u> Volume 75(6) Issued June 1978(WY SOCKI, L. J. et al.) "Panning for lymphocytes: A method for cell selection" See pages 2844-2848</td> <td style="text-align: center; vertical-align: top;">1-5</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td><u>Journal of Immunology</u> Volume 137(7) Issued 1 October 1986(LANIER L.L. et al.) "Distinct Epitopes on the T cell antigen receptor of HPB-ALL Tumor cells identified by monoclonal antibodies" See pages 2286-2292</td> <td style="text-align: center; vertical-align: top;">2, 3</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td><u>European Journal of Immunology</u> Volume 16 Issued July 1986(CARRELS et al.) "Monoclonal antibodies against idiotypic determinant(s) of the T cell receptor, from HPB-ALL cells induce IL-2 production in Jurkat cell without apparent evidence of binding "See pages 823-828</td> <td style="text-align: center; vertical-align: top;">2, 3</td> </tr> </table>			Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	<u>Proceedings of the National Academy of Sciences USA</u> Volume 75(6) Issued June 1978(WY SOCKI, L. J. et al.) "Panning for lymphocytes: A method for cell selection" See pages 2844-2848	1-5	Y	<u>Journal of Immunology</u> Volume 137(7) Issued 1 October 1986(LANIER L.L. et al.) "Distinct Epitopes on the T cell antigen receptor of HPB-ALL Tumor cells identified by monoclonal antibodies" See pages 2286-2292	2, 3	Y	<u>European Journal of Immunology</u> Volume 16 Issued July 1986(CARRELS et al.) "Monoclonal antibodies against idiotypic determinant(s) of the T cell receptor, from HPB-ALL cells induce IL-2 production in Jurkat cell without apparent evidence of binding "See pages 823-828	2, 3
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
Y	<u>Proceedings of the National Academy of Sciences USA</u> Volume 75(6) Issued June 1978(WY SOCKI, L. J. et al.) "Panning for lymphocytes: A method for cell selection" See pages 2844-2848	1-5												
Y	<u>Journal of Immunology</u> Volume 137(7) Issued 1 October 1986(LANIER L.L. et al.) "Distinct Epitopes on the T cell antigen receptor of HPB-ALL Tumor cells identified by monoclonal antibodies" See pages 2286-2292	2, 3												
Y	<u>European Journal of Immunology</u> Volume 16 Issued July 1986(CARRELS et al.) "Monoclonal antibodies against idiotypic determinant(s) of the T cell receptor, from HPB-ALL cells induce IL-2 production in Jurkat cell without apparent evidence of binding "See pages 823-828	2, 3												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"4" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> Date of the Actual Completion of the International Search 15 March 1989 International Searching Authority ISA/USA </td> <td style="width: 50%; vertical-align: top;"> Date of Mailing of this International Search Report 15 MAY 1989 Signature of Authorized Officer  Michelle S. Marks </td> </tr> </table>			Date of the Actual Completion of the International Search 15 March 1989 International Searching Authority ISA/USA	Date of Mailing of this International Search Report 15 MAY 1989 Signature of Authorized Officer  Michelle S. Marks										
Date of the Actual Completion of the International Search 15 March 1989 International Searching Authority ISA/USA	Date of Mailing of this International Search Report 15 MAY 1989 Signature of Authorized Officer  Michelle S. Marks													

III DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication where appropriate, of the relevant passages	Relevant to Claim No
Y	<u>Immunogenetics</u> Volume 18 Issued May 1983 (BONO, M.R. et al) "NH ₂ -Terminal sequence of the α and B chains of human DC-1 antigen isolated from the J4 cell line. Homology with murine I-A Molecules." See pages 453-459.	2,3
Y	<u>Proceedings of the National Academy of Science USA</u> Volume 84 Issued May 1987 (SEED, B. et al) "Molecular cloning of the CD2 receptor antigen, the T-cell erythrocyte receptor, by a rapid immuno selection procedure " See pages 3365-3369 particularly page 3368, first full paragraph and page 3365 right column.	1-6
Y	<u>Journal of Immunology</u> Volume 141(2) Issued 15 July 1988 (VAN SEVENTER, et al.) Differential recognition by human cytotoxic T cell clones of human M1 Fibroblasts transfected with an HLA-B7 Gene(JY 150) suggest the existence of 2 different HLA-B7 alleles in the cell line J4 (HLA-A2, 2; B7, 7; CW-,-, DR4, w6)	2,3
Y	<u>Chemical Abstracts</u> Volume 106(21) Issued 25 May 1987 (MAY, R.D. et al) "Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22- ricin A chain immunotoxins" See pages 35-36	18,19
Y	<u>Chemical Abstracts</u> Volume 109(7) Issued 15 August 1988 (INUI, S.) "Antigen CD 40. Expression on B-cells and carcinomas" See page 502	21
Y	<u>Journal of Immunology</u> Volume 138(1) Issued I January 1987 (PEZZUTTO, A. et al) "Amplification of human B cell activation by a monoclonal anti-body to the B cell-specific antigen CD22 Bp130/140" See pages 98-103	19

III DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X, P Y, P	EMBO Journal Volume 7(4) Issued April 1988 (STENGLIN, S. et al) "Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning" See pages 1053-1059, particularly page 1056, and figures 5 and 7.	1, 4-5, 6, 15-16 2-3, 17-21
X, P Y, P	Nature Volume 333 Issued 9 June 1988 (Simmons D. et al.) "The Fcγ receptor of natural killer cells is a phospholipid-linked membrane protein" See pages 568-570	1,6, 15-16 2-3, 17-21
X Y	Journal of Experimental Medicine Volume 166(6) Issued June 1987 (STUART S.G. et al) "Isolation and expression of cDNA clones encoding a human receptor for IgG (Fc R II)" See pages 1668-1684, particularly figure 2	6, 15-16 1, 2-5
X Y	Nature Volume 331 Issued 18 February 1988 (SIMMONS, D. et al) "ICAM an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM" See pages 624-627, particularly figure 4	20,6 1-5, 15-19, 21
X, P Y, P	Cell, Volume 52 Issued 25 March 1988 (STAUNTON, DE. et al) "Primary Structure of I CAM demonstrates interaction between members of the immunoglobulin and integrin supergene families"	20 1-6, 15-19, 21

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages 1:	Relevant to Claim No 1:
X Y, P	EMBO Journal, Volume 7(3) Issued March 1988 (EINFELD, P.A. et al.) "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains" See pages 711-717	17 1-5,6, 15,16, 18-21
X Y, P	Journal of Experimental Medicine Volume 167 Issued June 1988 (STAMENKOVIC, I et al) "Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, BP35) A type III integral membrane protein "See pages 1975-1980, particularly figure 2	17 1-6, 15-16, 18-21
Y	Leucocyte Typing III Oxford University Press Volume B3.9 Issued 1987 (VALENTINE M.A. et al) "Structure and function of the B-cell specific 35-37 kDA CD20 protein" See pages 440-443	1,6, 17

26 FEB. 2001

REVISED
VERSION*

PCT

Modtaget
WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07K 1/00, C12N 9/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/26230 (43) International Publication Date: 11 May 2000 (11.05.00)</p>
<p>(21) International Application Number: PCT/DK99/00541 (22) International Filing Date: 12 October 1999 (12.10.99) (30) Priority Data: PA 1998 1402 30 October 1998 (30.10.98) DK PA 1998 01645 25 November 1998 (25.11.98) DK PA 1999 01417 4 October 1999 (04.10.99) DK (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors: ROGGEN, Erwin, Ludo; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). OLSEN, Arne, Agerlin; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). ERNST, Steffen; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With a revised version of the international search report.</i> (88) Date of publication of the revised version of the international search report: 20 July 2000 (20.07.00)</p>
<p>(54) Title: LOW ALLERGENIC PROTEIN VARIANTS (57) Abstract The present invention relates to a method of selecting a protein variant having reduced immunogenicity as compared to the parent protein comprising the steps of screening a random peptide display package library with antibodies raised against any protein of interest, sequencing the amino acid sequence of the antibody binding peptides, or the DNA sequence encoding the antibody binding peptides, identifying epitope patterns of a protein by sequence alignment of the reactive peptide sequence, localisation of epitope patterns on the primary 3-dimensional structure of the parent protein, defining an epitope area including amino acids situated within 5 Å from the epitope amino acids, and affecting antibody binding to the epitope, changing the localised epitope patterns, or amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein without impairing functionality of the protein using the emerging epitope database for eliminating amino acid substitutions creating new or duplicating existing epitope patterns, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

REVISED
VERSION

1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 99/00541

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 1/00, C12N 9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9938978 A1 (SOSIN, HOWARD), 5 August 1999 (05.08.99), see abstract; page 7, line 31 - page 8, line 11; claims --	1-21,37
X	WO 9621016 A2 (LEUVEN RESEARCH & DEVELOPMENT VZW), 11 July 1996 (11.07.96), see page 5, line 1 - line 35 and example 4 --	22-36

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

19-04-2000

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Hampus Rystedt/Eö

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00541

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 8070866 A (CHUGAI SHOJI KK) 1996-03-19 (abstract) World Patents Index (online). London, U.K.: Derwent Publications, Ltd. (retrieved on 2000-03-30). Retrieved from: EPO WPI Database. DW199621, Accession No.1996-203147; & JP 8070866 A (CHIYUUGAI SHOJI KK) 1996-07-31 (abstract). (online) (retrieved on 2000-03-30). Retrieved from: EPO PAJ Database --	22-36
X	Dialog Information Services, File 155, MEDLINE, Dialog accession no. 08032657, Medline accession no. 95031937, Moola ZB et al: "Erwinia Chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes"; & Biochem J (ENGLAND) Sep 15 1994, 302 (Pt 3) p921-7 --	1-37
X	Journal of Immunological Methods, Volume 213, 1998, S.C. Williams et al, "Identification of epitopes within beta lactoglobulin recognised by polyclonal antibodies using phage display and PEPSCAN" page 1 - page 17 --	1-21,37
X	WO 9311794 A1 (XOMA CORPORATION), 24 June 1993 (24.06.93), see claims --	22-36
A	WO 9210755 A1 (NOVO NORDISK A/S), 25 June 1992 (25.06.92) --	1-37
A	WO 8604145 A1 (UNIVERSITY OF NEW MEXICO), 17 July 1986 (17.07.86) -- -----	16-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK99/00541

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see extra sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK99/00541

According to Article 34 (3) (a-c) and Rule 13.2, an international application shall relate to one invention only or to a group of inventions linked by one or more of the same or corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art. The present application relates to two such groups of inventions, namely:

1. A method for obtaining a protein with reduced immunogenicity, according to claims 1-21, and the use of a random peptide library for obtaining said peptide, according to claim 37.
2. A protein with reduced immunogenicity, according to claims 22-30, and means for producing it, according to claims 31-36.

Methods for reducing immunogenicity of proteins are well known in the art, as is proteins with reduced immunogenicity. The technical features characteristic of invention 1 is the use of a random peptide library for finding the epitopes suitable for modification. The technical feature characteristic of invention 2 is that the immunogenicity is reduced to at least 75% of the original immunogenicity and that the amino acid sequence of the protein should differ from the amino acid sequence of the original protein. No special technical feature linking inventions 1 and 2 has been found. The application is therefore not considered to fulfill the requirements of Rule 13.2.

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/12/99

International application No.

PCT/DK 99/00541

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
WO	9938978	A1	05/08/99	NONE	
WO	9621016	A2	11/07/96	AU 705119 B	13/05/99
				AU 4437796 A	24/07/96
				BG 101556 A	27/02/98
				BR 9606724 A	13/01/98
				CA 2206479 A	11/07/96
				CN 1168156 A	17/12/97
				CZ 9702104 A	12/11/97
				EA 121 B	00/00/00
				EP 0721013 A	10/07/96
				EP 0721982 A	17/07/96
				EP 0793723 A	10/09/97
				FI 972862 A	03/09/97
				HU 9802915 A	29/03/99
				JP 8289790 A	05/11/96
				NO 973083 A	04/08/97
				PL 321181 A	24/11/97
				SK 89297 A	06/05/98
				US 5695754 A	09/12/97
				US 5951980 A	14/09/99
WO	9311794	A1	24/06/93	CA 2103887 A	14/06/93
				EP 0571613 A	01/12/93
				JP 6506362 T	21/07/94
				US 5766886 A	16/06/98
				US 5770196 A	23/06/98
				US 5821123 A	13/10/98
				US 5869619 A	09/02/99
WO	9210755	A1	25/06/92	AT 170630 T	15/09/98
				AU 9052891 A	08/07/92
				CA 2095852 A	06/06/92
				DE 69130113 D,T	12/05/99
				EP 0561907 A,B	29/09/93
				SE 0561907 T3	
				FI 932561 A	04/06/93
				JP 6502994 T	07/04/94
				US 5766898 A	16/06/98
WO	8604145	A1	17/07/86	DE 3590392 C,T	14/01/93
				GB 2181433 A,B	23/04/87
				JP 5076960 B	25/10/93
				JP 62501449 T	11/06/87
				US 4732863 A	22/03/88

THIS PAGE BLANK (USPTO)